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SUMMARY 
INTRODUCTION: The renal effects of Tenofovir Disoproxil Fumarate (TDF) and antiretroviral 
treatment (ART) outcomes remain under-reported in African settings. The study sought to 
assess immunological outcomes and to compare renal function outcomes between patients 
exposed to TDF and unexposed patient group.  
METHODS: Phase 1 of the study was a retrospective case control analysis of serum creatinine 
data for 312 ART naïve adult patients exposed to TDF and 173 unexposed patients enrolled on 
ART between Dec 2006 and Jan 2011 at Roma Health Service Area in Lesotho. Sub-optimal 
renal function outcomes were serum creatinine clearance values <50 ml/min calculated using 
the Cockcroft-Gault equation. Phase 2 was based on re-sampling of the study population and 
analysis of CD4 counts of 516 adult naïve HIV-positive patients. Univariate logistic regression 
(p<0.1) and multivariate analyses (p<0.05) were performed using STATA® version 11 software.   
RESULTS: Overall, 153 (31.5%) patients had moderate baseline (30-60 ml/min) renal 
insufficiency. Renal function improved by +2 ml/min at 24 months. Almost 18% (n=312) of the 
patients on TDF were erroneously put on TDF. The use of TDF was a marginally significant 
factor (p=0.054) associated with CrCl<50 ml/min outcomes in univariate analysis but was 
insignificant (p=0.122) in multivariate analysis. Female gender (p=0.016), high blood pressure 
(p=0.009), ages over 60 (p=0.004), and underweight (p<0.001) were significantly associated 
with CrCl<50 ml/min outcomes. The proportion of patients who developed immunological failure 
in this study was low (6.8%, n=516). The mean CD4 count increased significantly after 
treatment (p<0.001). Baseline CD4 count below 50 cells/mm3 (p=0.049) and male gender 
(p=0.005) were significantly associated with sub-optimal immunological outcomes. 
CONCLUSIONS: TDF is a weak contributing factor associated with renal impairment outcomes 
compared to other variables such as hypertension, older age, underweight and female gender. 
More research on long term effects of TDF is recommended.  Baseline renal function screening 
should be improved to minimise leakages of patients contraindicated of TDF. Although the 
patients’ immunological status generally improved, males and patients with low baseline CD4 
counts should be monitored closely while on ART.  
Key words: Tenofovir; antiretroviral treatment; CD4 count; immunological failure 
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CHAPTER 1:  INTRODUCTION 
1.1 Background 
Human immunodeficiency virus (HIV) is a lentivirus (slowly replicating retrovirus) that 
causes acquired immunodeficiency syndrome (AIDS) (Cochrane, 2011). According to a 
report by the Government of Lesotho (GoL), Lesotho has an adult HIV and AIDS 
prevalence rate of 23% (GoL, 2012). The country ranks third highest in the world after 
Botswana and Swaziland which have prevalence rates of 25% and 26% respectively 
(Government of Botswana (GoB), 2012; Government of Swaziland (GoS), 2012). The 
Government of Lesotho launched the decentralised antiretroviral treatment (ART) 
programmes as part of the effort to mitigate the impact of HIV and AIDS. Nonetheless, 
some of the challenges facing the decentralised ART programmes include limited 
access to specialised laboratory tests such as viral load tests required to check for 
emergence of HIV drug resistance and a limited number of first-line and second-line 
ART regimens. 
Tenofovir Disoproxil Fumarate (TDF) was introduced at Roma Health Service Area in 
2008. The assessment of renal function in patients on TDF-based ART regimens is 
important because TDF has been associated with renal toxicity (Young, Buchacz, 
Baker, Moorman, Wood, Chmiel & Brooks, 2007). Renal function outcomes following 
the use of TDF have not been reported at Roma Health Service since TDF was 
introduced. The assessment of TDF renal toxicity is also of particular importance in 
Lesotho because the success of current ART programmes in Lesotho depends so 
much on the performance of the drug TDF, which currently forms the backbone of first-
line ART drugs.  
In the first reports on TDF-associated renal outcomes at Scott Hospital in Lesotho by 
Bygrave, Kranzer, Hilderbrand, Jouquet, Goemaere, Vlahakis, Triviño, Makakole & 
Ford (2011a) in 2008 and Bygrave, Ford, van Cutsem, Hilderbrand, Jouquet, 
Goemaere, Vlahakis, Triviño, Makakole & Kranzer (2011b) in 2009, TDF showed 
favourable outcomes with rare cases of TDF-associated renal toxicity. However, the 
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follow up time was limited to 24 months. The prevalence of sub-optimal renal function 
outcomes in HIV patients on TDF need to be investigated in different cohorts preferably 
with longer duration of treatment to establish the trend of TDF-associated renal function 
outcome in Lesotho. Moreover, data on TDF-associated renal function outcomes 
compared to renal function outcomes in HIV patients on non-TDF-based regimens in 
Lesotho are scarce. 
The assessment of treatment outcomes in terms of immunological outcomes as 
assessed by clusters of differentiation 4 (CD4) counts in Lesotho is another important 
issue where there is a gap. It is not known if the introduction of TDF at Roma Health 
Service Area has resulted in improved treatment outcomes. ART outcomes in Lesotho 
are still measured by CD4 counts despite the limited utility of CD4 counts in detecting 
HIV treatment failure (Kanapathipillai, McGuire, Mogha, Szumilin, Heinzelmann & 
Pujades-Rodriguez, 2011). According to Tiam (2008), Lesotho may be a fertile ground 
for the emergence of drug resistance and treatment failure mainly due to poor 
adherence to antiretroviral drugs. Summarily, the study had two main aims. Firstly, to 
assess renal function outcomes and secondly, to assess immunological outcomes of 
patients and compare the outcomes of the TDF-exposed patients to a control group of 
TDF-unexposed patients.  
1.2 Problem Statement 
Although numerous studies report that TDF is generally safe to use with respect to 
nephrotoxicity, other studies have found evidence of TDF-associated renal toxicity. The 
most common conclusions from the studies on TDF safety stated that TDF-associated 
nephrotoxicity is a rare event and that most patients who develop severe nephrotoxicity 
on exposure to TDF have pre-existing renal disorders. The studies include Reid, Stöhr, 
Walker, Williams, Kityo, Hughes, Kambugu, Gilks, Mugyenyi, Munderi, Hakim & Gibb 
(2008) in Zimbabwe; Brennan, Evans, Maskew, Naicker, Ive, Sanne, Maotoe & Fox 
(2011) in South Africa; Gérard, Chazallon, Taburet, Girard, Aboulker & Piketty (2007) in 
France; and O'Donnell, Scarsi, Darin, Gerzenshtein, Postelnick & Palella (2011) in the 
USA. 
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Contrarily, various studies have found evidence of TDF nephrotoxicity in non-
predisposed patients. In one African setting (Senegal), De Beaudrap, Diallo, Landman, 
Guèye, Ndiaye, Diouf, Kane, Etard, Girard, Sow & Delaporte (2010), reported that 
patients on TDF had higher rates of transition from mild to moderate renal insufficiency.  
Young et al. (2007) in the USA and Manosuthi, Mankatitham, Lueangniyomkul, 
Prasithsirikul, Tantanathip, Suntisuklappon, Narkksoksung, Nilkamhang & 
Sungkanuparph (2010b) in Thailand found that TDF-exposed groups had significantly 
higher incidences of renal disorder compared to TDF-unexposed groups. The use of 
TDF in HIV treatment therefore remains controversial with respect to renal safety. The 
controversy underpins the need to monitor patients on TDF-based ART.  
Besides TDF-associated nephrotoxicity, data on immunological outcomes are lacking. 
This problem is not unique to Lesotho only, but generally to many African settings. The 
evaluation of immunological outcomes is important in many ways. Firstly, the 
evaluation of immunological outcomes may highlight the overall performance of the 
ART programme in meeting the goals of ART. Secondly, the evaluation of 
immunological outcomes may show the effectiveness of ART drugs in use as well as 
the recently introduced drug TDF. 
1.3 Aims and Objectives 
1.3.1 Aims 
The study had two main aims. The first aim was to determine the extent to which TDF 
may cause renal toxicity by comparing the differences in renal function outcomes 
between patients who are on TDF-based ART regimens and the patients on non-TDF-
based ART regimens. The second aim was to determine the incidence of sub-optimal 
immunological outcomes based on CD4 counts. 
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1.3.2 Study Objectives 
The objectives of the study were: 
i. To determine incidence of renal function insufficiency at baseline and variables 
associated with renal insufficiency function at baseline; 
ii. To determine general renal function outcomes and the variables associated with the 
development of sub-optimal serum creatinine clearance (CrCl) outcomes (CrCl<50 
ml/min); 
iii. To determine general immunological outcomes based on CD4 counts and the 
proportion of patients with sub-optimal immunological outcomes (immunological 
failure);  
iv. To identify risk factors associated with sub-optimal immunological outcomes based on 
CD4 counts.  
1.4 Dissertation Outline 
Chapter 1 outlines the research problem concerning TDF-associated renal toxicity and 
immunological outcomes. Chapter 2 reviews the literature pertinent to the 
understanding of the principles of antiretroviral therapy, renal function, and 
immunological response. The literature reviewed in chapter 2 formed the basis of the 
research design outlined in chapter 3. Chapter 3 outlines how data for renal outcomes 
based on serum creatinine data and immunological outcomes based on CD4 counts, 
were collected and analysed. Chapter 4 presents results, beginning with renal 
outcomes and then the immunological outcomes. Chapter 5 discusses the results. 
Chapter 6 wraps up the study with an analogical account of the implications of the 
results obtained as well as giving recommendations in light of the current literature on 
TDF-associated nephrotoxicity and immunological outcomes. Chapter 7 lists the 
references cited in the study. Chapter 8 (Appendices) comprises ethical clearance 
documents and more detailed technical methodologies used in data analysis.    
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CHAPTER 2: LITERATURE REVIEW 
The chapter summarised the impact of HIV and AIDS on the health sector in 
Lesotho; the challenges facing the current ART regimens in Lesotho; principles of 
antiretroviral therapy, immunological response, and renal function; as well as the 
laboratory tests required for initiating ART and monitoring patients while on ARVs. 
The chapter also critically assessed the evidence on TDF renal toxicity and weighed 
the effect of other risk factors for developing renal abnormalities against the threat 
from TDF. Other pertinent themes central to the study objectives or informative to 
the subjects in focus were also included. 
2.1 Background Information on HIV and AIDS in Lesotho and 
Current ART Practice 
2.1.1 Impact of HIV and AIDS on the health sector, intervention 
programmes; and the challenges 
Lesotho, which is located in the eastern part of Southern Africa, is a landlocked 
country completely surrounded by the Republic of South Africa. According to a 
report by the Government of Lesotho, Lesotho has an adult HIV and AIDS 
prevalence rate of 23% (GoL, 2012). The country ranks third highest in the world 
after Botswana and Swaziland which have the prevalence rates of 25% and 26% 
respectively (GoB, 2012; GoS, 2012).  
The disease HIV and AIDS has had a devastating impact on the economy 
particularly the health sector. For instance, HIV and AIDS alone has caused a drop 
in life expectancy over the past two decades from over 50 years to the current 
estimate of 41 years. In 2011 alone, official figures showed that 8 500 people (close 
to 0.5% of the entire population) died from HIV and AIDS related illnesses (GoL, 
2012). According to 2011 estimates, 289 841 adults and children (about 15% of the 
population) were living with HIV and AIDS. Out of the number living with HIV and 
AIDS, 123 187 or 42% were in immediate need of antiretroviral therapy. Moreover, 
19% of the total demand for ART was by children under the age of 15. According to 
GoL (2012), the total 2010 annual investment in HIV and AIDS intervention 
programmes was about eight hundred and thirteen million Maloti in Lesotho 
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currency (M 813 million) which was equivalent to one hundred and eight million 
United States Dollars (USD 110 million). The total annual expenditure on HIV and 
AIDS was 12.6% of the national budget. HIV and AIDS is therefore, a significant 
burden on the national budget. 
This monetary budget could only meet 70% of the total cost estimates and the other 
30% was supplemented by development partners such as Global Fund, President's 
Emergency Plan For AIDS Relief (PEPFAR), Millennium Challenge Account, Clinton 
Health Access Initiative, World Bank, European Union, Irish Aid, Baylor International 
Paediatric AIDS Initiative, the Kellogg Foundation among others (GoL, 2012). The 
large number of development partners involved indicates that the disease HIV and 
AIDS poses a huge financial challenge to Lesotho. 
The Government of Lesotho has made great efforts to mitigate the impact of HIV 
and AIDS. Some of the intervening steps taken by the Government include 
increasing the budget allocation for HIV and AIDS and decentralising the provision 
of ART at the health center level (GoL, 2012). However, the decentralised ART 
programmes are facing many challenges which include limited resources to perform 
basic and specialised laboratory tests such as viral load tests, and lack of 
adherence to ART by some patient groups (Tiam, 2008).  
Following recommendations by the WHO, the Government of Lesotho switched 
patients on Stavudine-based antiretroviral drug regimens to TDF-based regimens 
(WHO, 2010). Since then, TDF has become the cornerstone of antiretroviral 
treatment of HIV and AIDS in Lesotho. The switching from Stavudine was in 
principle based on the premised survival rates of patients taking TDF-based 
regimens at higher CD4 count thresholds of 350 cells/mm3 as compared to 
Stavudine-based regimens (Figure 2.1). Moreover, the WHO recommendations 
seemed to be based on recommendations by some key researchers on antiretroviral 
drugs who postulated that TDF may even be considered for the prophylaxis of HIV 
infections (De Clercq, 2009; WHO; 2009).   
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Figure 2.1: Projected survival curves for the different ART treatment models.  
(Walensky, Wood, Ciaranello, Paltiel, Lorenzana, Anglaret, Stoler & Freedberg, 2010). 
The use of TDF-based antiretroviral drugs has been associated with renal toxicity. 
The similarity among TDF and structurally related nephrotoxic drugs is what brought 
about the concerns of TDF safety in the first place (Fernandez-Fernandez, Montoya-
Ferrer, Sanz, Sanchez-Niño, Izquierdo, Poveda, Sainz-Prestel, Ortiz-Martin, Parra-
Rodriguez, Selgas, Ruiz-Ortega, Egido & Ortiz, 2011). Researchers then began 
TDF safety trials on laboratory animals and human beings. Unfortunately, while the 
debate on renal safety of TDF still rages on, numerous HIV patients in many 
countries, including Lesotho, are already taking the drug. Therefore, despite the 
survival benefits attributable to the use of TDF, TDF may pose a risk of renal 
toxicity. This review begins by looking at current antiretroviral drug repertoire and 
regimens combinations used in Lesotho before moving on to review the profiles of 
the drug regimens. 
2.1.2 The rationale of use of ART regimens in Lesotho and the challenges 
The current practice in Lesotho recommends the use of three ARV drugs given as a 
combination. In HIV patients who have never been on HIV treatment before 
(treatment naїve), the first line treatment consists of two nucleoside reverse 
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transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase 
inhibitor (NNRTI) selected from the recommended drugs shown in Table 2.1 (GoL, 
2010). The use of regimens based on at least two drug classes is done to minimise 
emergence of drug resistance among the patients taking the antiretroviral drugs. 
NRTIs currently in use include TDF as shown in Table 2.1.  
Table 2.1:  Current first line and second line ART drugs recommended for adults in 
Lesotho. 
NRTI = Nucleoside reverse transcriptase inhibitor; * = drug not available; NNRTI = non-nucleoside 
reverse transcriptase inhibitor (GoL, 2010). 
The number of alternative ART regimens is severely limited. For example, in the 
second line NRTI category, DDI is no longer being supplied. Atazanavir co-
formulated with a dosage booster drug, Ritonavir (ATV/r) is also not widely available 
in Lesotho. The limited number of possible combinations for the currently available 
ART regimens is further limited by the existence of drug to drug interactions, 
adverse drug reactions and patient conditions such as comorbidities and pregnancy 
(See Table 2.2). For example, in HIV patients on TB treatment that includes 
Rifampicin, the number of ART combinations is even more limited. Rifampicin 
reduces concentrations of NNRTIs (especially Nevirapine) and some Protease 
inhibitors (PIs) because Rifampicin induces the cytochrome P450 enzymes and a 
drug efflux pump called permeability glycoprotein (P-gp) (Wilson, Cotton, Bekker, 
Meyers, Venter & Maartens, 2008). HIV patients co-infected with TB therefore may 
need to be given a PI drug, Lopinavir boosted with Ritonavir (LPV/r) at an added 
expense.  
First line drugs Second line drugs 
NRTIs  NNRTIs  NRTIs  Protease inhibitors (PIs)  
Lamivudine (3TC) Nevirapine (NVP) Didanosine (DDI)* Lopinavir/r (LPV/r) 
Tenofovir Disoproxil 
Fumarate (TDF) 
Efavirenz (EFV) Abacavir (ABC) Atazanavir/r (ATV/r)* 
Zidovudine (AZT)    
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Table 2.2:  Current guidelines on ART practice in Lesotho.  
Target 
population 
Preferred 
option  
Alternative Indications and contraindications criteria 
Adults and 
Adolescents 
(>12 years and 
>35 kg) 
TDF+3TC+EFV 
 
AZT+NVP TDF+3TC+EFV is the preferred 1st-line 
regimen. May use ABC if TDF is 
contraindicated.  Avoid TDF if BL CrCl is <50 
ml/min. 
Pregnant women TDF+3TC+EFV  
 
TDF+NVP 
or  
AZT+NVP 
Use NVP in women who expect to become 
pregnant. Do not initiate EFV in the first 
trimester. Avoid AZT in patients with 
Hb<8mg/dl (use TDF). NVP in women with BL 
CD4 between 250 and 350 may cause 
hepatotoxicity. 
HIV with TB 
comorbidity 
TDF+3TC+EFV 
 
AZT or 
boosted 
LPV/r 
Initiate ART as soon as possible within the 
first 8 weeks. Avoid NVP in patients on TB 
treatment. Use AZT+3TC+EFV. Use LPV/r if 
Efavirenz is contra-indicated. 
HIV with 
Hepatitis 
comorbidity 
TDF+3TC+EFV 
 
NVP Do HBsAg screening at BL. Use two ARVs 
with anti-HBV activity 
AZT = Zidovudine; 3TC = Lamivudine; EFV = Efavirenz; LPV/r = Lopinavir/Ritonavir; NVP = 
Nevirapine; TDF = Tenofovir; ABC = Abacavir; CrCl = serum creatinine clearance (GoL, 2010). 
Stavudine is no longer used and has been phased out due to adverse drug 
reactions as recommended by the World Health Organisation (WHO, 2010). The 
phasing out of Stavudine presented a challenge to ART programmes in Lesotho 
because a smaller number of drug combinations remained. Furthermore, the 
available ART drug combinations in Lesotho may pose even a greater challenge to 
ART programmes in future if serious cases of drug resistance emerge. 
To illustrate the predicament that the limited ART regimens pose, a pregnant female 
in the first trimester with baseline renal insufficiency and tuberculosis-HIV (TB/HIV) 
co-infection (not an uncommon event in Lesotho) would be contra-indicated for TDF, 
NVP, and EFV (Table 2.2), meaning that such a patient would be treated with 
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Abacavir and probably LPV/r, drugs which happen to be in the second line. 
Moreover, according to Lesotho guidelines, TDF should be ceased if calculated 
creatinine clearance is less than 50 ml/min (GoL, 2010). In cases where patients are 
anaemic and at the same time cannot be treated with TDF due to renal insufficiency, 
AZT and TDF are ruled out leaving the clinicians with no other first line drug 
combination (GoL, 2010). Putting some patients in the second line because of the 
limited first line drug combinations might compromise the national arsenal of drugs 
for future use against emerging HIV drug resistant strains.   
Switching to second line is recommended in cases where treatment failure as 
assessed by clinical and CD4 count is suspected or confirmed by viral load tests. 
However, both access to viral load tests and access to second line ARVs in Lesotho 
is limited (GoL, 2010). The limitations imply that the capacity to prove explicitly that 
a patient needs second line therapy as well as the capacity to supply more 
efficacious but expensive ARVs is greatly curtailed.  
Notwithstanding the proven efficacy that TDF has shown against HIV and Hepatitis 
(De Clercq, 2009), over-dependence on one drug such as TDF might result in the 
emergence of transmitted HIV drug resistance cases. Transmitted HIV drug 
resistance may occur if individuals with acquired drug resistance, probably due to 
lack of adherence to TDF pass the infection to ART naїve individuals (Clavel & 
Hance, 2004; Gianella & Richman, 2010).  
Therefore, the Lesotho national guidelines on HIV-AIDS care and treatment have 
TDF as one drug of choice for first line treatment. The main challenges facing the 
ART programmes in Lesotho include a limited number of ARV combinations, limited 
access to viral load tests and overdependence on one drug TDF. 
2.2 Nephrotoxicity of TDF: The Evidence; the Controversy; and the 
Discrepancies in the Studies on TDF Nephrotoxicity 
2.2.1 The evidence and the controversy 
Tenofovir disoproxil fumarate (TDF) has been generally approved to be a safe drug 
for HIV-1 treatment (Gallant & Deresinski, 2003). In 2009, the WHO recommended 
that TDF and Zidovudine replace Stavudine. However, animal studies (Lebrecht, 
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Venhoff, Kirschner, Wiech, Venhoff & Walker, 2009), case reports (Herlitz, Mohan, 
Stokes, Radhakrishnan, D'Agati & Markowitz, 2010) and observational studies 
(Wood, Shah, Steenhoff, Meyers, Kaplan & Rutstein, 2009; Agarwala, Mohan, 
Herlitz & Cheng, 2010; Soler-Palacín, Melendo, Noguera-Julian, Fortuny, Navarro, 
Mellado, Garcia, Uriona, Martín-Nalda & Figueras, 2011) have shown that high 
doses of TDF can cause nephrotoxicity.  
Fewer studies have been done on the African continent compared to other 
continents such as Europe. A study carried out in Johannesburg, South Africa by 
Brennan, Evans, Maskew, Naicker, Ive, Sanne, Maotoe & Fox (2011), reported that 
TDF may exacerbate pre-existing renal disorders but may not be responsible for 
initiating renal dysfunction in patients with baseline CrCl>50 ml/min. The study 
however recommended screening renal function before the administration of TDF 
and dose adjustments in patients with CrCl<50 ml/min.  
Another study done in Senegal by De Beaudrap et al. (2010) had a sample of 40 
patients exposed to TDF. Patients on TDF experienced a higher rate of transition 
from mild to moderate renal impairment when compared with patients on non-TDF 
regimens. In a study carried out in Zimbabwe, by Reid et al. (2008), the researchers 
reported that renal impairment in patients on ART was evidently related to 
intercurrent or concomitant disease. The same study did not find any significant 
differences among ART regimens with respect to renal function. Reid et al. (2008) 
were however cautious. They recommended that studies on long term use of ART 
may be necessary. 
High doses of TDF have been observed to cause nephrotoxicity in some animal 
studies (Van Rompay, Brignolo, Meyer, Jerome, Tarara, Spinner, Hamilton, Hirst, 
Bennett, Canfield, Dearman, Von Morgenland, Allen, Valverde, Castillo, Martin, 
Samii, Bendele, Desjardins, Marthas, Pedersen & Bischofberger, 2004). Cases of 
severe renal dysfunction and significant reductions in creatinine clearance among 
TDF-treated patients were reported after the drug was certified for public use 
(Antoniou, Raboud, Chirhin, Yoong, Govan, Gough, Rachlis & Loutfy, 2005; 
Winston, Amin, Mallon, Marriott, Carr, Cooper & Emery, 2006). Current international 
guidelines contraindicate use of TDF when creatinine clearance falls below 50 
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ml/min but some exceptions can be made if dosages of TDF are sufficiently reduced 
(Antoniou et al., 2005).  
However, TDF was not associated with significant renal toxicity or changes in 
glomerular filtration rate (GFR) in clinical trials of patients with baseline CrCl>50 
ml/min (Schooley, Ruane, Myers, Beall, Lampiris, Berger, Chen, Miller, Isaacson & 
Cheng, (2002); Izzedine Hulot, Vittecoq, Gallant, Staszewski, Launay-Vacher, 
Cheng & Deray, 2005). In a study carried out in the United Kingdom with a relatively 
large sample size of 10 343 adults who were all exposed to TDF-containing ART, 51 
patients developed serious renal disorders and 227 developed increased serum 
creatinine (Nelson, Katlama, Montaner, Cooper, Gazzard, Clotet, Lazzarin, Schewe, 
Lange, Wyatt, Curtis, Chen, Smith, Bischofberger & Rooney, 2007). Baseline risk 
factors for the development of increased serum creatinine were elevated serum 
creatinine, concomitant nephrotoxic medications, underweight, advanced age, and 
lower CD4 count.  
In other studies conducted in the USA by Gallant, Winston, DeJesus, Pozniak, 
Chen, Cheng & Enejosa (2008) and in France by Izzedine et al. (2005), the authors 
concluded otherwise. The USA study included 556 on TDF and 555 control patients 
on Stavudine or Zidovudine. The France study included 299 on TDF and 301 on 
Stavudine. Both studies had a similar duration of 144 weeks. Only small clinically 
insignificant differences in GFR over 144 weeks were noticed. The France study 
even reported that TDF and Stavudine had similar renal safety profiles in treatment-
naive HIV-infected patients who had the baseline CrCl>50 ml/min. 
The effect of TDF is likely to become clearer with time as many more patients 
continue to take the drug. In a study conducted by Crum-Cianflone, Ganesan, 
Teneza-Mora, Riddle, Medina, Barahona & Brodine (2010), renal dysfunction was 
associated with duration of tenofovir use, older age and lower CD4 nadir where CD4 
nadir refers to lowest CD4 cell count measured after HIV infection. Long term use of 
TDF therefore is a major concern. 
Very few studies attempted to establish empirical evidence of TDF on renal tubules 
or mitochondria in renal tubular cells. Maggi, Montinaro, Bellacosa, Pietanza, Volpe, 
Graziano, Strippoli & Angarano (2012) attempted to demonstrate TDF-associated 
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mitochondrial damage and tubular cell damage by measuring urinary cytochrome C 
and alpha-glutathione S-transferase (α-glutathione S-transferase) respectively. 
Mitochondrial damage was confirmed by moderate increases in urinary cytochrome 
C but tubular cell damage could not be confirmed. 
Since 2005, many prospective and retrospective studies, including case reports, 
have been published. The studies do not agree on the renal safety of TDF. A 
summary of studies on the link between use of TDF and development of renal 
disorders is given in Table 2.3. The differences in conclusions by different 
researchers may indicate the need for more research in different settings and 
patients’ characteristics to ascertain the renal outcomes of patients on TDF. 
2.2.2 Methodology discrepancies in the studies on renal safety of TDF 
According to Young et al. (2007), the apparent differences in findings outlined in 
Table 2.3 may stem from methodologies employed by different studies on the renal 
safety of TDF. Intervention studies or clinical trials, cohort studies, case control 
studies and a fourth type of study called case series were the main methodologies 
used in the studies on renal safety of TDF. However, the majority of the studies 
were cohort and case control studies. Comparing the studies is compounded by the 
the fact that each study had its own unique objectives which required specific 
methodologies to be followed. This section begins by defining and outlining the 
limitations of cohort, case control, clinical trials, and case studies; and goes on to 
point out some of the major differences, similarities, and gaps in the studies on renal 
toxicity of TDF cited in Table 2.3. 
As is noticeable in Table 2.3, the number of clinical trials reported on TDF is 
relatively small when compared to other types of studies. Apparently, conclusions by 
the two clinical trials included in Table 2.3 concurred to a large extent with minor but 
suspicion-rising conclusions. While Izzedine et al. (2005), concluded that TDF had 
similar renal safety profile to Stavudine, Gallant et al. (2008), noted that there were 
small differences in GFR between groups on TDF and the group on Stavudine and 
Zidovudine although the differences were not clinically significant. Conclusions from 
the two studies failed to allay the concerns on TDF renal safety by other 
researchers, hence the debate on TDF renal safety continues. 
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Table 2.3:  A summary of studies on TDF-associated renal injury.  
Study, Place  Study design Measure of 
renal clearance 
Main Findings 
Antoniou et al. 
(2005), Canada 
Prospective cohort of 
172 patients exposed to 
TDF; observed over 25 
months 
Serum creatinine 
data 
Slight increases in serum 
creatinine occurred with TDF. 
Significant nephrotoxicity was 
rare. 
Izzedine et al. 
(2005), France 
Double-blind  clinical 
trial over 36 months; 299 
patients exposed to TDF 
vs 301 patients on D4T-
based regimens 
Serum creatinine 
data 
TDF and Stavudine, had similar 
renal safety profile in treatment-
naive HIV-infected patients with 
normal renal function at baseline 
Padilla et al. 
(2005), Spain 
Retrospective case-
control study  over 12 
months; 122 on TDF + 
Lopinavir/ ritonavir vs 
194 unexposed 
Serum creatinine 
data 
5 patients in the TDF group 
versus 1 in the control group 
developed grade 1 or higher 
serum creatinine elevations 
(p=0.018). 
Gérard et al. 
(2007), France 
Prospective cohort  over 
12 months; 53 patients 
on TDF + Atazanavir/ 
ritonavir 
Serum creatinine 
data 
TDF dosage was not associated 
with changes in CrCl. Severe 
TDF-related nephrotoxicity was a 
rare event. 
Nelson et al. 
(2007), UK 
Prospective cohort  over 
48 months in 10343 
adults exposed to TDF-
containing regimens 
Serum creatinine 
data 
51 developed serious renal 
disorder. 227 developed elevated 
serum creatinine. Baseline risk 
factors were elevated serum 
creatinine, concomitant 
nephrotoxic medications, low 
body weight, advanced age, and 
lower CD4 count. 
 
Young et al. 
(2007), USA 
Prospective cohort over 
36 months in 593 
patients exposed to TDF 
vs 521 unexposed  to 
Cockcroft-Gault Renal disease was diagnosed in 
7 TDF-exposed and 3 TDF-
unexposed patients. 
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TDF 
Gallant et al. 
(2008), USA 
Randomised - controlled 
clinical trial over 36 
months; 556 on TDF-
based regimens vs 555 
patients on D4T or AZT-
based regimens 
Cockcroft-Gault Although small differences in 
GFR over time were noted, there 
was no clinically relevant renal 
disease or adverse event 
recorded in antiretroviral-naive 
patients treated with TDF. 
Reid et al. 
(2008), 
Zimbabwe 
Prospective study over 
24 months in 3 316 
patients; TDF-exposed 
vs TDF-unexposed 
Cockcroft-Gault Severe eGFR impairment was 
infrequent regardless of ART 
regimen and was generally 
related to intercurrent disease. 
Wood et al. 
(2009), USA 
Case report: Two 
adolescents perinatally 
infected by HIV; patients 
exposed to TDF-
containing regimens.  
Serum Creatinine 
data 
There was an abrupt rise in 
serum creatinine while on TDF. 
One patient had an underlying 
kidney disease. The other patient 
on TDF developed rickets and 
hypophosphataemia. 
Agarwala et al. 
(2010), USA 
Case report : 41 year old 
patient exposed to TDF-
containing regimen 
Urine protein, 
creatinine 
The patient developed proximal 
tubular dysfunction consistent 
with TDF toxicity. 
Chaisiri et al. 
(2010), Thailand 
Retrospective study with 
21 months follow-up  in 
405 adults with low body 
weight; patients exposed 
to TDF-containing  
regimens 
Serum creatinine 
data 
The study revealed high 
incidence of TDF-associated 
renal function decline among 
patients with low-body weight and 
BMI 
Crum-Cianflone 
et al. (2010), 
USA 
Retrospective study over 
24 months in 717 adult 
patients; TDF-exposed 
vs TDF-unexposed 
group 
MDRD Renal dysfunction was associated 
with duration of TDF use, lower 
CD4 nadir and old age. 
De Beaudrap et 
al. (2010), 
Senegal 
Prospective cohort over 
42 months; 40 patients 
on TDF vs 388 patients 
Cockcroft-Gault 
and MDRD 
After 12 months, patients on TDF 
experienced a higher rate of 
transition from mild to moderate 
renal impairment when compared 
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unexposed to TDF with patients not on TDF. 
Manosuthi et al. 
(2010b), 
Thailand 
Prospective cohort; 28 
patients on TDF + EFV 
vs 34 on TDF + NVP 
group; observed over 6 
months 
MDRD TDF-associated renal impairment 
was higher in the group receiving 
TDF with Nevirapine compared to 
TDF with Efavirenz. 
Patel et al. 
(2010), India 
Observational 
longitudinal cohort of 
1271 adults over 42 
months; all patients 
exposed to TDF-
containing  regimens 
Cockcroft-Gault 79 developed impaired serum 
creatinine and 5 developed 
Fanconi’s syndrome. All the 
patients’ serum creatinine levels 
normalised after stopping TDF. 
Post et al. 
(2010), UK 
Prospective cohort  over 
12 months in 385 
patients; Abacavir+3TC, 
TDF+EFV, and FTC + 
EFV 
Urinary excretion 
of retinol-binding 
protein and  β2-
microglobulin 
Patients in the TDF with Efavirenz 
group had higher levels of retinol-
binding protein and                    
β2-microglobulin. No significant 
difference in GFR between the 
test groups. 
Brennan et al. 
(2011), South 
Africa 
Retrospective cohort  
over 48 months in 890 
adults; all patients 
exposed to TDF-
containing regimens 
Serum creatinine 
data 
Renal dysfunction in TDF patients 
is likely related to pre-existing 
renal disorder. TDF exacerbates 
pre-existing renal disorder. 
 
Calza et al. 
(2011), Italy 
Retrospective case-
control study over 24 
months; 201 TDF-
exposed vs 123 TDF-
unexposed to TDF 
MDRD The TDF-exposed group had a 
greater decline in GFR through 
24 months. Reduced GFR was 
significantly associated with older 
age, diabetes, hypertension and 
concomitant therapy with a 
protease inhibitor. 
 
Manosuthi et al. 
(2011), Thailand 
Retrospective over 6 
months; 130 adults 
exposed to TDF-
Serum creatinine 
data 
Incidence of acute renal failure 
was 0.26 per 100 person-months. 
Renal function progressed to 
irreversible damage in one 
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containing  ART formula patient. 
Nishijima et al. 
(2011), Japan 
Retrospective cohort of 
495 patients exposed to 
TDF-containing  
regimens 
MDRD. Renal 
dysfunction 
defined as >25% 
in CrCl from 
baseline 
97 (19.6%) patients had TDF-
associated renal dysfunction. 
Small body weight was a 
significant risk while small body 
mass index had marginal 
significance (p=0.058). 
O'Donnell et al. 
(2011), USA 
A retrospective cohort 
over 72 months in 514 
patients; TDF-exposed 
vs TDF-unexposed 
group 
Serum creatinine 
data 
Renal impairment occurred in 
14% of the cohort and was not 
correlated with exposure to TDF 
but rather to chronic comorbidity 
conditions such as diabetes, old 
age, weight loss and low endpoint 
CD4 counts. 
Pavie et al. 
(2011), France 
Case report: one adult 
male patient exposed to 
TDF-containing  regimen 
- The patient developed acute 
renal failure 2 weeks after 
introduction of TDF based ART. 
Renal impairment was not 
reversed two years after 
switching to non-TDF formula. 
Soler-Palacín et 
al. (2011), Spain 
Prospective cohort over 
77 months; 40 infants 
and adolescents 
exposed to TDF-
containing regimens for 
at least six months 
Serum 
creatinine, urine 
protein, serum 
phosphate and 
potassium. 
TDF use showed a significant 
association with renal tubular 
dysfunction in HIV-infected 
paediatric patients. 
Tordato et al.  
(2011), Italy 
Retrospective case-
control in 1 505 patients; 
TDF-exposed vs TDF-
unexposed group 
Cockcroft-Gault TDF and protease inhibitors were 
associated with a greater risk of 
decreased renal function as 
measured by estimated GFR. 
There was a relatively high rate of 
mild renal dysfunction in the 
absence of ART. 
Viganò et al. 
(2011), Italy 
Prospective cohort over 
60 months in 26 infants 
Serum creatinine 
and phosphate, 
TDF had an excellent renal safety 
profile in HIV-infected children, 
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TDF = Tenofovir Disoproxil Fumarate; EFV = Efavirenz; NVP = Nevirapine; FTC = Emtricitabine;  
3TC = Lamivudine; D4T = Stavudine; ABC = Abacavir; BMI = Body Mass Index; MDRD = 
Modification of Diet in Renal Disease; CrCl = Creatinine Clearance;  vs = versus.  
According to Wassertheil-Smoller (2004), each of the two study types has 
limitations. For example, case control studies may be said to be liable to sampling 
bias especially in the selection of control cases where the selected controls may not 
be a good representative sample of the reference population. Another drawback for 
case control studies is that they are usually done retrospectively whilst cohort 
studies are usually done prospectively. Cohort studies are therefore less liable to 
bias because the cases are detected and defined as they occur during the study. 
However, cohort studies need longer study times and may not be practical in 
situations where observation time is limited. Hence, in principle, the studies on renal 
toxicity of TDF are fundamentally different and the reported results may need to be 
compared with the methodological differences in mind.  
and adolescents; 
Baseline: D4T and a 
protease inhibitor (PI). 
D4T switched with TDF 
and the PI switched with 
EFV 
urine protein, 
urine glucose, 
and urine α-1-
microglobulin.  
adolescents and young adults 
regularly followed up for 60 
months. 
Chua et al. 
(2012), 
Singapore 
Retrospective cohort:  
226 patients on TDF-
based ART 
Cockroft-Gault. 
Serum creatinine 
7.9% of patients had renal 
impairment outcomes          
(CrCl<50 ml/min). Renal toxicity 
was rare and transient among the 
patients 
Maggi et al. 
(2012), Italy 
Prospective cohort: 73 
patients on TDF/FTC-
based regimen vs 28 
patients on ABC/3TC-
based regimens 
MDRD. Serum 
creatinine, uric 
acid, cytochrome 
C, α-glutathione 
S-transferase 
Urinary excretion of phosphate 
and uric acid significantly 
increased in patients on TDF 
compared to those on Abacavir.  
Moderate increases in                
α-glutathione S-transferase 
indicated low-level mitochondrial 
damage. 
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With reference to Table 2.3, the majority of the studies were cohort and case control 
studies. Although the majority of cohort studies were done prospectively, some of 
the cohort studies were done retrospectively. There are several documented 
limitations of using retrospective data obtained from medical records (Chua, Llorin, 
Lai, Cavailler & Law, 2012). Limitations include incomplete data, difficulty in verifying 
the data, and variability in the quality of documentation among physicians. 
Therefore, it may not be surprising that the differences in the conclusions given by 
the studies in Table 2.3 may have emanated from the differences in the 
methodologies used in the studies. 
There were differences in methods used for estimation of GFR and in the criteria for 
defining renal dysfunction. Others used the Cockcroft-Gault formula (Gallant et al., 
2008; Patel, Patel, Ranjan, Patel & Patel, 2010) to calculate renal clearance while 
some studies used modification of diet in renal disease (MDRD) formula (Crum-
Cianflone et al., 2010; Calza, Trapani, Tedeschi, Piergentili, Manfredi, Colangeli & 
Viale, 2011) for GFR. Some studies did not indicate the estimation equations and 
cut-off they used to evaluate and define renal dysfunction. Serum creatinine is 
known to be affected by demographic factors such as age, gender, ethnic group, 
muscle mass and diet (Harmoinen, Lehtimaki, Korpela, Turjanmaa & Saha, 2003). 
Use of different methodologies with respect to GFR estimation may have 
contributed to the variation in the results obtained.  
The other major discrepancy among the studies was the sample size. The smallest 
sample in Table 2.3 was 26 (Viganò, Bedogni, Manfredini, Giacomet, Cerini, di 
Nello, Penagini, Caprio & Zuccotti, 2011) and the largest was 10 343 (Nelson et al., 
2007). The disparity in sample size may complicate the comparability of the studies.  
According to Young et al. (2007), the criteria for defining renal dysfunction differ 
among different studies. The lack of uniformity in defining the sub-optimal threshold 
of renal function may be one reason why different studies concluded differently on 
the renal safety of TDF. The other disparity in study methodology was observed in 
residual confounding with respect to concomitant therapies for intercurrent disease 
such as TB, diabetes and hypertension (Young et al., 2007). The clinical and socio-
demographic characteristics of the study populations are also strikingly different. 
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The differences in the demographic characteristics make the comparison of different 
studies difficult. 
Another major discrepancy was variation in the duration of the studies.  The duration 
of the studies excluding case reports and clinical trials ranged from six months up to 
77 months. The median duration of the studies excluding clinical trials was              
24 months. Studies with longer duration are therefore still needed to allow better 
comparisons of the studies on renal toxicity of TDF. 
2.3 Mechanisms and the Risk Factors of Renal Disease 
2.3.1 General risk factors for renal disease 
The process of ascertaining causes of renal disease in HIV patients is complicated 
by the numerous possible causes of renal disease, including HIV itself, which has 
been associated with renal impairment on its own (Sakka, Bakoyannis, Chini, 
Gargalianos, Sambatakou, Antoniadou, Chrysos, Paparizos, Daikos, Katsarou, 
Touloumi & Lazanas, 2012). According to Farag, Kari & Singh (2012), diabetes, 
obesity and hypertension are the main threats in some countries such as Saudi 
Arabia. In a cohort of HIV-positive Greek patients, older age and female gender 
were significant determinant variables for chronic kidney disease (Sakka et al., 
2012). 
In another cohort study in Iran (Tohidi, Hasheminia, Mohebi, Khalili, Hosseinpanah, 
Yazdani, Nasiri, Azizi & Hadaegh, 2012), female gender was also a significant 
determinant. Other variables that were significantly associated with the development 
of chronic kidney disease included age, family history, low baseline GFR, diabetes 
mellitus and hypertension. However, Tohidi et al. (2012), reported that there were 
clear-cut differences between male and female gender. The same researchers 
recommended that investigations of risk factors for developing chronic kidney 
disease be done separately between males and females. 
In one study done in the USA, African-American ethnicity, Hepatitis C co-infection, 
low CD4 cell count and high viral load while on ART were associated with higher 
risk of chronic kidney disease (Kalayjian, Lau, Mechekano, Crane, Rodriguez, 
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Salata, Krishnasami, Willig, Martin, Moore, Eron & Kitahata, 2012). Use of TDF and 
a Ritonavir-boosted protease inhibitor was also associated with higher CKD risk. 
2.3.2 Mechanisms of drug-induced nephrotoxicity 
The major function of the kidney is to concentrate and excrete toxic metabolites and 
drugs. The kidneys are therefore a frequent site of drug toxicity. Drugs may damage 
the kidney through several mechanisms. Tubular cell toxicity is one of the 
mechanisms by which drugs may cause renal injury. The role of the proximal tubule 
in concentrating and reabsorbing the glomerular filtrate makes it vulnerable to toxic 
injury (Schetz, Dasta, Goldstein & Golper, 2005). Tubular toxicity is, at least in part, 
dose-dependent and is the cause of kidney injury associated with aminoglycosides, 
amphotericins, antiviral drugs such as Foscarnet, Cidofovir and antiretroviral drugs 
such as Tenofovir. 
Interstitial nephritis, characterised by inflammation of the renal interstitial tissue and 
tubules has been associated with antibiotics such as beta-lactams (β-lactams) and 
quinolones especially Ciprofloxacin, Rifampicin, Macrolides, Sulfonamides, 
Tetracyclines; diuretics  such as Thiazides, Allopurinol; antiviral drugs such as 
Acyclovir and Indinavir; and non-steroidal anti-inflammatory drugs (NSAIDs) (Schetz 
et al., 2005; Loh & Cohen, 2009). A number of drugs may cause interstitial nephritis. 
It appears most antibiotics belonging to the β-lactams quinolone groups may cause 
interstitial nephritis.   
Nephrotoxicity of NSAIDs can inhibit renal prostaglandin synthesis, resulting in 
unbalanced vasodilation and vasoconstriction forces. Moreover, antibiotics and 
analgesics, including NSAIDs, commonly cause tubulo-interstitial nephritis probably 
because they are widely used throughout the world (Loh & Cohen, 2009).  
Another mechanism through which drugs may cause glomerular injury is immune 
complex deposition. Immune complex deposition on the glomerular membrane may 
result in membranous glomerulonephritis. Though membranous glomerulonephritis 
looks simple to understand, the exact mechanism and threshold of immune complex 
deposits required before pathological manifestations are noticed, remains elusive to 
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researchers. Numerous drugs, including NSAIDs, Captopril and Probenecid, are 
associated with glomerulonephritis (Loh & Cohen, 2009). 
The precipitation of crystals (nephrolithiasis) in distal tubular lumens depends on pH 
and hydration status which explains why precipitation of crystals is triggered by 
drugs such as Acyclovir, Sulfonamide, Methotrexate, Indinavir and Triamterene 
(Schetz et al., 2005; Loh & Cohen, 2009) and other drugs such as alcohol, thiazide 
diuretics, Cyclosporine, Furosemide and Cisplatin (Loh & Cohen, 2009). 
Hypercalcaemia due to excess vitamin D may result in calcium phosphate 
deposition. Consuming foods with high vitamin C content may also promote the 
formation of calcium oxalate crystals.  
Some drugs such as Indinavir, Cyclosporine and Quinine are known to cause 
thrombotic microangiopathy which is characterised by findings typical of haemolytic 
uraemic syndrome (Schetz et al., 2005). Osmotic nephrosis, on the other hand, is 
the mechanism of nephrotoxicity associated with high doses of sucrose-rich 
intravenous plasma volume expanders such as sucrose, dextrans, and starches 
(Schetz et al., 2005; Loh & Cohen, 2009).  
Therefore, numerous drugs are associated with renal toxicity. As would be 
expected, the use of different drugs such as is the case in HIV treatment, increases 
the vulnerability of the kidney. These drugs however will not cause disease in every 
patient who takes them. A number of risk factors have been identified which 
predisposes certain groups of individuals. 
2.3.3 Risk factors for drug-induced nephrotoxicity 
The risk of drug-induced nephrotoxicity increases with age probably due to 
reduction of GFR which occurs in old age (Thomson, 1995; Naughton, 2008; 
Muhlberg & Platt, 1999). Biological differences between men and women have also 
been found to contribute to different responses to nephrotoxic drugs (Schwartz, 
2003). 
Patients with pre-existing renal insufficiency have a higher risk of developing drug-
induced nephrotoxicity and chronic kidney disease (Harbarth et al., 2001; Naughton, 
2008) and diabetes (Blackshear, Davidman & Stillman, 1983; Naughton, 2008). In 
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addition, patients with sepsis (Schrier & Wang, 2004), sodium depletion and patients 
on diuretics (Blackshear Davidman & Stillman, 1983; Schetz et al., 2005) are at risk 
of developing drug-induced nephrotoxicity. 
According to the explanations given by Schetz et al. (2005) and Naughton, (2008), 
sepsis increases the risk of nephrotoxicity due to the associated systemic and renal 
haemodynamic alterations. The use of angiotensin converting enzyme (ACE) 
inhibitors, and angiotensin receptor blockers (ARB) may result in GFR decrease 
because the kidney relies on efferent vasoconstriction for the maintenance of 
glomerular filtration pressure. Sodium-depleted patients also have impaired renal 
haemodynamics and impaired renin–angiotensin system. Use of diuretics is 
associated with higher risk of nephrotoxicity because diuretics can reduce 
circulating volume and increase renal excretion of sodium (Schetz et al., 2005).  
Other factors that may increase risk of drug-nephrotoxicity include higher drug 
dosages, using nephrotoxic drugs for long time, frequent use of nephrotoxic drugs, 
parenteral route of drug administration, and drug formulation type with lipid 
formulations having less risk (Schetz et al., 2005). 
2.3.4 Weighing the effect of TDF versus other risk factors 
The evidence linking the use of TDF and the development of renal disease has 
always been controversial. Most methodologies that have been used to rule out the 
effect of other factors such as demographic factors and comorbidities have largely 
relied on multivariate analysis. Empirical evidence linking the use of TDF and renal 
tubular cell or mitochondrial damage is very scarce. However, the effect of 
confounders can never be ruled out with certainty even when multivariate logistic 
regression analysis is used.  
Several studies have identified possible factors that may increase the risk of TDF 
nephrotoxicity among patients taking the drug. It is interesting to compare the effect 
that TDF might have on renal function relative to other factors. In most cases, 
researchers have listed several factors associated with renal impairment. For 
example, a study by Crum-Cianflone et al. (2010) reported that use of TDF, female 
gender, older age, African-American ethnicity and lower CD4 count were some of 
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the factors associated with renal impairment. Nelson et al. (2007) identified elevated 
serum creatinine, concomitant nephrotoxic medications and low body weight as 
additional risk factors associated with developing TDF-linked renal disorders 
besides older age and lower CD4 count.  Such long lists of factors imply that the 
effect of TDF alone is unlikely to be isolated without some form of empirical 
evidence given.  
Hypertension and diabetes are conditions frequently mentioned in the literature as 
some of the major risk factors of developing TDF-associated nephrotoxicity (Young 
et al., 2007; Calza et al., 2011). Obesity is another factor which may contribute to 
renal disease (Tesauro, Mascali, Franzese, Cipriani, Cardillo & Di Daniele, 2012). 
Hypertension is cited in the literature as both a potential cause and consequence of 
chronic renal disease (Dworkin & Shemin, 1999). Therefore, it is important to 
understand how hypertension, diabetes, and obesity are linked to renal disease. It is 
also important to know why hypertension, diabetes and obesity are important factors 
of renal disease in African settings. 
The link between hypertension and chronic renal disease seems to emanate from 
the disrupted renal function particularly the gromerulus and the ill-controlled 
activation of the renin-angiotensin system. Initially, hypertension increases 
glomerular capillary pressure (Dworkin & Shemin, 1999). The immediate 
consequence of the impaired glomerular capillary pressure seems to be increased 
protein filtration and endothelial damage resulting in increased release of cytokines 
that promote fibrosis of kidney tissue. According to the literature, one of the most 
common kidney diseases associated with hypertension is chronic glomerulonephritis 
(Chobanian, Bakris, Black, Cushman, Green, Izzo, Jones, Materson, Oparil, Wright 
& Roccella, 2003). Therefore, hypertension is an important confounding factor in the 
analysis of TDF-associated renal toxicity.  
The prevalence of hypertension in African settings may probably give an indication 
of the general trend that TDF-associated nephrotoxicity is likely to take. On the other 
hand, the prevalence of hypertension may be inextricably intertwined with the 
prevalence of a host of other co-morbidities such as diabetes, pregnancy, hormonal 
imbalances and other factors implicated in hypertensive disorders (Sutters, 2009).  
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Whereas the prevalence of hypertension is estimated to be about 10-15% among 
white Americans, the prevalence of hypertension is estimated to be twice as high 
among African-Americans (Naicker, 2003; Sutters, 2009). In a recent study by 
Hendriks, Wit, Roos, Brewster, Akande, de Beer, Mfinanga, Kahwa, Gatongi, Van 
Rooy, Janssens, Lammers, Kramer, Bonfrer, Gaeb, van der Gaag, Rinke, Lange & 
Schultsz (2012), the prevalence of hypertension was as high as 38% in one urban 
Namibian cohort. Hendriks et al. (2012) also reported hypertension prevalences of 
at least 20% in Kenya, Tanzania and Nigeria. Alarmingly enough, at least one-third 
of the individuals with hypertension had grade II (>160/100 mmHg) or grade III 
hypertension (>180/110 mmHg). In one Nigerian cohort study, 43.3% of the 
individuals with hypertension had grade II or III hypertension (Hendriks et al., 2012). 
Patients suffering from both hypertension and diabetes need special attention due to 
poor prognosis when the two conditions occur concurrently and the increased risk of 
developing diabetic nephropathy. According to the guidelines by the British National 
Formulary (BNF, 2006), patients with both hypertension and diabetes should be 
given ACE inhibitors or angiotensin-II receptor antagonists while having closer blood 
pressure monitoring (BNF, 2006). However, in the case that the patient has renal 
impairment in addition to hypertension, ACE inhibitors should be used with caution. 
Maintaining a strict drug regime as recommended is still a challenge in African 
settings due to limited drug choices and laboratory tests. 
Many cases of hypertension and diabetes in remote African settings may remain 
undiagnosed due to the intricate procedures for diagnosing hypertension and 
diabetes as discussed in section 2.5.4 and 2.5.5 respectively. For instance, 
according to Sutters (2009), an HIV patient with an elevated blood pressure reading 
would be required to visit the hospital for a second blood pressure measurement 
within one month. In most cases, this protocol is not followed, resulting in a wrong 
diagnosis. Due to the high prevalence of hypertension in African settings, 
investigations for TDF-associated renal disease in African settings need to rule out 
hypertension as the primary cause of renal disease despite the challenges. 
According to Tesauro et al. (2012), obesity and hypertension are some of the critical 
factors that can accelerate the progression of kidney disease. The search for the 
chemical factors or hormones linking obesity, hypertension and chronic nephropathy 
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has been on-going for years. Recently, some possible links between obesity, 
hypertension and kidney disease have been reported. Dipocytokines such as leptin 
and adiponectin are some of the potential leads. Leptin precipitates hypertension 
possibly through increasing serum catecholamine levels which are linked with 
hypertension when sustained for extended periods. In addition to increasing blood 
pressure, leptin has been associated with glomerulosclerosis through induction of 
type I collagen synthesis in mesangial cells and type IV collagen in glomerular 
endothelial cells (Ballerman, 1999). In contrast to leptin, it is rather the lack of 
adiponectin which is associated with hypertension and consequently, kidney 
disease.  
Some genetic lineages expressing certain genetic polymorphisms in the gene 
encoding for adiponectin have been associated with obesity and therefore, 
increased risk of developing kidney disease (Iwashima, Katsuya, Ishikawa, Ouchi, 
Ohishi, Sugimoto, Fu, Motone, Yamamoto, Matsuo, Ohashi, Kihara, Funahashi, 
Rakugi, Matsuzawa & Ogihara, 2004). These genetic disorders could be the reason 
why obesity has been linked to family history. For example, Iwashima et al. (2004) 
described the link between arterial hypertension in Japanese individuals and genetic 
polymorphism for the gene encoding adiponectin. In addition to genetic 
polymorphisms, the links between obesity and kidney disease have also been 
attributed to metabolic syndrome. Metabolic syndrome is a risk factor for 
hypertension and diabetes (Bakris, 2007).  
Another risk factor for developing kidney disease is smoking. Smoking has been 
linked to microvasculature disturbance which means that smoking may damage 
small vessels in the circulatory system resulting in increased risk of atherosclerosis 
(Odden, Tager, Gansevoort, Bakker, Fried, Newman, Katz, Satterfield, Harris, 
Sarnak, Siscovick & Shlipak, 2013). 
Small body weight due to small stature is a potential risk factor especially in African 
settings. Nishijima, Komatsu, Gatanaga, Aoki, Watanabe, Kinai, Honda, Tanuma, 
Yazaki, Tsukada, Honda, Teruya, Kikuchi & Oka (2011), reported that small body 
weight is associated with a higher risk of developing TDF-associated renal 
impairment. According to Nishijima et al. (2011), patients of Japanese descent have 
smaller stature on average compared to White Americans and African-Americans. 
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Patients of African descent are smaller in stature on average than people of 
European and American descent. Therefore Africans may also be at higher risk of 
TDF-associated renal impairment compared to other races with bigger stature. 
Other risk factors include exposure to high doses of TDF, pre-existing renal 
disorders and extensive pre-treatment with nucleoside reverse transcriptase 
inhibitors (Noah, 2012). The use of Atazanavir/ ritonavir (Gérard et al., 2007) 
concurrently with TDF is associated with a higher risk of developing renal disorder. 
The results of the study by Gérard et al. (2007) also augmented the theory that 
concomitant nephrotoxic medications may increase the risk of developing TDF-
associated renal disorder. The renal disorder is believed to emanate from the 
interaction between the protease inhibitors with the renal transport of organic ions 
which leads to accumulation of TDF in the proximal tubules.  
There is need despite the challenges, to control for a host of other risk factors that 
may cause or worsen renal impairment besides TDF. It seems the high prevalence 
of hypertension and diabetes coupled with lack of resources to diagnoses and 
manage these two disease conditions in African settings poses a greater challenge 
than the threat that TDF poses to renal function. More efforts are therefore 
warranted in strengthening laboratory systems in African settings.    
2.4 Profiles of Antiretroviral Drugs: Rationale of Use; Mechanisms 
of Action; and Adverse Reactions 
According to Wilson et al. (2008), only three classes of ARVs are commonly 
available in Southern Africa. The other drug classes such as integrase inhibitors and 
entry inhibitors are not available due to resource limitations. The three classes of 
ARVs available are nucleoside reverse transcriptase inhibitors (NRTIs); non-
nucleoside reverse transcriptase inhibitors (NNRTIs); and protease inhibitors (PIs). 
NRTIs and NNRTIs are drugs that inhibit HIV reverse transcriptase. PIs are drugs 
that interfere with HIV protease. Other classes of antiretroviral drugs such as entry 
inhibitors are not available due to costs associated with acquiring and monitoring the 
use of the drugs. The profiles of the different ARV drug classes available in 
Southern Africa, including molecular structures, mechanisms of action and adverse-
effects of the drugs, are outlined in Section 2.4.1. 
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2.4.1 Profile of Tenofovir Disoproxil Fumarate  
2.4.1.1 Structure and mechanism of action 
TDF (structure shown in Figure 2.2) targets HIV reverse transcriptase and acts as a 
chain terminator, following intracellular phosphorylation to the diphosphate form 
(See Figure 2.3). TDF is a drug synthesized by modifying the organic chemical 
Tenofovir. Tenofovir disoproxil fumarate is rapidly absorbed and converted to 
tenofovir following oral administration. Structurally, TDF is slightly different from 
other nucleoside reverse transcriptase inhibitors (NRTIs) in that it contains only one 
phosphate group (Fernandez-Fernandez et al., 2011).  
 
Figure 2.2: Chemical structure of Adefovir, Cidofovir and Tenofovir:  
(Fernandez-Fernandez et al., 2011). 
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Figure 2.3: Mechanism of antiviral action of Tenofovir.  
PR = Pyrophosphate; PRPP = Phosphoribosyl Pyrophosphate; PMPA = 
Phosphonylmethoxy-propyl adenine; PMPAp =  Phosphonylmethoxy-propyl adenine 
monophosphate; PMPApp =  Phosphonylmethoxy-propyl adenine diphosphate; RNA = 
Ribonucleic Acid; DNA = Deoxyribonucleic acid;  AMP = Adenosine Monophosphate,  
(De Clercq, 2004). 
TDF is found in Atripla® tablets made by Bristol-Myers Squibb & Gilead Sciences; 
Truvada® and Viread® which are made by Gilead Sciences. Whereas Atripla® 
tablets contain 600mg Efavirenz, 200mg Emtricitabine and 300mg TDF; Truvada® 
contains 200mg Emtricitabine and 300mg TDF; and Viread® contains 300mg TDF 
(Noah, 2012).  
As mentioned in Section 2.1.1, the structural similarity between Tenofovir, Adefovir 
and Cidofovir (Figure 2.2) is what brought about the concerns about TDF’s renal 
safety in the first place (Fernandez-Fernandez et al., 2011). After renal toxicity 
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concerns were confirmed in patients taking TDF, researchers focused on ways of 
reducing uptake by renal proximal tubular cells. 
Two methods to reduce uptake by renal proximal tubular cells were identified 
(Fernandez-Fernandez et al., 2011). The methods included esterifying the TDF 
compound with an alkoxyalkyl group and ribose-modification. Esterifying TDF 
compound resulted in a TDF derivative which could be disguised as 
lysophospholipids. One such compound was hexadecyloxypropyl-Tenofovir and is 
shown in Figure 2.2. 
The second method of ribose-modification resulted in a chemical similar to the usual 
substrate for viral ribonucleic acid (RNA)-directed deoxyribonucleic acid (DNA) 
polymerase and therefore may have less renal toxicity. However, success with the 
derivatives of TDF is not yet reported. 
2.4.1.2 Mechanisms of TDF nephrotoxicity; clinical effects; and reversibility of 
TDF nephrotoxicity 
The proposed mechanisms by which TDF causes renal toxicity are associated with 
renal proximal tubule injury and glomerular toxicity. Renal proximal tubules are 
known to be involved in the excretion of drugs such as TDF (Kohler, Hosseini, 
Green, Abuin, Ludaway, Russ, Santoianni & Lewis, 2011). Studies have unraveled 
possible mechanisms by which TDF damages renal proximal tubules. The first 
proposed mechanism is premised on the possible interaction between TDF and 
organic anion transporters, code-named human organic ion transporter 1 and 3 
(hOAT1 and hOAT3), which transport ions across renal tubular cells (See Figure 
2.4). Researchers have come to realise that TDF affects hOAT1 more than it does 
on OAT3 (Herlitz, Mohan, Stokes, Radhakrishnan, D'Agati & Markowitz, 2010).  
The second proposed mechanism is based on the possible interaction between TDF 
and mitochondrial DNA polymerase γ. Due to the abundance of mitochondria in 
renal tubular cells and proximity of the mitochondria to the organic anion 
transporters, TDF is likely to enter mitochondria and cause damage. Tenofovir may 
decrease mtDNA content by inhibiting mitochondrial DNA polymerase gamma (γ) 
(POLG in Figure 2.4) resulting in mitochondrial injury which may lead to premature 
death of the tubular cell (apoptosis).  
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Figure 2.4: Proposed mechanism of TDF renal toxicity.  
OAT = organic ion transporter; POLG = mitochondrial DNA polymerase γ; CytC = 
Cytochrome C; mtDNA = mitochondrial DNA; AIF = Apoptosis-inducing factor 
(Fernandez-Fernandez et al., 2011). 
The resultant apoptosis is thought to be mediated by enzymes of the respiratory 
chain such as cytochrome C which are released in response to mitochondrial stress. 
Cytochrome C is believed to trigger pro-apoptotic events when released into the 
cytosol (Ow, Green, Hao & Mak, 2008). Following the release of cytochrome C, 
some form of diffuse cytoplasmic injury is noticeable on lysosomes and other 
organelles. The alpha-glutathione S-transferase (α-glutathione S-transferase) 
enzyme has also been put forward as a potential biomarker of the diffuse 
cytoplasmic injury on renal tubular cells (Maggi et al., 2012) 
Measuring cytochrome C has been postulated as a plausible means of measuring 
mitochondrial damage (Zager, Johnsos & Hanson, 2004). Following mitochondrial 
damage, levels of urinary cytochrome C increases and may save as a marker of 
mitochondrial damage. Maggi et al. (2012) recently demonstrated the concept of 
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detecting mitochondrial damage and tubular cell necrosis by measuring urinary 
cytochrome C and α-glutathione S-transferase respectively. Although no decisive 
pattern could be observed for α-glutathione S-transferase, patients on TDF-based 
ART had a low-level increase in cytochrome C after 12 months. 
The other problem which exacerbates TDF’s renal toxicity is that there are several 
drugs which interfere with both organic anion transporters and apical membrane 
transporters. The interaction with the transporters results in accumulation of TDF in 
the renal tubular cells. Drugs that interact with the TDF transporters and their effects 
are shown in Table 2.4. 
Given that proximal tubules contribute to drug excretion from the body and that TDF 
interferes with ion transport across renal tubular cells, it is highly likely that TDF can 
lead to the development of renal toxicity. Didanosine and Ritonavir are also known 
to interfere with transport of ions across the tubular cell membranes. As a result, 
TDF taken concomitantly with Didanosine or Ritonavir can result in worse renal 
damage. 
Although the exact intracellular targets in renal tubular cells are not clear, the clinical 
effects of TDF are now better understood. Some authors believe that the depletion 
of mitochondrial DNA results in a compromised respiratory chain and consequently 
dysfunctional metabolic pathways. For instance, impaired respiratory chain results in 
less consumption of reduced adenosine triphosphate (NAD) and reduced flavin 
adenine dinucleotide (FAD). NAD and FAD are end-products of fatty acid oxidation. 
Reduced consumption of NAD and FAD may result in negative feedback and 
accumulation of intracellular triglycerides. 
Typical clinical results of mitochondrial toxicity include liver damage, impaired fat 
distribution, skeletal muscle weakness (myopathy), poly-neuropathy, hypo-
phosphataemia due to a diminished renal phosphate re-absorption and Fanconi’s 
syndrome due to impaired re-absorption of proteins and solutes (Fernandez-
Fernandez et al., 2011). Depending on the affected tissue or organ, mitochondrial 
toxicity may result in deposition of lipids in liver tissues (steatohepatitis). 
Steatohepatitis may result in liver failure and lactic acidosis. 
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Table 2.4:  Drugs that interfere with TDF transporters and the effects of the drugs.  
Transporter  Drug interaction  Effect 
Organic anion 
transporter-1 (hOAT1) 
Probenecid inhibits hOAT1 Probenecid might decrease the renal 
toxicity by  TDF as it is known to 
decrease the renal toxicity of Cidofovir 
 NSAIDs inhibit hOAT1 NSAIDs such as aspirin and Ibuprofen 
are associated with Tenofovir 
nephrotoxicity 
 Acyclovir competes with TDF Acyclovir increases serum 
concentrations of Tenofovir 
 Didanosine (DDI) competes with 
Tenofovir Disoproxil Fumarate 
(TDF) 
Tenofovir increases DDI levels 
Apical membrane 
transporter (MRP-4) 
Probenecid, Dipyridamole and 
NSAIDs inhibit MRP-4 
NSAIDs associated with Tenofovir 
nephrotoxicity 
 Acyclovir and other related 
drugs such as Cidofovir inhibit 
MRP-4 
Acyclovir increases serum 
concentrations of Tenofovir 
Apical membrane 
transporter (MRP-2) 
Ritonavir is transported by MRP-
2 and therefore competes with 
TDF 
Ritonavir increases Tenofovir 
concentration and has been associated 
with Tenofovir nephrotoxicity 
NSAIDs = non-steroidal anti-inflammatory drugs; TDF = Tenofovir Disoproxil Fumarate; DDI = 
Didanosine; hOAT1 = human organic ion transporter (Fernandez-Fernandez et al., 2011). 
It is important to note that Fanconi’s syndrome is one of the most common side 
effects of TDF (Izzedine, Thibault, Valantin, Peytavin, Schneider & Benhamou, 
2010). Classically, Fanconi’s syndrome is characterized by an increased amount of 
phosphate, amino acids and glucose in the urine, and low phosphate levels in the 
blood (Noah, 2012). The urinary loss may manifest clinically in the form of increased 
urination, thirst, tiredness, bone pain or weakness. However, not every decrease in 
blood phosphate levels may be linked to Fanconi’s syndrome as there are other 
causes as well. 
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TDF is also associated with loss of bone mineral density. A two-year follow-up study 
by Luetkemeyer, Havlir & Currier (2010), identified a high rate of pathological bone 
loss over time and a high prevalence of Vitamin D deficiency in the TDF cohort.  
Concerning reversibility of TDF nephrotoxicity, Patel et al. (2010) reported that TDF-
associated renal impairment was reversible in all the patients who had developed 
impaired serum creatinine after taking TDF-containing ART when the patients 
stopped taking TDF. In contrast, a study by Wever, van Agtmael & Carr (2010) 
concluded that TDF-related renal toxicity is not reversible.  
Some researchers believe that TDF-associated renal injury may only be reversed by 
using drug interventions. Recently, some studies on Rosiglitazone, a drug that may 
reverse renal toxicity of TDF have been conducted in rats (Libório, Andrade, 
Pereira, Sanches, Shimizu & Seguro, 2008). Rosiglitazone is known to induce 
expression of ion transporters, thereby rejuvenating the lost renal function in 
patients with damaged kidneys. However, use of the drug in human beings was 
terminated in European markets shortly after the drug was licensed due to the 
association of the drug with cardiovascular problems (Blind, Dunder, De Graeff & 
Abadie, 2011). 
Another drug which has been tried in patients with TDF-associated renal injury is 
Probenecid (Izzedine et al., 2010). Probenecid might decrease the renal toxicity by 
TDF as it is known to decrease the renal toxicity of Cidofovir, a drug closely related 
to TDF (See Table 2.5). Use of Probenecid in reducing TDF nephrotoxicity is 
however limited due to adverse effects of Probenecid (Lalezari, Stagg, 
Kuppermann, Holland, Kramer, Ives, Youle, Robinson, Drew & Jaffe, 1997). The 
search for drug interventions against TDF nephrotoxicity therefore continues. 
2.4.2 Profiles of nucleoside reverse transcriptase inhibitors (NRTIs) other 
than TDF  
Zidovudine (AZT), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), 
Diadnosine (DDI) and Abacavir (ABC) belong to the nucleoside analogue reverse-
transcriptase inhibitor (NRTI) class of antiretroviral drugs (De Clercq, 2004). The 
most important functional group in the structures of AZT, 3TC, ABC, D4T, and FTC 
(See section A in Figure 2.5), is the organic hydroxyl group which can easily be 
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phosphorylated resulting in triphosphate analogues of DNA building blocks such as 
thymidine. Section B in Figure 2.5 shows the structures of non-nucleoside reverse 
transcriptase inhibitors that are reviewed in section 2.4.3. The phosphorylated 
metabolites of the drugs are therefore the active forms of the drugs. 
 
Figure 2.5: Structure of nucleoside reverse transcriptase inhibitors (NRTIs) and 
non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
(De Clercq, 2004). 
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Zidovudine (AZT) is an analogue of thymidine.  AZT inhibits HIV's reverse 
transcriptase, the enzyme that the virus uses to copy RNA into DNA (De Clercq, 
2004). NRTIs such as AZT, being structurally similar to the natural nucleotide 
building blocks of DNA, can block the conversion of viral RNA into proviral DNA. 
The NRTIs however, cannot work unless they are tri-phosphorylated first inside the 
cells (Figure 2.6).  
 
Figure 2.6: Mechanism of action of Zidovudine. 
(De Clercq, 2002). 
The major drawback associated with NRTIs is that the NRTIs also inhibit 
mitochondrial DNA polymerase which results in adverse effects of NRTIs such as 
hyperlactaemia and steatohepatitis. Didanosine and Stavudine are the common 
drugs known to impair mitochondrial function which explains why Stavudine has 
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been discontinued in many parts of the world, including Lesotho (Wilson et al., 
2008). 
Selectivity of AZT emanates from the fact that AZT has more affinity for HIV viral 
DNA polymerase than for human DNA polymerase and also from the fact that 
human cells have the ability to quickly repair their own DNA chains if they are 
broken by AZT whereas HIV does not have that ability (Tomas & Adrian, 2010). 
Moreover, the azido group of AZT which is lipophilic (See Figure 2.6) enables the 
drug to permeate cell membranes of infected cells faster than other ARVs 
(Zimmerman, Mahony & Prus, 1987). Table 2.5 summarises adverse drug reactions 
for AZT and other NRTI drugs; and adverse drug reactions of protease inhibitors 
which are reviewed in section 2.4.4. AZT has to be used in combination with the 
other NRTIs to reduce the chances of drug resistance development. HIV has the 
potential to gain resistance to AZT by mutation of its reverse transcriptase (Re, Bon, 
Monari, Gibellini, Schiavone, Vitone, Chiodo & La Placa, 2003). AZT, like most ART 
drugs, has adverse-effects. 
Lamivudine (3TC) is an analogue of cytidine. It can inhibit HIV-1 or HIV-2 reverse 
transcriptase and also the reverse transcriptase of Hepatitis B virus. The 
mechanism of action for 3TC is similar to that of AZT (Figure 2.6). The active forms 
of 3TC are phosphorylated metabolites that compete for incorporation into HIV viral 
DNA where they competitively inhibit HIV reverse transcriptase enzyme and 
terminate DNA synthesis by blocking the formation of the 5' to 3' phosphodiester 
bond essential for elongation of the DNA chain (De Clercq, 2004). The development 
of resistance to 3TC is due to mutations in the reverse transcriptase gene of HIV 
(Re et al., 2003).  
Stavudine (D4T) is an analogue of thymidine. The active form of the drug, Stavudine 
triphosphate is formed through a process of phosphorylation (De Clercq, 2002). 
Stavudine triphosphate competitively inhibits HIV reverse transcriptase which results 
in termination of DNA synthesis. The most common side effects of D4T are 
peripheral neuropathy, lipoatrophy and lipodystrophy (Table 2.5). In 2009, the WHO 
recommended that countries phase out the use of D4T, and switch to AZT, TDF or 
ABC because of the long-term, irreversible adverse effects of D4T (WHO, 2010).  
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Abacavir (ABC) targets HIV reverse transcriptase enzyme where it acts as a chain 
terminator, following intracellular phosphorylation (De Clercq, 2004). ABC is the 
drug of choice in patients with resistance to AZT (Hawkins, 2010). Prior to initiation 
of ABC, it is recommended that patients be tested for human leukocyte antigen 
(HLA) typing to rule out the likelihood of the patients developing hypersensitivity 
reaction commonly associated with the B*5701 allele (Zolopa & Katz, 2009).  The 
main side effect of ABC, therefore, is severe hypersensitivity and the risk of heart 
attack which in some studies has been reported to be increased by nearly 90%   
(See Table 2.5). ABC may also aggravate liver condition in patients with 
compromised liver function. 
Emtricitabine (FTC) is an analogue of cytidine (De Clercq, 2004). The Food and 
Drug Administration (FDA) agency of the United States approved the use of 
Truvada© which contains FTC and TDF and also Atripla© which contains Efavirenz, 
FTC and TDF. FTC also has activity against Hepatitis B virus (De Clercq, 2004). 
Skin discolouration is the only side-effect which is more common among people 
taking FTC compared with other antiretroviral drugs in clinical trials (Hawkins, 2010). 
FTC is excreted via the kidneys. Abnormal kidney function has been reported in a 
few people receiving FTC. However, there is no significant interaction between the 
FTC and Tenofovir. 
Didanosine (DDI) is a nucleoside analogue of guanosine and is a reverse 
transcriptase inhibitor. The presence of hypoxanthine component attached to the 
sugar ring and not the usual bases used in the synthesis of DNA is what 
differentiates DDI from nucleoside analogues (De Clercq, 2004). Inside the cell, DDI 
is phosphorylated to dideoxyadenosine triphosphate (ddATP) which is the active 
form of the drug. It terminates DNA synthesis by competing with natural 
deoxyadenosine triphosphate (dATP) required for viral reverse transcription (De 
Clercq, 2004). DDI is mainly eliminated through the kidneys (Zapor, 2004). DDI 
interacts with Allopurinol, Indinavir, Ketoconazole, Itraconazole, Ciprofloxacin and 
Delavirdine which explains why co-administration of these drugs is contra-indicated.  
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Table 2.5:  Adverse effects associated with antiretroviral drugs  
ARV class ARV Drugs Adverse drug reactions 
NRTIs Zidovudine (AZT) 
 
Anaemia, elevated MCV, neutropaenia, nausea, headache, 
myalgia, myopathy, hyperlactaemia, steatohepatitis, lipoatrophy 
 Didanosine (DDI) Peripheral neuropathy, pancreatitis, nausea, diarrhoea, 
hyperlactaemia, steatohepatitis. 
 Lamivudine (3TC) Hyperlactaemia, steatohepatitis, Hepatitis B flare if discontinued, 
red blood cell aplasia 
 Stavudine (D4T) Peripheral neuropathy, elevated MCV, hypertriglyceridaemia, 
lipoatrophy, hyperlactaemia and steatohepatitis. 
 Abacavir (ABC) Systemic hypersensitivity reaction, hyperlactaemia, 
steatohepatitis 
 Tenofovir (TDF) Renal failure, decreased mineral density, hyperlactaemia, 
steatohepatitis, hepatitis flare if discontinued. 
 Emtricitabine 
(FTC) 
Headache, nausea, hyperpigmentation, hyperlactaemia, 
steatohepatitis, hepatitis flares if discontinued. 
NNRTIs Nevirapine (NVP) Rash, hepatitis 
 Efavirenz (EFV) Rash, neurosychiatric symptoms, hepatitis, dyslipidaemia 
PIs Nelfinavir Diarrhoea, insulin resistance, dyslipidaemia, hepatitis 
 Indinavir Kidney stones, unconjugated hyperbilirubinaemia, 
gastrointestinal (GI) upset, hair loss, insulin resistance, 
dyslipidaemia 
 Ritonavir Poorly tolerated and rarely used as sole PI in adults, GI upset, 
hepatitis, taste perversion, insulin resistance, and dyslipidaemia. 
 Saquinavir Mild GI upset, headache, hepatitis, insulin resistance, 
dyslipidaemia 
 Atazanavir Unconjugated hyperbilirubinaemia, GI upset, insulin resistance, 
dyslipidaemia, 
 Fosamprenavir Rash, GI upset, hepatitis,  insulin resistance, dyslipidaemia 
 Lopinavir/ritonavir GI upset, hepatitis, insulin resistance, dyslipidaemia. 
MCV = Mean Cell Volume, GI = Gastrointestinal (Wilson et al., 2008). 
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2.4.3 Profiles of non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Nevirapine (NVP) and Efavirenz (EFV) are non-nucleoside reverse transcriptase 
inhibitors (See Figure 2.5) that inhibit the same enzyme target, the reverse 
transcriptase (De Clercq, 2004). The main difference between the nucleoside and 
the non-nucleoside reverse transcriptase inhibitors is that unlike NRTIs, which bind 
at the enzyme's active site, NNRTIs bind at another site away from the active site 
generally known as the NNRTI pocket (De Clercq, 2004). NVP and EFV are not 
effective against HIV-2, because the pocket of HIV-2 reverse transcriptase has a 
different structure. As with other ART drugs, HIV quickly develops drug resistance if 
NVP is not used in combinations with three or more antiretroviral drugs.  
NVP and EFV are widely available in Southern Africa. Whereas, NVP and EFV 
commonly cause hypersensitivity rashes and hepatitis, NVP causes more severe 
rashes and hepatitis. EFV is well known to cause neuropsychiatric symptoms such 
as insomnia and dizziness. Moreover, EFV is thought to have teratogenic potential 
which may cause congenital deformities such as neural tube defects (Wilson et al., 
2008).  
Anti-tuberculosis drugs especially Rifampicin significantly lower Nevirapine levels 
(Niemi, Backman, Fromm, Neuvonen & Kivistö, 2003). Rifampicin and NVP can 
induce the activity of cytochrome P450 enzymes in the liver (Niemi et al., 2003). The 
two drugs should therefore not be administered concurrently. Manosuthi, 
Tantanathip, Chimsuntorn, Eampokarap, Thongyen, Nilkamhang & Sungkanuparph 
(2010a), however recommended that NVP-based ART is an option for HIV-infected 
patients who receive Rifampicin in resource limited countries especially those who 
cannot tolerate EFV.  
The World Health Organisation approved the use of Nevirapine prophylaxis in many 
developing countries as a way of reducing mother-to-child transmission of HIV 
(Guay, Musoke, Fleming, Bagenda, Allen, Nakabiito, Sherman, Bakaki, Ducar, 
Deseyve, Emel, Mirochnick, Fowler, Mofenson, Miotti, Dransfield, Bray, Mmiro & 
Jackson, 1999). According to Guay et al. (1999), Nevirapine can reduce the rate of 
HIV transmission by almost 50% compared with a short course of Zidovudine (AZT) 
prophylaxis. However, some researchers are concerned that NNRTI resistance, 
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commonly observed in both mothers and infants after they are given Nevirapine, 
may compromise the response to future regimens containing NNRTIs (Eshleman, 
Mracna, Guay, Deseyve, Cunningham, Mirochnick, Musoke, Fleming, Glenn Fowler, 
Mofenson, Mmiro & Jackson, 2001).  
EFV in combination with TDF/ 3TC or AZT/ 3TC is recommended in treatment-naïve 
patients in adults and adolescents (De Clercq, 2004). EFV is metabolised by the 
liver, and is both a substrate and inducer of the cytochrome P450 system (Zapor, 
2004). EFV may therefore interact with other drugs metabolised in the liver. For 
example, EFV lowers blood levels of most protease inhibitors such as Amprenavir, 
Atazanavir, Indinavir or Saquinavir. This can result in incomplete inhibition of viral 
replication, which can allow multi-drug resistant viruses to evolve. The other NNRTI, 
Delavirdine, is rarely used due to its comparatively less potency and inconvenient 
dosage requirements (Zolopa & Katz, 2009). 
It is important to understand the role played by cytochrome 450 in drug metabolism 
because the cytochrome P450 enzymes are central to drug metabolism 
(Guengerich, 2008). The cytochrome P450 enzymes are haemo-protein enzymes 
because they contain a haeme iron centre. The cytochrome P450 enzymes catalyse 
the oxidation of organic substances such as lipids, steroidal hormones, and drugs.  
Drugs may induce cytochrome P450 enzymes through the biosynthesis of an iso-
enzyme or inhibit cytochrome P450 enzymes by direct enzyme inhibition 
(Guengerich, 2008). It is important to note that this is a major source of adverse 
drug interactions, since changes in cytochrome P450 enzyme activity may affect the 
metabolism and hence the clearance of drugs. Typically, if one drug inhibits the 
cytochrome P450 enzyme-mediated metabolism of one drug, the second drug may 
accumulate within the body resulting in toxicity. 
2.4.4 Profiles of Protease Inhibitors 
HIV-1 protease is an aspartic acid protease (Collier & Squires, 2003). HIV protease 
is an enzyme that consists of two 99 amino acid chains non-covalently bound 
together. The HIV-1 protease plays a crucial role in cleaving small proteins from the 
HIV-1’s polyprotein precursor known as group-specific antigens (Gag). This cleaving 
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step allows the creation of structural and enzymatic proteins such as p24 and p17 
which are crucial for the formation of mature virions (Collier & Squires, 2003).  
Most HIV-1 PIs (see Figure 2.7) are transition state analogues of HIV-1 protease 
meaning that they are structurally similar to substrate molecules normally acted 
upon by HIV-1 protease.  
 
  
 Saquinavir Ritonavir Indinavir 
 
  
 Amprenavir Tipranavir Fosamprenavir 
 
 
 
Nelfinavir Darunavir Lopinavir 
 
  
Atazanavir   
Figure 2.7: Structures of Protease Inhibitors. 
(De Clercq, 2004). 
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Besides Tipranavir, all PIs are peptidomimetic which means that PIs contain 
hydroxyethylene scaffolds which can mimic the normal peptide linkage that is 
normally cleaved by the HIV protease. If the HIV-1 protease is inhibited, ineffective 
viral proteins are produced (De Clercq, 2009). 
Saquinavir is a hydroxyethylamine transition state analogue of HIV-1 protease 
(Collier & Squires, 2003). Saquinavir can act against HIV-1 and HIV-2 (De Clercq, 
2004). Interestingly, most PIs, including Saquinavir, are metabolised by the 
cytochrome P450 system which means besides inhibiting and inducing various 
cytochrome P450 enzymes, the PIs are also associated with various drug-
interactions (Zolopa & Katz, 2009). Detailed information on adverse effects 
commonly associated with PIs is shown in Table 2.5. The most common adverse 
effects of protease inhibitors (PIs) are insulin resistance, dyslipidaemia, and 
gastrointestinal disturbances usually associated with nausea, vomiting and 
diarrhoea. Increased risk of myocardial infarction has also been noted among 
patients on PIs (Wilson et al., 2008). 
Ritonavir’s mechanism of action is similar to Saquinavir. However, Ritonavir is less 
effective against HIV-2 (Danner, 2003). Significant gastrointestinal adverse effects 
and the requirement for multiple dosages are the main drawbacks of Ritonavir. 
However, being a strong inhibitor of the cytochrome P450 enzymes, Ritonavir is 
usually used in a combination with other protease inhibitors such as Indinavir and 
Saquinavir for pharmacokinetic boosting (Danner, 2003). Small doses of Ritonavir 
increase plasma concentration and prolong half-lives of other PIs. For this reason, 
Ritonavir is normally combined in formulations with other PIs such as in 
Lopinavir/ritonavir formulations. The Lopinavir/ritonavir formulation is available for 
second line therapy in Lesotho. Unfortunately, Ritonavir-boosting of PIs increases 
the risk of adverse effects such as insulin resistance and dyslipidaemia (Wilson et 
al., 2008). 
Indinavir, a hydroxyethylene HIV-1 protease inhibitor, is a molecular analogue of 
phenylalanine-proline cleavage sites of HIV-1 Gag-polyproteins. Indinavir is 
normally given in combination with Ritonavir (Gulick, 2003). Indinavir causes 
nephrotoxicity and is also known to cause kidney stones (Zolopa & Katz, 2009). Due 
to these reasons, the drug has since been discontinued in many parts of the world. 
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Nelfinavir was one of the first protease inhibitors to be used for treatment of 
pediatric HIV infection (Haubrich & Havlir, 2003). Another protease inhibitor, 
Amprenavir, has fewer chiral centres and therefore is easier to synthesise and is 
more soluble in aqueous solvents giving it a better oral bioavailability. However, 
Amprenavir has since been replaced by its prodrug, Fosamprenavir, because 
Fosamprenavir is rapidly and extensively metabolised and has an even better 
solubility and bioavailability than Amprenavir (Brunton LL, Parker KL, Blumenthal 
DK, & Buxton, 2008). Darunavir is a non-peptidic analogue of Amprenavir, with a 
change in the terminal tetrahydrofuran group. Darunavir is more effective in binding 
with the HIV protease (Murphy, 2003). 
Lopinavir is structurally identical to Ritonavir. Lopinavir is normally co-formulated 
with Ritonavir under the trade name Kaletra. Lopinavir is known for its activity 
against Ritonavir resistant isolates HIV-1 (Johnson & Kuritzkes, 2003) 
Atazanavir’s mechanism of action is similar to Saquinavir (De Clercq, 2004). 
Atazanavir has better drug resistance profile than the other HIV protease inhibitors. 
However, Atazanavir has been associated with the development of kidney stones 
(Chan-Tack, Struble & Birnkrant, 2007; Gérard et al., 2007). The kidney stones may 
result from the fact that about 7% of Atazanavir is normally excreted unchanged in 
urine (Chan-Tack et al., 2007). Atazanavir combined with Ritonavir is one other 
second line ARV formulation available in Lesotho.  
The other PI, Tipranavir, is a non-peptidic HIV-1 protease inhibitor whose activity is 
based on a different principle termed ―coumarin scaffold‖ (De Clercq, 2009). 
Tipranavir has broad antiretroviral activity against HIV-1 strains, including resistant 
strains (De Clercq, 2009). 
2.4.5 Profiles of other antiretroviral drugs 
Apart from the ART drugs mentioned and profiled so far, numerous other drugs 
which still fall in the classic categories of NRTI, NNRTI, PIs, integrase inhibitors 
such as Raltegravir and entry inhibitors which include fusion inhibitors and 
chemokine co-receptor 5 (CCR5) antagonists are in development. However, despite 
the impressive dynamics of antiretroviral drug research and experimentation in more 
Chapter 2:  Literature Review 
 
48 
 
affluent countries, the number of PIs used in resource limited countries such as 
Lesotho remains minimal. For instance, only three PIs are available in Lesotho, 
which are Lopinavir and Atazanavir co-formulated with Ritonavir (Table 2.1). The 
reason is due to the high costs of acquisition and laboratory monitoring required for 
some of the PI drugs (Wilson et al., 2008). For instance, Maraviroc, a CCR5 
receptor antagonist can only be used after determining chemokine receptor tropism 
in the patient because the drug is only effective against CCR5-tropic HIV (Zolopa & 
Katz, 2009; Wilson et al., 2008). Another entry inhibitor is Enfuvirtide, which is 
expensive and requires daily injections (Tortora, Funke & Case, 2012) 
Maturation inhibitors inhibit the conversion of a precursor of capsid protein to mature 
capsid protein, resulting in a dysfunctional capsid that makes the virus non-
infectious (Tortora, Funke & Case, 2012). Other potential drugs are Tetherins, which 
fix the newly formed virus to the cell, preventing its release and spread to other cells 
(Tortora, Funke & Case, 2012). It is important to note that most desirable ARVs 
would be drugs that can eradicate the virus in its dormant stage in the latent 
reservoirs. 
2.5 Essential Laboratory Tests and the Associated Physiological 
Principles for Initiating and Monitoring Patients on ART  
Monitoring treatment progress in patients on ART is a challenging task especially in 
areas where access to crucial laboratory tests are often very limited. Accurate 
interpretation of the laboratory tests required for monitoring patients on ART 
depends on the extent to which one understands the physiological principles 
associated with the tests. Therefore, it was important to review the current methods 
of assessing various physiological systems pertinent to the monitoring of HIV 
treatment such as renal, liver, and pancreatic function; the diagnosis and 
management of diabetes and hypertension; and lipid profile. Diagnostic methods for 
hypertension and diabetes, as well as treatment methods were included in this 
section because of their relevance to the themes of the study. 
To clarify the utility and limitations of the CD4 counts, a detailed account of the 
immunological role played by CD4 cells and the methods of assessing CD4 counts 
was necessary. It was also necessary to review current perspectives on HIV’s 
unique structure, pathogenicity, and the laboratory tests for detecting drug 
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resistance to ARVs because of the scale of the literature concepts pertinent to the 
study.  
2.5.1 Full blood count and the diagnosis of haematological abnormalities 
The full blood count or complete blood count directly measures four parameters: red 
blood cell count (RBC count), haemoglobin concentration, mean corpuscular volume 
(MCV) and red blood cell distribution width (RDW); and derives other parameters  
such as haematocrit, mean cell haemoglobin (MCH) and mean cell haemoglobin 
concentration (MCHC) from the parameters directly measured (Hoffbrand, Moss & 
Pettit, 2006). The full blood count is essential in monitoring patients on ART 
especially for detection of anaemia, opportunistic infections and other 
haematological abnormalities that are common in HIV patients. Anaemia, being the 
most common haematological abnormality, has to be checked often and managed if 
diagnosed in HIV patients (Wilson et al., 2008).  
Few studies from Southern Africa address the region’s ethnic and geographical 
diversity with respect to haematological reference ranges. Table 2.6 presents 
haematological reference ranges for people of the Basotho lineage (Lawrie, 
Coetzee, Becker, Mahlangu, Stevens & Glencross, 2009). The reference ranges of 
platelet count are in people of Basotho lineage are still to be determined. However, 
according to WHO, (2008), the cutoff value of normal haemoglobin range in non-
pregnant women is 11.0 x 1012/l and 13.0 x 1012/l for men aged 15 or older. 
Anaemia type is usually diagnosed from red blood cell size or from the evaluation of 
red blood cell production, destruction and loss (Hoffbrand et al, 2006). Microcytic 
anaemia is indicated if red blood cells are smaller than 80 fermito-litres (fl). 
Normocytic anaemia is given as the diagnosis if the red blood cells are between 80 
and 100 fl in size and macrocytic anaemia is indicated if red blood cells are larger 
than 100 fl. Causes of normocytic anaemia include acute blood loss, aplastic 
anaemia, anaemia of chronic disease and haemolytic anaemia (Hoffbrand et al, 
2006). 
The use of MCV to diagnose anaemia is advantagious in that it quickly exposes 
some of the common causes of anaemia; for instance, a microcytic anaemia is often 
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the result of iron deficiency (Hoffbrand et al, 2006). Macrocytosis, which is the result 
of a disruption to the division and maturing of pro-erythroblasts in the bone marrow, 
is usually due to vitamin B12 and folic acid deficiency (Hoffbrand et al, 2006). 
Macrocytosis is uncommon in HIV except in patients on AZT (Mitsuyasu, 2003). 
Table 2.6:  Haematological reference ranges for people of Basotho lineage.  
Haematological parameter Male Female 
Red blood cell count (RBC) (1012/l) 4.49-5.90  3.85-5.25 
Haemoglobin (HGB) (g/dl) 13.7-17.8  11.7-16.0 
White blood cell count (WBC) (109/l) 2.53-8.43  2.90-9.10 
Haematocrit (HCT) (l/l) 0.41-0.52  0.35-0.47 
Mean cell volume (MCV) (fl) 81-99                        81-99 
Mean cell haemoglobin (MCH) (pg) 27.2-33.6                  27.2-33.6 
Mean cell haemoglobin concentration (MCHC) (g/dl) 32.1-35.5                  32.1-35.5 
Platelet concentration (109/l)a 137-373   178-400 
Neutrophils (109/l) 0.958-6.403              0.958-6.403 
Lymphocytes (109/l) 1.012-2.972 0.840-3.256 
Monocytes (109/l) 0.082-0.607              0.082-0.607 
Eosinophils (109/l) 0-0.276                     0-0.276 
a = Platelet concentration values were adapted from the South African National Health Laboratory 
Service; fl = femto-litre; pg = pico-gramme (Lawrie et al., 2009). 
A systematic approach to entangling the cause of anaemia as presented in Figure 
2.8 is useful before attempts to treat anaemia are taken. Although the suggested 
methods of further classifying the type of anaemia and treatments look simple in 
Figure 2.8, many cases of anaemia in African settings are not fully investigated due 
to resource limitations. For example, few health centres and hospitals have 
laboratories with the capacity to process bone marrow aspirate biopsy and few 
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patients have access to hormone therapy such as erythropoietin. Low levels of 
vitamin B12 and folate are a common occurrence in HIV patients and giving vitamin 
B12 and folate supplements may correct some of the abnormalities (Wilson et al., 
2008). 
 
Figure 2.8: Evaluation of anaemia in HIV infection.  
EPO = erythropoietin, GI = gastrointestinal, Hb = haemoglobin (Mitsuyasu, 2003). 
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Classifying anaemia by evaluating production, destruction or loss of red blood cells 
needs the reticulocyte count results. Reticulocyte count is usually used to 
differentiate decreased red blood cell production from increased red blood cell 
destruction. Increased reticulocyte count may therefore indicate haemolysis. Lactate 
dehydrogenase (LDH) may also indicate cell destruction or bleeding (Hoffbrand et 
al, 2006). 
Anaemia in HIV is typical of the anaemia of chronic disease (ACD) phenomenon. 
The anaemia in HIV and AIDS is usually normochromic and normocytic with low 
reticulocyte count (Mitsuyasu, 2003). Chronic infections are known to result in 
cytokine-mediated sequestration of iron in macrophages (Wilson et al., 2008). 
Cytokines increase the release of hepcidin from hepatocytes. The cytokines that 
increase hepcidin release are interleukin-1, interleukin-6 and tumour necrosis factor-
α. The released hepcidin is thought to result in the destruction of a transmembrane 
transporter protein known as ferroportin in macrophages. The resultant limited iron 
availability restricts growth of microorganisms (Wilson et al., 2008). 
Iron studies are not readily available in resource limited settings such as Lesotho. 
Despite this, the mean haemoglobin concentration (MHC) can confirm iron 
deficiency anaemia. For example, if the MHC is very low and there are signs of 
cytokine-mediated weight loss, fever, and active infections, iron supplements may 
be given and haemoglobin response assessed after two weeks (Wilson et al., 2008). 
Other common findings in HIV patients include low white cell count (leucopaenia) 
involving neutrocytes, lymphocytes, and monocytes (Wilson et al., 2008). Atypical 
lymphocytes may also occur. Neutropaenia is usually associated with drugs such as 
AZT and D4T. Severe lymphopaenia signals advanced HIV and AIDS disease 
stages. Low platelet count is usually characterised by platelet destruction and 
disseminated intravascular coagulation. Impaired making of platelets due to stem 
cell damage coupled with altered reticulo-endothelial dysfunction are some of the 
factors which are thought to contribute to the thrombopaenia (Wilson et al., 2008).  
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2.5.2 Liver function tests and the diagnosis of liver disease 
Although total liver failure is rare, liver toxicity related to the use of ARVs is a 
significant cause of death among HIV-infected patients (Joshi, O'Grady, Dieterich, 
Gazzard & Agarwal, 2011). According to Price & Thio, (2010), the prevalence of 
severe hepatotoxicity among HIV patients on ARVs is as high as 10% of the 
patients.  
Hepatotoxicity may occur through several mechanisms, including hypersensitivity 
reaction, direct toxicity, mitochondrial toxicity and immune reconstitution. 
Hypersensitivity reaction has been associated with the use of NVP (Sulkowski, 
Thomas, Mehta, Chaisson & Moore, 2002), ABC and Maraviroc (Joshi et al., 2011). 
NNRTIs can also cause direct toxicity on the liver (Price & Thio, 2010). Nucleoside 
analogs may lead to mitochondrial toxicity. One other cause is immune 
reconstitution syndrome while on ART, is associated with increased cytolytic activity 
against Hepatitis virus infected liver cells, a decline in HIV RNA and an increase in 
CD4 T cell count (Price & Thio, 2010). 
As a general rule, patients with pre-existing liver disease need strict monitoring 
when taking high risk ARVs. Risk factors for severe hepatotoxicity while on ART 
include elevated liver enzymes before initiating treatment, chronic Hepatitis B or C, 
and concomitant hepatotoxic medication. Use of protease inhibitors such as 
Lopinavir, Ritonavir, Indinavir, Tipranavir and Atazanavir has also been associated 
with hepatotoxicity (Chan-Tack, Struble & Birnkrant, 2008; Torti, Lapadula, Antinori, 
Quirino, Maserati, Castelnuovo, Maggiolo, De Luca, Paraninfo, Antonucci, 
Migliorino, Lazzarin, Di Perri, Rizzardini, Esposito & Carosi, 2009). Atazanavir and 
Indinavir inhibit the hepatic enzyme uridine diphospho-glucuronosyl transferase 
(UDP-glucuronosyl transferase), increasing the level of bilirubin in up to 50% of 
patients (Torti et al., 2009). Although, the mechanisms of hepatotoxicity for protease 
inhibitors such as Tipranavir boosted with Ritonavir (Tipranavir/r) are not clear, use 
of Tipranavir/r has been associated with transaminase elevations (Chan-Tack, 
Struble & Birnkrant, 2008). Other factors mentioned in the literature include older 
age, obesity, female gender, thrombocytopenia, high alcohol intake, increased viral 
load and even renal dysfunction (Servoss, Kitch, Andersen, Reisler, Chung & 
Robbins, 2006; Nunez & Soriano, 2005).  
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Liver function tests (LFTs) are tests designed to ascertain the state or cause of liver 
disease. LFTs can be used to monitor ART drugs because some of the ART drugs 
may cause liver damage. LFTs are generally indicated in HIV patients who are 
beginning hepatotoxic ART regimens such as Nevirapine and Stavudine-containing 
ART regimens. LFTs are also indicated in HIV patients with a history of liver disease 
and in patients with signs of hepatomegaly (Wilson et al., 2008). Wilson et al. (2008) 
recommended that Hepatitis B and C should be screened before ART is initiated 
and may be routinely checked if resources permit.  
Liver disease is classified into two categories of injury: cell necrosis and cholestasis 
(Burke, 2002; Chung & Sherman, 2003). Cell necrosis is further classified into acute 
or chronic type. Whereas viral hepatitis, toxic hepatitis, alcoholic hepatitis and 
ischaemic necrosis are classified under acute necrosis, chronic active hepatitis, 
autoimmune hepatitis and cirrhosis are classified under chronic cell necrosis. 
Cholestasis may be intra-hepatic or extra-hepatic.  
Albumin, whose main functions are to maintain osmotic balance in the vascular 
space and to transport minerals in the blood such as calcium, is used to assess liver 
function. Elevated albumin indicates dehydration whilst low albumin indicates liver 
dysfunction (Burke, 2002). High concentrations of albumin in urine usually signify 
chronic liver diseases such as nephrotic syndrome. 
Alkaline phosphatase (ALP) is a liver enzyme found primarily in liver cells 
particularly the liver cells lining the biliary ducts. Elevated ALP levels usually indicate 
cholestatic injury, bile duct obstruction or intrahepatic cholestasis (Burke, 2002).  
The enzyme alanine transaminase (ALT) or alanine aminotransferase (ALAT) is 
primarily found in the cytoplasm of hepatocytes. ALT is regarded as the most 
sensitive and specific test for hepatocellular injury (Chung & Sherman, 2003). 
Raised ALT levels in the blood may indicate the occurrence of damaged liver tissue. 
Liver tissue damage may occur as a result of many causes, including drug toxicity, 
and obstructed bile ducts or cirrhosis of the liver. ALT should however be interpreted 
in conjunction with other LFTs. 
Aspartate transaminase (AST) or aspartate aminotransferase (ASAT) is produced 
by liver parenchymal cells, muscle cells and red blood cells. Raised AST levels in 
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blood indicate increased red blood cell destruction, acute liver damage, and cardiac 
or skeletal muscle damage. AST is therefore not a specific indicator of liver damage 
or disease. However, using the ratio of AST to ALT may increase the diagnostic 
accuracy of both ALT and AST (Chung & Sherman, 2003). 
The liver processes bilirubin by conjugating it and secreting it into bile, which is 
finally excreted into the intestines (Burke, 2002). Bilirubin, which is one of the 
breakdown products of haeme, is formed during the destruction of red blood cells. In 
liver disease bilirubin is not processed. The unprocessed bilirubin accumulates in 
the body, causing a condition called jaundice which is characterised by dark urine 
and yellowing of the skin or eyes.  
If the level of unconjugated bilirubin is high, then the cause of liver disease is most 
likely to be located in pre-hepatic areas of the blood stream. Typical causes of high 
levels of unconjugated bilirubin include haemolysis, viral hepatitis, or liver cirrhosis. 
Conjugated bilirubin is normally elevated in cases where the liver is able to 
conjugate bilirubin but is not able to excrete the conjugated bilirubin due to bile duct 
obstruction (Burke, 2002). 
Gamma glutamyl transpeptidase (GGT) is reasonably specific to the liver and is 
generally regarded as a better indicator of cholestatic damage than other LFTs such 
as ALP. High levels of GGT are synonymous with chronic alcohol toxicity and drug-
induced cholestatis (Chung & Sherman, 2003). GGT may be elevated even with 
minor damage of the liver. GGT is also crucial in identification of the causes of 
elevated ALP. 
Hepatitis B and C are important liver diseases in the management of HIV patients. 
Hepatitis B or C co-infection in HIV patients is common in Southern Africa. Whereas 
Hepatitis B virus – HIV (HBV/HIV) co-infection may be as high as 10% or more in 
HIV positive patients, Hepatitis C co-infection with HIV is relatively less prevalent 
(Kapembwa, Goldman, Lakhi, Banda, Bowa, Vermund, Mulenga, Chama & Chi, 
2011; Patel, Davis, Tolle, Mabikwa & Anabwani, 2011; Mayaphi, Roussow, 
Masemola, Olorunju, Mphahlele & Martin, 2012). Some researchers have stated 
that there is a need for monitoring liver disease in HIV patients in Africa (Rockstroh, 
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Peters & Wedemeyer, 2011). Hence, a short review of current methods for 
diagnosis of viral Hepatitis infections especially Hepatitis B and C is important. 
Hepatitis B infection is a serious disease caused by Hepatitis B virus (HBV). HBV 
infects the liver causing chronic liver problems. HIV/HBV co-infection complicates 
the management of ARVs. Diagnosis of acute HBV infection is based on the 
presence of immunoglobulin M (IgM) antibodies to Hepatitis B core antigens (anti-
HBc) or the presence of Hepatitis B surface antigens (HBsAg). HBV can also persist 
as a chronic infection. Diagnosis of chronic HBV infection is based on the absence 
of anti-HBc IgM antibodies and the presence of HBsAg, Hepatitis e antigen (HBeAg) 
or HBV DNA (Pincus, Tierno, Fenelus, Bowne, Bluth, 2011). 
2.5.3 The renal system and methods of assessing renal function 
2.5.3.1 Structure and function of the renal system 
Understanding the structure and function of the kidney gives a better understanding 
of the development of kidney disease. The review of the structure and function of 
the kidney is also crucial for clarification of how the diagnostic methods for kidney 
disease work.  
The main function of the kidney is to regulate the volume and composition of body 
fluids by allowing ultra-filtration of plasma at the glomerulus and reabsorbing some 
of the components of the ultra-filtrate at specific points along the nephron (Barrett, 
Barman, Boitano & Brooks, 2010). The kidney plays a central role in the excretion of 
urea, ammonia and creatinine from the breakdown of protein; uric acid from nucleic 
acids; drugs and toxins.  
The functional unit of the kidney is the nephron (Barrett et al., 2010). Each nephron 
consists of several important fuctional structures that include renal tubules, the 
glomerulus, and Bowman’s capsule as shown in Figure 2.9. It is important to note 
that the kidney cannot regenerate new nephrons when damaged. Therefore, renal 
injury, normal ageing, or disease gradually decreases the number of nephrons. For 
example, the number of functioning nephrons usually decreases about 10% every 
10 years after the age of 40. This means that at age 80, there may be 40% fewer 
nephrons than there were at age 40 (Guyton & Hall, 2011). 
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Figure 2.9: Morphology of the nephron and the associated blood supply.  
(Barrett et al., 2010). 
Different parts of the kidney serve distinct functions (Barrett et al., 2010). The cortex 
produces erythropoietin in response to hypoxia. The medulla, which consists of lipid-
laden interstitial cells, is important in prostaglandin production. The epithelium of the 
collecting ducts is made up of principal cells and intercalated cells. The principal 
cells are involved in sodium reabsorption and vasopressin-stimulated water 
reabsorption. The intercalated cells are involved in acid secretion and bicarbonate 
transport.  
The reabsorption of some of the components of the ultra-filtrate at specific points 
along the nephron is a key function of the kidney. The reabsorption of sodium and 
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chloride ions is crucial for the control of electrolyte and water levels in the body 
(Guyton & Hall, 2011). The transport of sodium is coupled to the movement of H+ 
ions, glucose, amino acids, organic acids, phosphate, and other electrolytes and 
substances across the renal tubule walls. Sodium is reabsorbed through passive 
diffusion and active transport by sodium-potassium-ATPase pumps located in the 
basolateral membranes.  
Kidneys are also important for excretion of calcium and phosphate (Guyton & Hall, 
2011). The most important factor controlling this reabsorption of calcium is 
parathyroid hormone (PTH). Renal phosphate excretion is controlled by the 
concentration of phosphate ions in the plasma through negative feedback 
mechanism and parathyroid hormone (Guyton & Hall, 2011). PTH can directly 
increase the renal excretion of phosphate. The kidney is also essential for vitamin D 
metabolism; it hydroxylates 25-hydroxycholecalciferol to the active form, 1,25-
dihydroxycholecalciferol. The failure of this process contributes to the 
hypocalcaemia and bone disease of chronic renal failure. 
A variety of hormonal and chemical factors affect kidney function. For example, 
adrenocortical steroid hormones such as aldosterone increase sodium reabsorption. 
Prostaglandins such as prostaglandin E2 (PGE2) have an opposite effect to 
aldosterone. PGE2 causes urinary loss of sodium. Angiotensin II acts on proximal 
tubules resulting in increased reabsorption of sodium and bicarbonate. Endothelial-
derived nitric oxide decreases renal vascular resistance, increases renal 
vasodilation and therefore increases GFR. Renin, a protease enzyme, acting 
together with angiotensin-converting enzyme (ACE) in the kidneys convert part of 
the circulating angiotensin I and some of the angiotensin I synthesized in the 
kidneys to angiotensin II (Guyton & Hall, 2011).  
Therefore, the kidney plays a central role in regulation of various plasma 
components. The kidney is also an important gland which produces several 
hormones. Understanding renal function is key to unravelling the causes of renal 
disease, including the effect of TDF. 
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2.5.3.2 Methods of assessing renal function  
Renal function tests are designed to assess the state or cause of kidney disease. 
Glomerular filtration rate (GFR) provides a useful index for assessing renal function 
(Watnick & Dirkx, 2009). GFR is usually estimated by measuring the renal clearance 
of substances that are freely filtered through the glomerulus using the formula: 
Renal clearance of substance Y =  
Where U and P represent urine and plasma concentrations of substance Y, and V 
represents the urine flow rate in ml/min (Watnick & Dirkx, 2009). 
The direct methods for assessing renal function which happen to be the gold 
standard methods for measuring renal clearance use chemicals such as inulin, 
iohexol, 51Cr-EDTA, 99Tc-DTPA, and 125Iodine-labelled iothalamate. These 
substances are expensive, require estimates of body surface area and are not 
readily available (Risch & Huber, 2005; Mouton & Holder, 2006). These substances 
also require intravenous infusion and timed urine collections over a period of several 
hours making it costly and cumbersome. As a result, a number of alternative 
measures for estimating GFR have been devised. 
GFR derived from serum creatinine values is normally used to measure renal 
function in rural settings. Creatinine, serum electrolytes, and blood urea nitrogen 
(BUN) are indirect indicators of renal function. While creatinine and BUN are 
generally adequate in diagnosing the cause of kidney disease, BUN and creatinine 
may not indicate kidney disease until 50% of kidney function is impaired (Risch & 
Huber, 2005). Hence, the most accurate indicators of renal function such as 
glomerular filtration rate estimated by creatinine clearance is measured to assess 
renal function in most cases. 
A low or decreasing GFR as estimated from serum creatinine is generally 
considered to be an indicator of chronic kidney disease though the utility of serum 
creatinine is limited by the inaccuracy of serum creatinine measurement. Serum 
creatinine concentration is affected by age, gender, muscle mass, diet and race 
(Harmoinen et al., 2003; Mouton & Holder, 2006). Serum creatinine values are also 
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affected by haemolysis which can occur if serum is not separated from clotted 
venous blood for more than 16 hours (Ford & Berg, 2008). In more affluent 
countries, serum cystatin C has replaced serum creatinine (Risch & Huber, 2005). 
The use of equations such as Cockcroft-Gault or the modification of diet in renal 
disease (MDRD) formulae in estimating GFR has been shown to give more valid 
estimates of GFR than serum creatinine alone (Froissart, Rossert, Jacquot, Paillard 
& Houillier, 2005). The Cockcroft-Gault formula for calculating GFR is derived from 
serum creatinine values as follows: 
GFR (ml/min) = [(140-age) x weight (kg)]/ [serum creatinine (µmol/l) x 1.23(men) or 
1.04(women)].  
Therefore, in addition to patients’ serum creatinine, the Cockcroft-Gault formula 
incorporates patients’ age, gender and weight.  
Looking closer at the Cockcroft-Gault equation, it becomes clear that the equation is 
dependent on age, weight and gender. People with low body weight, older age and 
female gender will have higher serum creatinine values than people with higher 
body weight, younger age and male gender for the same amount of serum 
creatinine 
The most recently adopted tool for calculating the estimated GFR is the MDRD 
formula. The MDRD equation on the other hand incorporates age, gender and 
ethnicity but not weight (Froissart et al., 2005). The MDRD formula in mg/dl for 
estimating GFR is shown below.  
GFR (ml/min) = 186 X Serum Creatinine-1.154 X Age-0.203 X [1.212 if Black] X [0.742 if 
Female] 
The diagnostic accuracy of the Cockcroft-Gault and MDRD equations has been 
found to be comparable to the accuracy of serum cystatin C (Harmoinen et al., 
2003). However, the MDRD equation has been demonstrated to be more accurate 
in patients of African descent (Levey, Bosch, Lewis, Greene, Rogers & Roth, 1999). 
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The chronic kidney disease epidemiology collaboration (CKD-EPI) published a new 
formula for estimating GFR in 2009 (Levey, Stevens, Schmid, Zhang, Castro, 
Feldman, Kusek, Eggers, Van Lente, Greene & Coresh, 2009) which was expected 
to improve accuracy in estimating GFR. According to Matsushita, Selvin, Bash, 
Astor & Coresh, (2010), the CKD-EPI equation performs better than the MDRD 
equation, especially at higher GFR.  
Another indirect indicator of kidney disease is raised level of protein in urine 
(proteinuria). Albumin is usually the major protein found in chronic kidney disease 
(Mouton & Holder, 2006) although other proteins such as β2-microglobulin 
(Gatanaga 2006) and retinol-binding protein (Del Palacio, Romero & Casado, 2012) 
may also be found. Moreover, β2-microglobulin has been reported to be even more 
sensitive than serum creatinine in detecting damage of renal tubules by TDF 
(Gatanaga 2006). 
Sodium, potassium, chloride and bicarbonate are the four serum electrolytes that 
are crucial in the diagnosis of renal tubular acidosis (Watnick & Dirkx, 2009). Renal 
tubular acidosis which has been identified as the hallmark sign of tenofovir-
associated renal damage (Kohler et al., 2011) is characterised by acidosis and 
electrolyte imbalances (Watnick & Dirkx, 2009). The acidosis and electrolyte 
imbalances are usually a result of impaired renal hydrogen ion excretion, impaired 
bicarbonate re-absorption, or rarely, a result of abnormal production of aldosterone 
hormone. The renal tubules also regulate potassium and sodium levels. Therefore, 
impaired renal tubules can be detected by sodium, potassium, chloride and 
bicarbonate (Watnick & Dirkx, 2009). 
2.5.4 Diagnosis, treatment and classification of hypertension 
Besides serum creatinine, urea and electrolytes; the measurement of blood 
pressure is equally essential for the diagnosis and prognosis of renal disease 
because hypertension is a risk factor of renal disease (Sutters, 2009). Hypertension 
classified into different stages depending on the level of blood pressure. According 
to Chobanian et al. (2003), hypertension stage I is when the measured blood 
pressure >140 mmHg systolic and/or >90 mmHg diastolic. Blood pressure values 
>160 mmHg systolic and/or >100 mmHg diastolic are classified as hypertension 
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stage II (Chobanian et al., 2003). Individuals at high risk of developing hypertension 
(pre-hypertension) have blood pressure measurements >120 mmHg systolic and/or 
>80 mmHg diastolic but falling below the hypertension stage I range.  
Guidelines generally recommend treatment to be initiated with the cheapest and 
most cost-effective drug such as thiazide diuretics unless there are 
contraindications. Thiazides such as Hydrochlorothiazide are examples of diuretic 
drugs that may be used to control hypertension. Thiazides lower blood pressure 
initially by decreasing plasma volume, and have also been associated with the 
reduction of peripheral vascular resistance in the long term (Sutters, 2009). Diuretics 
on their own may not be adequate to control hypertension, hence β-blockers such 
as Atenolol, and ACE inhibitors (angiotensin-converting enzyme inhibitors) such as 
Captopril may be used in combination with the diuretic drugs (British National 
Formulary (BNF), 2006).  
ACE inhibitors primarily act by inhibiting the renin–angiotensin–aldosterone system. 
β-blockers (β-adrenergic blocking agents) act through decreasing the heart rate and 
cardiac output (Sutters, 2009). Angiotensin-II receptor antagonists may be used in 
cases where ACE inhibitors are contraindicated. Calcium-channel blockers such as 
Nifedipine may also be used where thiazides are contraindicated. In principle, 
calcium-channel blockers act by increasing peripheral vasodilation.  
In cases where hypertension is resistant to treatment, α-blockers may also be used 
in combination with other antihypertensive drugs. Again in principle, α-blockers such 
as Prazosin reduce blood pressure by lowering peripheral vascular resistance. 
Antihypertensive drugs also include drugs that lower blood pressure by stimulating 
the α-adrenergic receptors in the central nervous system, thus reducing efferent 
peripheral blood flow. Examples of such drugs include Methyldopa which is also 
known as Aldomate. Drug treatment for hypertension has many challenges due to 
contraindications in many disease conditions and age restrictions. For example, 
thiazides are contraindicated in gout (BNF, 2006). 
Treatment for hypertension is usually done by using a combination of drugs. Use of 
two or more drugs allows lower dosages to be used while achieving the desired 
effect. Low dosages minimise adverse reactions. Appropriate combinations include: 
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a diuretic with a β-blocker, an ACE inhibitor, or an angiotensin II receptor antagonist; 
and a calcium-channel blocker plus either an ACE inhibitor, an angiotensin II 
receptor antagonist, or a β-blocker. Alpha blockers may be used with any of the 
other classes but are usually reserved for third-line therapy unless specifically 
indicated for some reason. 
Some anti-hypertensive drugs have been associated with renal toxicity. Although it 
is not clear whether the toxicities are dose-dependent or not, long term use of some 
anti-hypertensive drugs may accelerate renal damage. Typical anti-hypertensive 
drugs that are potentially nephrotoxic include Captopril, Atenolol, and Nifedipine. 
Furosemide has also been included in the list of potentially nephrotoxic drugs (BNF, 
2006).   
Researchers have identified various possible risk factors and causes of 
hypertension which may be ascertained through laboratory tests and clinical 
examinations. Some of the possible causes of hypertension include chronic kidney 
disease, Cushing syndrome and pheochromocytoma. Whereas Cushing syndrome 
is a disorder resulting from increased adrenocortical secretion of cortisol, 
pheochromocytoma is a rare catecholamine-secreting hypertension-associated 
tumour of the adrenal medulla. Other possible causes of hypertension include 
excessive secretion of aldosterone hormone, thyroid and parathyroid disease.  
Hypertension may also be caused by certain drugs such as nonsteroidal anti-
inflammatory drugs (NSAIDs) and chemicals such as sodium and ethanol.  
Laboratory tests such as electrocardiogram (ECG) and other tests for metabolic 
states such urinalysis, creatinine, blood glucose, including GFR, potassium and lipid 
profiles, are recommended before initiating anti-hypertensive drugs in order to 
identify the cause. Interestingly, reduced GFR indicates a poor prognosis for 
hypertension and has been associated with increased risk of cardiovascular disease 
(Mann, Gerstein, Pogue, Bosch & Yusuf, 2001).  
2.5.5 Diagnosis, treatment, classification, and clinical effects of diabetes 
mellitus 
Diabetes mellitus is a metabolic disease that may result from defects in insulin 
secretion or action which means diabetes mellitus may be caused by insulin 
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deficiency (type I diabetes) or insulin resistance (type II diabetes). Insulin deficiency 
has been associated with autoimmune destruction of the β-cells of the pancreas 
whilst insulin resistance has been associated with inadequate compensatory insulin 
secretory response (American Diabetes Association (ADA), 2009). Insulin is a 
critical hormone that regulates blood glucose levels. Hypertension occurs with twice 
the frequency in the diabetic compared with the non-diabetic population, and up to 
50% of patients with type 2 diabetes mellitus. 
Diabetes mellitus is characterised by hyperglycaemia. Therefore, hyperglycaemia in 
the fasting state or after a challenge with an oral glucose load is used as a 
diagnostic marker of diabetes mellitus. According to guidelines set by the ADA, 
diabetes mellitus is defined as the presence of a non-fasting blood glucose of >11.1 
mmol/l, a fasting blood glucose of >7.0 mmol/l, or blood glucose of >11.1 mmol/l 
during an oral glucose tolerance test normally administered over two hours (ADA, 
2009). Diabetes mellitus is a confounder to analysis of kidney damage associated 
with TDF because the disease is associated with failure of various organs, including 
the kidneys (ADA, 2009). 
Insulin and glucagon, secreted by the pancreas, are the two important hormones 
that regulate blood glucose levels (Guyton & Hall, 2011). The β-cells in the 
pancreatic islets of Langerhans secrete insulin whilst α-cells secrete glucagon.  
Insulin exerts its effect by combining with insulin receptors which trigger intracellular 
cascade of events. Summarily, activated insulin receptors trigger the tyrosine kinase 
activity, which results in phosphorylation of enzymes that catalyse glucose, fat and 
protein metabolism (Guyton & Hall, 2011). The end result is increased cellular 
uptake of glucose, accelerated protein and fat synthesis. The rate of glucose cellular 
uptake is organ and tissue specific. For example, muscle cells, adipose tissue and 
liver cells are more responsive to insulin-activated glucose intake. 
Glucagon, cortisol, growth hormone, progesterone and estrogen are other 
hormones that may increase insulin secretion although progesterone and estrogen 
can do so to a lesser extent (Guyton & Hall, 2011). Therefore, these hormones may 
increase the risk for developing diabetes mellitus through exhaustion of the β-cells 
of the islets of Langerhans. Generally, glucagon opposes the effect of insulin. 
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Typically, glucagon increases the blood glucose concentration when the levels 
become too low. 
The effect of hyperglycaemia is dehydration due to increased osmotic pressure in 
the extracellular fluids. Chronic hyperglycaemia causes tissue injury, including 
kidney tissues. Damage to kidney tissue usually manifests as diabetic nephropathy. 
Retinal damage, heart attacks, peripheral tissue damage, and peripheral nerve 
problems are some of the effects of hyperglycaemia. Another effect of 
hyperglycaemia is the depletion of the body’s proteins and fat.  
Treatment of diabetes mellitus type I is simply done by giving insulin. Several forms 
of therapeutic insulin, which differ mainly in duration of activity, are commercially 
available (Guyton & Hall, 2011). Some long-acting insulin forms are precipitated with 
zinc or protein derivatives to delay absorption and therefore have lasting effects. 
In contrast to type I, type II diabetes is associated with increased plasma insulin 
concentration (Guyton & Hall, 2011). The hyperinsulinaemia occurs as a 
compensatory mechanism for insulin resistance on target cells and tissues. Obesity 
is the main factor which contributes to insulin resistance. Typically, insulin 
resistance triggers a cascade of metabolic disorders collectively known as the 
metabolic syndrome. 
Treatment for type II diabetes may not need the use of drugs.  Dieting and exercise 
may be adequate to induce weight loss and to reverse the insulin resistance 
(Guyton & Hall, 2011). However, drugs such as metformin, thiazolidinediones, and 
sulfonylureas, may be used to increase insulin sensitivity or to stimulate increased 
pancreatic secretion of insulin.  
2.5.6 Lipid profile: Rationale of use in HIV treatment and methods of 
measurement   
Lipid profile is often important in HIV-positive patients with a history of 
cardiovascular disease. HIV has been associated with metabolic syndrome 
characterised by insulin resistance, lipodystrophy and dyslipidaemia (Rasheed, Yan 
& Lau, 2008; Crook, 2007). Dyslipidaemia in HIV patients on ART have been 
associated with exposure to Abacavir and protease inhibitors such as Ritonavir-
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boosted Indinavir (Young, Weber, Rickenbach, Furrer, Bernasconi, Hirschel, Tarr, 
Vernazza, Battegay & Bucher, 2005). Metabolic syndrome is a risk factor for 
hypertension and diabetes which are also risk factors for kidney disease (Bakris, 
2007). Therefore, understanding the rationale of lipid profile in HIV-positive patients 
and the methods of measurement of lipids is crucial for monitoring patients on ART. 
Cholesterol and triglycerides are the two common types of lipids in blood. Lipids are 
usually conjugated to lipoproteins. Lipoproteins contain globular particles known as 
apoproteins. The more the quantity of apoproteins a lipoprotein has, the higher the 
density of the lipoprotein. Conversely, triglycerides decrease the density of 
lipoproteins. In principle, high density lipoproteins (HDL) consist of more apoproteins 
and cholesterol. Low density lipoproteins (LDL) are less dense because they contain 
fewer apoproteins and more cholesterol. Very low density lipoproteins (VLDL) are 
the least in density and they mainly contain triglycerides.  
Lipoproteins may be classified in increasing order of density as: Chylomicrons, 
VLDL, LDL, and HDL. HDL facilitates the transfer of apoproteins among lipoproteins 
and cholesterol into other lipoproteins or directly into the liver. In principle, the higher 
the level of LDL cholesterol, the greater the risk of atherosclerotic heart disease; 
conversely, the higher the HDL cholesterol, the lower the risk (Gazi, Tsimihodimos, 
Filippatos, Saougos, Bairaktari, Tselepis & Elisaf, 2006).  
Triglycerides (TG), total cholesterol and HDL-cholesterol are the measured 
parameters and LDL-cholesterol, non-HDL-cholesterol as well as the ratio of total 
cholesterol: HDL-cholesterol; LDL-cholesterol: HDL-cholesterol; and TG: HDL-
cholesterol. Serum TG and total cholesterol are measured by enzymatic methods. 
Serum HDL-cholesterol is measured following the precipitation of the apoprotein B 
containing chylomicrons and lipoproteins of VLDL and LDL by phosphotungstic acid 
in the presence of magnesium ions. Serum LDL-C is derived from total cholesterol, 
HDL-cholesterol and Serum TG values using various formulae. The formulae were 
recently evaluated by Gazi et al. (2006). However, the Friedewald formula remains 
popular despite the reported limitations of the formula in patients with metabolic 
syndrome (Friedewald & Levy, 1972). The Friedewald formula formula is:  
LDL-C (mg/dl) = total cholesterol – HDL-C – (TG × 0.2) 
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Reference ranges for lipid profiles include total cholesterol <5 mmol/l, LDL 
cholesterol <3 mmol/l, HDL cholesterol in males >1 mmol/l, HDL cholesterol in 
females >1.2 mmol/l, and triglycerides <1.7 mmol/l. 
Extremely high levels of triglycerides have been associated with increased levels of 
chylomicrons or chylomicronaemia (Leaf, 2009). Chylomicronaemia has serious 
consequences, including acute pancreatitis, abdominal pain, lipaemia retinalis, and 
eruptive xanthomata. High levels of triglycerides have been reported in patients on 
protease inhibitors (Duro, Sarmento-Castro, Almeida, Medeiros & Rebelo, 2013). 
The report by Duro et al. (2013) encouraged the use of NNRTI instead of protease 
inhibitors because NNRTI drugs had a better lipid profile compared to protease 
inhibitors.  
2.5.7 Pancreatic enzymes: Rationale; utility; and methods of assessment 
Pancreatic disease presenting with pancreatic lesions is common in HIV-positive 
patients. Acute pancreatitis in HIV-positive patients attracted the attention of 
researchers during the early years of HIV research (Bonacini, 1991). Researchers of 
that time were noticing cases of pancreatitis evidenced by raised serum amylase 
enzyme sometimes associated with raised pancreatic lipase enzymes (Murthy 
DeGregorio, Oates & Blair, 1992).  
Traditionally, the diagnosis of pancreatitis has been based on both clinical features 
such abdominal pain with vomiting and elevation of serum concentrations of 
pancreatic enzymes - amylase and/or lipase (Gomez, Addison, De Rosa, Brooks & 
Cameron, 2012). In principle, a value three times greater than normal has been a 
diagnostic indicator of pancreatitis. Follow-up tests which include radiological 
imaging and CT scans are normally required to rule out possible causes of 
pancreatitis such as alcohol-induced pancreatitis, dyslipidaemia, and gall stones 
which can obstruct the biliary ducts and cause pancreatitis. Typically, obstructed 
biliary ducts would be accompanied by abnormal liver function tests as well. 
Fortunately, modern scanning methods can pin-point the cause of pancreatitis more 
precisely. In some cases, C reactive protein (CRP) levels may also be measured to 
probe the severity of acute pancreatits (Dervenis, Johnson, Bassi, Bradley, Imrie, 
McMahon & Modlin, 1999). 
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The utility of measuring serum amylase and lipase as indicators of pancreatic 
disease in HIV-positive patients was demonstrated by Hancock, Smith, Hawkins, 
Gazzard & Ball (1997) and Gomez et al. (2012). Serum amylase emerged as a 
poorer indicator of pancreatic disease compared to lipase. 
There has been controversy over the role of protease inhibitors in causing acute 
pancreatitis. Although some studies such as by Chapman, Woolley, Visvanathan & 
Korman (2007), implicated protease inhibitors with pancreatitis, Bush & Kosmiski 
(2003) and Riedel, Gebo, Moore & Lucas (2008) did not find the link between 
protease inhibitors and pancreatitis. The link between pancreatitis and protease 
inhibitors was pinned on the fact that protease inhibitors were known to increase 
levels of triglycerides. Increased levels of triglycerides had been associated with 
acute pancreatitis (Bush & Kosmiski, 2003). Other ART drugs that have been 
associated with pancreatitis include Stavudine (Riedel et al., 2008). According to 
Riedel et al. (2008) TDF, Abacavir, and Efavirenz are not associated with an 
increased risk of pancreatitis. ART drug combination of 
Lamivudine/Stavudine/Indinavir has also been associated with pancreatitis 
(Battillocchi, Diana, Dandolo, Stefanini, D'Amore & Negro, 2002). Non-ART drugs 
that may cause pancreatitis include warfarin and hydrochlorothiazide (Battillocchi et 
al., 2002). 
2.5.8 HIV and CD4 cells: Rationale and utility of CD4 counts in monitoring 
HIV treatment 
2.5.8.1 Structure of HIV and its genome 
The human immunodeficiency virus (HIV) is a retrovirus belonging to the lentivirus 
family. Lent is a Latin prefix which signifies slow disease progression (Cochrane, 
2011). Being a retrovirus, HIV has two single-stranded RNA molecules which are 
associated with three enzymes–namely: reverse transcriptase, integrase and 
protease which are necessary for viral DNA and RNA synthesis (Wood, 2006; 
Cochrane, 2011). The structure of HIV is shown in Figure 2.10. 
The nucleocapsid which covers the viral genome consists of p24 protein in the inner 
layer and p17 protein in the outer layer (See nucleocapsid in Figure 2.10). The p24 
is also called the viral matrix protein (MA). The p17 is also called the capsid protein 
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(CA). The CA may form an icosahedral or conical core, depending on the viral 
strain. The viral envelope mainly derived from the host cell is a lipid layer which 
contains spikes of gp41 (also known as the trans-membrane protein or TM) and the 
gp120 (also known as the external surface protein or SU). The gp120 is bound to 
the gp41 by non-covalent interactions (Cochrane, 2011). The gp41 protein traverses 
the lipid bilayer. The notation gp120 stands for a glycoprotein with a molecular 
weight of 120 000 Daltons (Da) (Tortora, Funke & Case, 2012).  
While the reverse transcriptase, the protease, the integrase enzymes, and the 
envelope proteins seem to have structural roles for the virus, there are other 
proteins which have regulatory roles. Six of such proteins with regulatory roles are: 
Vif, Vpu, Vpr, Tat, Rev, and Nef (Cochrane, 2011).  
 
Figure 2.10: Schematic diagram of HIV.  
(Wood, 2006). 
Tracing the proteins back to the genes that code for them unravels more mysteries 
of the virus. The gag-gene codes for structural proteins which include the p24 
proteins, the p17 proteins and other structural proteins (Virella, 2001). The pol-gene 
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codes for the reverse transcriptase. It is also believed that the pol-gene codes for 
proteins that play important roles, including the polymerase, the ribonuclease, and 
the endonucleases which include the integrase and the ligase. The env-gene codes 
for envelope glycoproteins. In addition, a gene located at the gag-pol junction codes 
for the protease enzyme (Cochrane, 2011). It is important to note that currently, 
antiretroviral drugs typically target the reverse transcriptase, the protease, the 
integrase enzymes as well as viral entry. 
The HIV genome codes for several regulatory proteins (Virella, 2001). The genes 
coding for regulatory proteins include: the tat or transactivator of transcription gene 
which promotes pro-viral genome expression during transcription; the rev-gene 
which regulates expression of viral structural proteins; the nef-gene or negative 
expression factor gene which down-regulates MHC-I and CD4 expression facilitating 
the evasion of attack from the body’s immune response. The schematic diagram of 
the HIV genome in Figure 2.11 depicts the specific regions of the genome and the 
corresponding proteins. 
 
Figure 2.11: Schematic diagram of HIV-1 genome and the associated proteins. 
LTR= long terminal repeat; MA= matrix; CA= capsid; PR= protease; RT= reverse 
transcriptase; IN = integrase; SU= surface; TM= transmembrane: Adapted from 
Montano & Sebastiani (2009). 
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2.5.8.2 Infectivity and pathogenicity of HIV 
In the initial stages of HIV infection, dendritic cells are the main vehicles that pick up 
the virus from the blood circulation and carry it to the lymphoid organs. Apparently, 
dendritic cells are essential for the initiation of primary antigen-specific immune 
response to many infections, including HIV infection, because dendritic cells have 
good antigen presenting properties (Noah, 2012). In the lymphoid organs, HIV gets 
its first contacts with the cells of the immune system which include mostly the 
activated T cells, where a massive initial immune response occurs (Tortora, Funke 
& Case, 2012). 
HIV infects cells expressing CD4 receptor molecules on the surface together with 
either of the two chemokine co-receptor molecules termed CCR5 and CXCR4 
(Tortora, Funke & Case, 2012). It is important to note that CCR5 nomenclature is 
based on the beginning amino acid sequence of the proteins. For example, CCR5 
means that the beginning sequence consists of cysteines, and Cx in CXCR4 
indicates some other proteins. Ideally, HIV infects the T helper cell population of 
lymphocytes as the primary target. Unfortunately, monocytes in blood, macrophages 
in tissues, and dendritic cells in blood and tissues are receptive for HIV. It is now 
believed that many other cells that do not express the CD4 molecule can also 
become infected, which means that there could be some other unknown receptors 
for HIV (Tortora, Funke & Case, 2012). The detail of the role played by the CD4 
receptor molecules and the chemokine co-receptor molecules in viral entry is 
outlined in section 2.5.8.5. 
After viral entry, viral RNA is released and transcribed into DNA by the enzyme 
reverse transcriptase (Tortora, Funke & Case, 2012). The transcribed viral DNA is 
integrated into the chromosomal DNA of the host cell with the aid of the integrase 
enzyme. According to Cochrane (2011), a copy of proviral DNA is integrated into the 
cell genome at a random site. The integrated proviral DNA at this stage may take 
control the production of new viruses or may lie dormant as a provirus for many 
years.  
The virus evades immune defenses by lying dormant or undergoing rapid antigenic 
changes. Retroviruses have a high mutation rate compared to DNA viruses and are 
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also known for lacking the corrective ―proofreading‖ capacity commonly noticed in 
DNA viruses (Tortora, Funke & Case, 2012). The mutations pause challenges 
especially in vaccine development, drug effectiveness and even diagnostic tests. 
The mutations have given rise to many variants of HIV which is broadly classified 
into HIV-1 and HIV-2. Researchers have since identified three HIV-1 groups–
namely: main (M), outlier (O) and non-M or non-O (N). Sub-group M is responsible 
for more than 95% of global HIV infections (Tortora, Funke & Case, 2012). The M 
subtype is sub-divided into further sub-classes denoted by ―A, B, C‖ notation of 
which M subtype C is the most prevalent in the world but concentrated in India, 
Eastern and Southern Africa. 
2.5.8.3 Stages of HIV infection and world health organization (WHO) clinical 
staging of HIV and AIDS disease 
Generally, disease progression of HIV infection has three main stages (Tortora, 
Funke & Case, 2012). The first stage is characterized by viral loads of up to 10 
million viral RNA/ml of blood. The immune response, led by CD8-labeled cytotoxic T 
cells, succeeds in reducing the number of infected CD4 cells at this point but a 
number of infected cells are not targeted due to viral latency. In the next phase, CD8 
cells continue to keep HIV under check. However, the CD4 cells remain subdued to 
the extent that some opportunistic infections such as yeasts, shingles, and diarrhea 
may take advantage.  
In the third phase, when CD4 counts drop below 350 cells/mm3, many more 
opportunistic infections such as cytomegalovirus eye infections; toxoplasmosis of 
the brain, tuberculosis; pneumocystis, and Kaposi’s sarcoma erupts (See Table 
2.7).  
The World Health Organization currently recommends four clinical stages according 
to the progression of HIV infection (WHO, 2010). The first clinical stage is generally 
asymptomatic although generalized lymphadenopathy may occur due to the 
massive initial immunological response in the lymph nodes. WHO clinical stage II is 
characterised by weight loss of not more than 10% and minor infections such as 
recurrent upper respiratory infections, and superficial fungal infections on the skin.  
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Manifestations of WHO clinical stage III are consistent with clinical features of 
declining immunity such as excessive weight loss, prolonged bacterial infections, 
and frequent fevers. Due to the weakening immunity, tuberculosis, oral candiasis 
and oral hairy leukoplakia are important signs of WHO clinical stage III. In the WHO 
clinical stage IV, more serious forms of infections as listed in Table 2.7 may occur. 
Table 2.7:  Common opportunistic infections associated with HIV infection.  
Pathogen type Disease  Disease description 
Protozoa Cryptosporidium hominis  Persistent diarrhoea 
 Toxoplasma gondii  Encephalitis 
 Isospora belli  Gastroenteritis 
Viruses Cytomegalovirus  Fever, encephalitis, blindness 
 Herpes simplex virus  Vesicles of skin and mucous membranes 
 Varicella-zoster virus  Shingles 
Bacteria Mycobacterium tuberculosis  Tuberculosis 
 M. avium-intracellulare  May infect many organs; gastroenteritis and other 
highly variable symptoms 
Fungi Pneumocystis jirovecii  Life-threatening pneumonia 
 Histoplasma capsulatum  Disseminated infection 
 Cryptococcus neoformans  Disseminated, but especially meningitis 
 Candida albicans  Overgrowth on oral and vaginal mucous membranes 
(stage 2 of HIV infection); Overgrowth in 
oesophagus, lungs (stage 2) 
Cancers Kaposi’s sarcoma  Cancer of skin and blood vessels (caused by human 
herpes virus 8) 
 Hairy leukoplakia  Whitish patches on mucous membranes; commonly 
considered precancerous 
 Cervical dysplasia  Abnormal cervical growth 
(Tortora, Funke & Case, 2012). 
Staging patients according to the WHO clinical staging criteria has always been 
difficult and controversial without CD4 counts. CD4 counts are more definitive for 
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staging the progression of HIV infection. In one study conducted in Uganda by 
Kagaayi, Makumbi, Nakigozi, Wawer, Gray, Serwadda & Reynolds (2007), WHO 
clinical criteria missed half the patients with CD4 cell counts of 200 cells/mm3 or 
less. Yet, in another study conducted in Saudi Arabia, Edathodu, Ali & Alrajhi 
(2009), reported that the WHO clinical staging correlates well with CD4 counts. 
Therefore, the WHO clinical criteria remain valuable but CD4 cell measurements are 
crucial for the scale-up of ART provision in resource-limited settings. 
2.5.8.4 HIV diagnosis and testing methods 
HIV testing is usually indicated in patients seeking medical attention for the various 
opportunistic infections such as sexually transmitted infections and any of the 
infections listed in Table 2.7. Although the enzyme-linked immunosorbant assay 
(ELISA) tests are standard procedure for detecting HIV antibodies, several tests 
which are cheaper and more rapid have been devised for remote areas where 
sufficiently equipped laboratories are not available (Tortora, Funke & Case, 2012). 
The basic principle for HIV screening tests is based on antigen-antibody binding. 
The formation of antibodies after infection generally begins with antibodies to p24 
and gp120 viral proteins. Therefore, antibodies to p24 and gp120 viral proteins are 
detectable at early stages of HIV infection (Noah, 2012). Antibodies to the other viral 
proteins such as the polymerase proteins (p31) generally occur in later stages of 
HIV infection (Fiebig, 2003). 
Central to ELISA tests is a micro-titer plate with 96 wells which are coated with HIV 
antigens and HIV antibodies. In the event of the serum having the antibodies to HIV 
viral proteins or HIV antigens, the antibodies bind to the antigens coated on the 
plate whereas the antigens bind to the antibodies coated on the plates. For 
detection of the reaction, enzyme-linked antibodies that bind to human antibodies 
are then added. Addition of a suitable substrate to the enzyme results is a colour 
change which can be measured by colorimetric detectors. 
Generally, the optical density correlates with the concentration of HIV antibodies in 
the sample of the patient. Several improvements have been incorporated into the 
original ELISA ideas. For example, in modern test systems, the solid phase consists 
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of microparticles coupled with the virus antigens and antibodies (Perry, Ramskill, 
Eglin, Barbara & Parry, 2008). Typical among the modern ELISA systems is the 
microparticle enzyme immunoassay or MEIA method.  
It is important to note that despite the strict demands for screening tests to have 
high specificities of more than 99% false-reactive results may still occur. False-
reactive results may occur in immunological conditions such as pregnancy, viral 
infections, vaccinations and autoimmune diseases (Noah, 2012). Thus, in certain 
patient groups an increased proportion of false reactive test results can occur. 
In Western Blot analysis, viral proteins are separated by their molecular weight 
using electrophoresis and transferred to a membrane. Recombinant HIV antigens 
are then directly sprayed onto a test membrane. The test membrane is incubated 
with the serum of the patient. If HIV-specific antibodies are present, they bind to the 
antigens. The resulting antigen-antibody complex is detected using enzyme-linked 
antibodies and corresponding substrates.  
Guidelines on HIV testing still differ between countries (Noah, 2012). For example, 
guidelines on HIV testing in Germany stipulate that Western Blot test result be 
considered positive when antibodies against an env protein and also against a gag 
protein and/or a pol protein are detected. However, the WHO guidelines recommend 
that Western Blots be considered positive when antibodies against at least two env 
proteins are detectable.  
A weak or inconclusive Western blot result may indicate an early phase of an HIV 
infection and further tests such as polymerase chain reaction (PCR) which can 
detect HIV RNA should be carried out. The PCR is recommended in case of a highly 
positive screening and negative confirmatory test result as well as in cases of 
suspicion of acute infection or vertical transmission. However, HIV PCR cannot 
replace the HIV antibody tests (Noah, 2012). It is important to note that PCR can 
only detect the viral RNA circulating in the blood and not in HIV-infected cells. It is 
also important to note that current methods of HIV testing cannot detect all of the 
variants of rapidly mutating HIV, but are limited to HIV subtypes that are prevalent in 
a population (Tortora, Funke & Case, 2012). 
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2.5.8.5 CD4 cells and the mechanisms of immunological response in HIV 
infection  
HIV infects cells expressing CD4 receptor molecules on their surfaces. To 
understand the concepts of CD4 counts and the methods of measurement in use, 
one has to probe further into the concepts of lymphocyte differentiation. All 
lymphocytes, like all blood cells, are derived from hematopoietic stem cells which 
have the rare capability of self-renewal and differentiation (Virella, 2001). Whereas 
self-renewal is the ability to give rise to at least two daughter cells at the same stage 
of development as the parent, differentiation is the orderly sequence of events that 
leads to cell maturation and restricted lineage potential.  
A given cellular antigen identified by each monoclonal antibody is designated by the 
prefix CD, which stands for clusters of differentiation followed by a number. The 
numbers are assigned based on the order of discovery, and the developmental 
order of appearance. CD4 refers to glycoproteins found on the surfaces of antigen 
presenting cells such as macrophages, T helper cells, dendritic cells and monocytes 
(Harrison, 1993; Murphy, 2012). These cells also express another glycoprotein 
called CD8 on their surfaces which is structurally different from the CD4 molecule. 
CD4 generally defines the T helper cell population. Although HIV infects a variety of 
cells, the virus mainly affects T helper cells (Wood, 2006). The CD4 molecule 
contains four immunoglobulin-like domains, as shown in Figure 2.12. 
CD8, another surface molecule important in immunological response, is expressed 
on T helper cells, some natural killer cells and most thymocytes. CD8 generally 
defines cytotoxic T cell population because CD8 is found on natural killer cells. CD8 
binds to major histocompatibility complex (MHCc) class I antigens during antigen 
presentation (See Figure 2.12). MHC class I molecules present peptides from 
pathogens, which are viruses in most cases, to CD8 cytotoxic T cells. 
The CD4 molecules function as co-receptors that facilitate interaction of the T cell 
receptor with antigen-presenting cells. CD4 molecules use their D1 domains to 
interact with β2-domains of MHC class II molecules during antigen presentation as 
shown in Figure 2.12. CD4 molecules are also important in the sense that they 
amplify the signal generated by T-cell receptors (Murphy, 2012; Wilson et al., 2008).  
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CD4 molecules play a central role in the two stages of HIV viral infection. CD4 cells 
facilitate binding of HIV to the host cell, and also facilitate fusion of the viral particles 
with the cell membrane to allow the virus to enter the cell (Wood, 2006). CD4 
molecules, gp120, gp41, and co-receptors, CCR5 and CXCR4, facilitate entry of 
HIV-1 viruses into T cells (Murphy, 2012).  
 
Figure 2.12: The schematic structures and interaction of the CD4, CD8, and the 
MHC molecules. 
(Murphy, 2012). 
During viral entry, the first event to occur is the binding of g120 to the CD4 molecule 
of the host cell (Wood, 2006). The next event to occur depends on the nature of 
gp41 on the surface of the virus. Gp41 of some HIV variants bind to CCR5 whilst 
some HIV variants can only bind to CXCR4. This selective binding is one other 
source of the existence of HIV variants. CCR5 is found on CD4 T cells, monocytes 
and dendritic cells whilst CXCR4 is only found on CD4 T cells. This means that a 
virus with an affinity for CCR5 may infect CD4 T cells, monocytes or dendritic cells. 
Such viral variants are called M-tropic viruses. Other HIV variants bind to CXCR4, 
which is only found on CD4 T cells but not on monocytes or dendritic cells (Wood, 
2006). Such HIV variants can therefore only infect T cells and are called T-tropic 
viruses.  
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The binding of the HIV-1 virus results in a conformational change in the viral 
proteins which eventually leads to viral entry (Murphy, 2012). The genetic 
expression of CCR5 chemokines on CD4 cells has been given as the reason why 
some individuals are resistant to HIV infection. A progressive decrease in the 
number of T cells expressing CD4 molecules is the hallmark of HIV infection 
because HIV enters the cells carrying the CD4 receptors, usually destroying the 
cells. The CD4 count is therefore used as a marker of HIV disease progression, 
including when to begin treatment during HIV infection and the success of ART.  
Several possible mechanisms through which CD4 cells decrease in HIV patients 
have been put forward. The mechanisms include direct destruction of CD4 cells by 
HIV and increased programmed cell death (Eggena, Barugahare, Okello, Mutyala, 
Jones, Ma, Kityo, Mugyenyi & Cao, 2005; Wilson et al., 2008). To understand 
mechanisms of CD4 cell destruction, more concepts have to be put in perspective.  
It is important to note that CD4 cells that are infected by the virus express viral 
antigens on their surface either as antigens presented by MHC class I or as soluble 
gp120 bound to CD4 molecules. CD4 T cells are therefore killed because of the 
expression of viral antigen (Wood, 2006). The killing of CD4 cells can occur through 
complement-mediated, antibody mediated, or CD8 mediated cytotoxic killing. 
Although there is nothing wrong with the killing of CD4 cells expressing viral 
antigens, the killing normally goes too far. Bearing in mind that the main type of 
infected cell is the CD4 T cells, the body ends up killing the same cells that are 
required to generate immune responses (Wood, 2006). 
Other important changes to the immune system occur after HIV infection. In the 
initial stages of HIV viral infection, the lymph nodes swell due to an influx of CD8 T 
cells. The influx of CD8 T cells destroys the integrity of the lymph nodes resulting in 
non-functional lymph nodes (Wood, 2006). Another major change to the immune 
system is the increase in serum immunoglobulins that are impaired and therefore 
unable to generate specific antibody responses. Moreover, another change is the 
increase in production of autoantibodies to red blood cells, spermatozoa or myelin 
sheath of nerves which possibly explains the appearance of eczematous skin 
reactions in some untreated HIV patients (Wood, 2006). 
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Lesotho guidelines recommend that HIV patients be treated with ART drugs when 
the CD4 counts fall below the threshold of 350 CD4 cells/mm3. Above 350 CD4 
cells/mm3 threshold, patients are thought to be still immune-competent enough 
without the aid of ART drugs. CD4 counts that are below the threshold of 200 
cells/mm3 are generally associated with AIDS-defining illnesses (Wilson et al., 
2008).  
2.5.8.6 Methods of measurement of CD4 cells and factors affecting CD4 
counts  
CD4 and CD8 cellular markers are most often measured using flow cytometry. Flow 
cytometry, based on immunofluorescence analysis, is the reference standard for 
CD4 counts and also the method of choice if large samples are analysed (Zijenah et 
al., 2006). Immunofluorescence analysis involves counting cells that are stained in 
suspension using fluorescence-labelled monoclonal antibodies (Paraskevas, 2009).  
In immunofluorescence analysis, a diluted blood sample is incubated with one or 
more fluorescent-labeled monoclonal antibodies (Virella, 2001; Paraskevas, 2009). 
The samples are then diluted further so that they can flow as a unicellular stream for 
analysis of light scattering and fluorescence properties. Forward light scattering 
measures sizes of cells and lateral light scattering determines the granularity of the 
cells. Fluorochromes are molecules that absorb light of one wavelength and emit 
light of another wavelength, usually a higher wavelength.  
The development of monoclonal antibodies against cell-surface markers of blood 
cells and their conjugation with certain fluorochromes enabled accurate detection of 
surface molecules such as CD4 cell markers (Paraskevas, 2009). The CD4 count 
value together with CD3, CD4, and CD8 is obtained by analysing the relative 
intensity of fluorescence emitted by the cells after staining with the specific 
monoclonal antibodies. The final computation of the CD4 count is based on cell 
gating which, in principle, means restricted analysis of cells of interest with similar 
characteristics.  
Efforts to develop affordable CD4 counting methods for resource-limited settings are 
on-going. To date, single-purpose or dedicated flow cytometers have been designed 
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for performing CD4 counts. Such machines include Becton Dickinson FACSCount 
and Partec CyFlow (Rodriguez, Christodoulides, Floriano, Graham, Mohanty, Dixon, 
Hsiang, Peter, Zavahir, Thior, Romanovicz, Bernard, Goodey, Walker & McDevitt , 
2005). Another CD4 measurement technology in the affordable range is the PIMA 
CD4 machine (Thakar, 2012). The PIMA CD4 machine, believed to eventually bring 
CD4 counts to the point of care, has been evaluated with success in India (Thakar, 
2012). 
Absolute and percentage CD4 (CD4%) are the two parameters that CD4 machines 
can measure. The absolute CD4 counts measure the amount of CD4 cells 
circulating in the blood. The absolute CD4 count is obtained from the total and the 
differential white cell count. On the other hand, CD4% is measured directly on a flow 
cytometer and is less variable with a smaller coefficient of variation compared to the 
absolute CD4 count (Giorgi, Cheng, Margolick, Bauer, Ferbas, Waxdal, Schmid, 
Hultin, Jackson, Park & Taylor, 1990). CD4% is more economical because it 
requires only the flow cytometer results not the white blood cell count and 
differential count which are required for the absolute CD4 count. In addition, a study 
conducted by Burcham, Marmor, Dubin, Tindall, Cooper, Berry & Penny (1991), has 
shown that the CD4% is a better predictor of HIV clinical progression. However, the 
absolute CD4 count remains popular among clinicians. 
CD4 counts are affected by many factors, including biological variations such as 
diurnal variation, gender, stress and variation in challenges to the immune system 
due to infections (Malone, Simms, Gray, Wagner, Burge & Burke, 1990; Grinsztejn, 
Smeaton, Barnett, Klingman, Hakim, Flanigan, Kumarasamy, Campbell & Currier, 
2011). Viral, bacterial, parasitic and fungal infections have been shown to have a 
marked impact on CD4 counts. The other factors listed in the literature include 
trauma, cancer chemotherapy and malnutrition. Even over-exercising, corticosteroid 
use, smoking, and pregnancy have been demonstrated to have effects on CD4 
counts (Malone et al., 1990).  
2.5.8.7 Utility and limitations of CD4 counts in monitoring HIV treatment 
Discrepancies between CD4 counts and viral load tests where immunological failure 
based on CD4 counts did not correlate with viral load results have been found in 
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some HIV patients. Some of the reasons given to explain the phenomenon include 
myelo-suppressive effects of ARV drugs such as Zidovudine (Huttner, Kaufmann, 
Battegay, Weber & Opravil, 2007); thymic involution related to old age (Teixeira, 
Valdez, McCune, Koup, Badley, Hellerstein, Napolitano, Douek, Mbisa, Deeks, 
Harris, Barbour, Gross, Francis, Halvorsen, Asaad & Lederman, 2001) and 
abnormal cell death due to higher immune activation related to frequent challenge 
by opportunistic infections (Eggena et al., 2005).     
Misgena (2011) recently reviewed the risk factors for immunological response or 
virological failure. The factors mentioned in the review include old age, poor 
adherence, previous exposure to ART, lower baseline CD4 count, co-morbidities 
such as Hepatitis B or C and tuberculosis; and low body weight. Prabhakar, Banu, 
Pavithra, Chandrashekhara & Sasthri (2011) recommended close monitoring to 
ensure strict adherence to ART in the patients starting ART at very low CD4 counts 
below 100 cells/mm3.  
Currently the WHO recommends defining immunological failure based on CD4 
counts in HIV patients whose CD4 count have either declined to pre-ART values, 
CD4 count dropped to less than 50% of peak on-treatment value or failure of the 
CD4 count to achieve a value greater than 100 cells/mm3 over six month intervals 
(WHO, 2010; Prabhakar et al., 2011). As a guideline, effective antiretroviral therapy 
should result in CD4 counts rising by at least 100 cells/mm3 in the first year and 
about 50-80 cells/mm3 in the subsequent years (Wilson et al., 2008). 
The debate on the utility of CD4 counts in detecting sub-optimal treatment outcomes 
is still going on. Some of the issues that have been commonly reported include the 
low predictive value of CD4 counts in detecting virological failure and the existence 
of discordant results between CD4 counts and viral load results (Badri, Lawn & 
Wood, 2008; Kanapathipillai et al., 2011). Therefore, the use of CD4 counts has 
limited utility and may be more useful if combined with clinical criteria and viral load 
tests where they are available. Table 2.8 shows a summary of selected studies on 
the occurrence of sub-optimal immunological outcomes based on CD4 counts and 
viral load tests and the utility of CD4 counts in detecting sub-optimal treatment 
outcomes.  
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Table 2.8:   A summary of studies on immunological outcomes based on CD4 
counts. 
Study reference, 
Place of Study  
Study 
design; 
duration  
Measure 
of ART 
outcome 
Main Findings 
Amenyah et al. 
(2006), Ghana 
Retrospective 
review of 
medical records 
of 3806 patients 
CD4 counts 40 (1.1%) had immuno-virological failure. Of 
the 40, 77% had IMF. 68% of immuno-
virological failure occurred in treatment naïve 
patients. Three patients had documented 
poor adherence. Half of the patients failed 
treatment within the first year of treatment.  
Chaiwarith et al. 
(2007), Thailand 
Retrospective 
cohort of 327 
patients; 6-42 
months  
VL, CD4 
counts, 
clinical 
criteria 
9.2% had VLF. Using IMF criteria and clinical 
criteria to detect treatment failure, the 
sensitivity was 20.0% and the specificity was 
85.9%. 
Badri et al. (2008), 
South Africa 
Observation 
cohort of 330 
patients with 
initial viral load 
suppression 
CD4 count, 
VL 
The association between a CD4 count 
decrease and VLF was poor (area under 
curve = 0.59; sensitivity = 53.0%; specificity 
= 63.6%; positive predictive value = 10.9%). 
Kantor et al. 
(2009), Kenya 
Observation 
cohort of 149 
patients; 23 
months 
CD4 count, 
VL 
IMF as a sole indicator of VLF resulted in a 
premature switch to second-line regimens for 
58% of patients who experienced a 25% 
decrease in CD4 count and for 43% patients 
who experience a 50% decrease in CD4 
count.  
Reynolds et al. 
(2009), Uganda 
Observation 
cohort of 1133 
patients; 20.2 
months 
(median) 
CD4 and VL 125 (11.0%) had IMF. VLF with VL >400 
copies/ml reached by 112 patients (9.9%). 
Only 26 (2.3%) had both IMF and VLF (2 
VL>400 copies/ml) during follow-up. 
Bello et al. (2011), 
Brazil 
Observation 
cohort of 139 
patients 
VL, CD4 
count 
12.2% had VLF. TB was a significant 
predictor of VLF. 
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IMF = immunological failure; VL = Viral load; and VLF = Virological failure. 
2.5.9 Viral load tests and drug resistance tests: Rationale; utility; current 
technologies; and availability in resource limited settings 
By definition, viral load is the quantity of viruses in a given volume of body fluid. Viral 
load measures the magnitude of a viral infection such as HIV-1 (Puren, Gerlach, 
Charpentier et al. 
(2011), Cameroon 
Observation 
cohort of 819 
patients 
CD4 count, 
VL, 
genotypic 
resistance 
testing 
36% had VLF. 17% had CD4 counts <200 
cells/mm3 and 37% < 350 cells/mm3, 
indicating either immunorestoration or IMF. 
20% of patients with VLF showed wild-type 
viruses susceptible to all ARV, indicating 
poor adherence. 
Kanapathipillai et 
al. (2011), Malawi 
Retrospective 
cohort of 227 
patients with 
IMF 
CD4 count, 
VL 
155 (68.2%) had VL testing. The positive 
predictive value of CD4 count was 28.4%. 
Repeated CD4 counts showed that 41% of 
patients initially positive for IMF did not have 
the IMF. 
Prabhakar et al. 
(2011), India 
Observation 
cohort of 251 
patients; 
3.7±1.14 years 
CD4 count, 
VL 
28 (13.59%) had discordant results (low CD4 
counts despite viral suppression). IMF 
without VL testing can result in unnecessary 
switches to 2nd line therapy. 
Zoufaly et al. 
(2011), Germany 
Multicenter 
cohort of 14,433 
patients with 
viral 
suppression.  
VL, CD4 
count 
Patients with discordant VL and CD4 count 
results had a higher AIDS event incidence. 
Discordant group had an incidence rate of 
55.06 and the immune responder group had 
a rate of 24.54. 
Eshun-Wilson et 
al. (2012), South 
Africa 
A retrospective 
cohort of 691 
patients 
CD4 count, 
VL and TB 
incidence. 
141 (20.4%) had IMF at six months on ART. 
Péré et al. (2012), 
Central African 
Republic 
Observation 
cohort of  386 
patients; 24 
months 
(median) 
CD4 
counts, VL, 
genotypic 
resistance 
testing 
28.5% had VLF (VL >3.7 log (10) copies/ml). 
24% of patients with VLF showed wild-type 
viruses, indicating poor adherence. There is 
a need for VL tests to monitor therapeutic 
failure. 
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Weigl, Kelso & Domingo, 2010). Viral load is usually given in RNA copies/ml of 
plasma. Viral load is useful in monitoring patients on ART. Three types of viral load 
tests are currently in use–namely: commercial nucleic acid amplification based 
tests, in-house nucleic acid amplification based tests and non-nucleic acid-based 
tests (Puren et al., 2010).  
Nucleic acid amplification-based tests either use the basic polymerase chain 
reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR) or the 
nucleic acid sequence based amplification (NASBA) method. RT-PCR is a form of 
PCR which uses RNA as the starting material and is then converted to double-
stranded DNA, using the reverse transcriptase enzyme. The NASBA method is a 
form of PCR which uses RNA as the target to make a copy of DNA. The DNA copy 
is then transcribed into RNA and amplified (Greengrass, Turnbull & Hocking, 2005). 
Viral load monitoring is not yet widely accessible in most resource limited settings 
such as in Lesotho although viral load tests are required more in these resource-
limited settings. Patients often continue first-line ART until immunologic failure is 
detected by WHO criteria of diagnosing immunological failure (Wilson et al., 2008).  
Currently, three main methods are used for detecting HIV antiretroviral resistance. 
The first method measures the virus phenotypic susceptibility to drugs directly by 
culturing virus in the presence of increasing concentrations of the antiretroviral drug 
of interest (Dunne, Mitchell, Coberly, Hellmann, Hoy, Mijch, Petropoulos, Mills & 
Crowe, 2001; Mazzotta, Lo Caputo, Torti, Tinelli, Pierotti, Castelli, Lazzarin, 
Angarano, Maserati, Gianotti, Ladisa, Quiros-Roldan, Rinehart & Carosi, 2003). The 
concentration of drug required to inhibit viral replication gives a measure of 
antiretroviral drug resistance. 
The second method uses genotyping assays to measure drug resistance and is 
based on determining the sequence of the HIV gene targeted by the antiretroviral 
drug and use the information to deduce drug susceptibility (Dunne et al., 2001). A 
third method of virtual phenotypic assays is a mixture of the first two methods, 
whereby the viruses of interest are sequenced and large databases of all known 
gene variants are created. Drug resistance is then tested by comparing the gene 
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sequences of viral repertoire in an individual to the stored dataset (Mazzotta et al., 
2003). 
Acquired and transmitted HIV drug resistances are confirmed phenomena which 
occur in many HIV patients. HIV drug resistance is transmissible to other individuals 
who contract the disease from one with drug resistance (Clavel & Hance, 2004). It is 
claimed that there are minor drug-resistant variants in every patient infected with 
HIV (Gianella & Richman, 2010). In addition, drug resistance to one drug can cause 
resistance to other drugs in the same drug class. 
According to Chakraborty, Smith, Dunn, Green, Duong, Doerholt, Riordon, Lyall, 
Tookey, Butler, Sabin, Gibb & Pillay (2008), poor adherence is the major cause of 
treatment failure in developing countries. Poor adherence implies that sub-inhibitory 
drug levels persist in the patient’s blood resulting in the development of drug 
resistance.  
HIV has a high rate of replication and a high number of errors during replication 
(Clavel & Hance, 2004). During viral replication, mutations happen resulting in 
daughter genomes differing from the parent template. Worse still, the mutated 
daughter genomes which favour survival tend to prevail. Hence, in individuals on 
ART therapy, there is a natural selection for viral progeny that are resistant to 
antiretroviral therapy (Clavel & Hance, 2004). 
Drug resistance tests allow clinicians to choose or adjust ART drug combinations. 
The information also enables national treatment programmes to make informed 
treatment guidelines especially in resource limited settings (Bennett, Myatt, 
Bertagnolio, Sutherland & Gilks, 2008). However, several questions remain to be 
answered regarding best use of drug resistance assays in resource limited settings 
such as the need for training clinical practitioners on how to interpret drug resistance 
tests.  
In developed countries, most patients on ART are monitored regularly by HIV-1 
RNA viral load measurements and genotypic resistance testing (Hammer, Eron, 
Reiss, Schooley, Thompson, Walmsley, Cahn, Fischl, Gatell, Hirsch, Jacobsen, 
Montaner, Richman, Yeni & Volberding, 2008). For example, guidelines in Europe 
stipulate that HIV therapy should suppress viral loads to undetectable levels by 24 
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weeks. If this does not happen and the patient has consistently elevated viral load 
during treatment, the patient should be tested for HIV drug resistance and the ART 
regimen modified accordingly (Clumeck, Pozniak & Raffi, 2008). 
2.6 Assessment of Nephrotoxicity of Tenofovir and Immunological 
Outcomes: Chapter Summary  
Assessing the extent to which TDF may cause renal toxicity is a huge challenge 
given the numerous drug combinations commonly administered to patients and 
other possible risk factors. The inevitable existence of comorbidities associated with 
HIV and AIDS such as diabetes, hypertension and metabolic syndrome may 
complicate the ability by researchers to attribute renal insufficiency solely to TDF. 
Moreover, the kidneys being a major organ for concentrating and excreting toxic 
metabolites and drugs, is by default at risk of drug toxicity through numerous 
mechanisms which are difficult to disentangle without suitable study controls. 
Unraveling the labyrinth of the confounding factors in resource limited areas is likely 
to be complicated by lack of baseline laboratory tests such as viral hepatitis 
screening; and limited laboratory capacity to assess the kidney condition routinely.  
Although the extent to which TDF may cause renal disease is not clear, the drug 
needs to be administered with caution. There is a need, meanwhile, to set aside 
enough resources to meticulously monitor patients on TDF in resource limited areas 
such as Lesotho. Efforts to find drug intervention means of reducing nephrotoxicity 
of TDF are likely to continue given the efficacious outcomes of TDF unless a drug 
with similar or better outcome model and affordability is developed (De Clercq, 
2009). It seems effective vaccines for HIV continues to evade researchers.  
Besides exposing the limitations facing researchers in resource limited areas with 
respect to researching on nephrotoxicity of TDF, the chapter indicated that there are 
some knowledge gaps that future research may cover. For example, there is a 
knowledge gap in viral hepatitis sero-status of HIV positive patients (Ford, Singh, 
Cooke, Mills, von Schoen-Angerer, Kamarulzaman & du Cros, 2012). Filling the gap 
would indicate the extent to which viral hepatitis may be contributing to renal 
insufficiency.  
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Assessing for immunological failure early in HIV patients on ART is also a challenge 
in resource limited settings due to the unavailability of viral load tests. CD4 counts, 
though helpful have limited utility in detecting sub-optimal immunological response 
(Kantor, Diero, Delong, Kamle, Muyonga, Mambo, Walumbe, Emonyi, Chan, Carter, 
Hogan & Buziba, 2009; Reynolds, Nakigozi, Newell, Ndyanabo, Galiwongo, Boaz, 
Quinn, Gray, Wawer & Serwadda, 2009; Prabhakar et al., 2011), However, 
detecting early signs of immunological failure based on CD4 counts and clinical 
signs remains vital to avoid the emergence of drug resistance in HIV patients on 
ART. Finding ways of improving access to viral load tests, by any means, though it 
may be elusive at the moment, should remain the prime target if the gains achieved 
so far are to be maintained. 
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CHAPTER 3: METHODOLOGY 
3.1 Study Design 
This study utilised an analytical design in two phases. Phase 1 of the study 
compared renal function outcomes of patients on TDF-based ART and patients on 
non-TDF-based ART. Phase 2 of the study, which was based on re-sampling the 
study population, analysed immunological outcomes based on CD4 counts.   
3.1.1 Rationale of the study design 
The research study was designed primarily to assess the renal function outcomes 
following the use of TDF based on a retrospective case-control method, and to 
evaluate the immunological outcomes following the use of TDF and other ARVs 
based on CD4 counts at Roma Health Service Area (RHSA) in Lesotho. A 
retrospective case-control method was chosen because of two reasons: (1) A 
retrospective case-control method allowed a long period of observation which was 
required between the exposure to TDF and the possible development of detectable 
sub-optimal renal function outcomes; (2) The method also allowed the comparison 
of renal function outcomes for the patients exposed to TDF and individuals not 
exposed to TDF.  
The assessment of immunological outcomes at RHSA was based on CD4 counts 
since data on viral load tests were very scarce because of limited access to viral 
load tests in Lesotho. The assessment of immunological outcomes was based on a 
pooled sample used in phase 1 of the study. Therefore, based on the study design, 
the main variables of interest were serum creatinine and CD4 counts. 
3.2 Study Setting 
The Roma Health Service Area (See map in the Addendum on page 185) has about 
114 000 inhabitants, a number which was estimated to be about 6% of Lesotho's 
population according to the 2006 national census. There is one mission hospital 
known as St Joseph’s Mission Hospital and five satellite health centres which cater 
for areas that are far from the Mission Hospital. The cumulative number of patients 
on ART in the different Health Centres since 2006 is shown in Table 3.1. Sampling 
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could not be done at all the health centres at Roma Health Service Area due to 
resource limitations. Patients at St Joseph’s Mission Hospital and at Nazareth 
Health Centre made up 80% of the total number of HIV patients on ART when 
combined. Sampling was therefore carried out at St Joseph’s Mission Hospital and 
Nazareth Health Centre as shown in Table 3.1.  
Table 3.1:  Number of patients on ART at Roma Health Service Area since 2006. 
Health Centre Cumulative number 
in HIV care 
Cumulative number 
on ART (%) 
Sample size (N, %) 
St Joseph’s 
Hospital 
4 175 2 410 (58%) 351 (15%) 
Nazareth 1 782 841 (47%) 188 (22%) 
Fatima 726 366 (50%)  
St Benedict 385 156 (41%)  
St Bernard 367 155 (42%)  
Tlali 309 188 (61%)  
Total 7 744 4 116 (53%) 539 (13.1%) 
Cumulative number of patients in HIV care refers to the number of patients who tested HIV positive 
but are not yet on ART. 
The HIV clinics followed national guidelines on ART which recommend prescribing 
TDF-containing ART regimens to all adults above 18 years of age with creatinine 
clearance equal or above 50 ml/min calculated using the Cockcroft-Gault formula as 
shown in Section 3.5. Patients on ART at the selected two hospitals were monitored 
for serum creatinine, urea and electrolytes, CD4 counts and liver function tests at 
least once every six months. Patients’ ART medical records were not computerised. 
3.3 Study Population and Sampling 
3.3.1 Sampling methods 
The research was carried out in two phases. The first phase was a retrospective 
case-control study to assess the nature of the association between exposure to TDF 
and the incidence of renal injury. This was conducted on adult HIV patients enrolled 
on ART at St Joseph’s Mission Hospital and at Nazareth Health Centre between 
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December 2006 and December 2012. Patients on TDF-based regimen with baseline 
serum creatinine and at least one other serum creatinine value recorded after the 
first six month interval were assigned to the sample group. Patients on ART 
regimens not containing TDF were assigned to the control group. The study 
procedures are outlined in Appendix A. 
Data for the two study phases were collected from the medical records of 539 
patients. During data cleaning stage, some patients had to be eliminated from the 
analysis of renal function outcomes because they did not meet the inclusion criteria. 
The final number of patients who were suitable for the assessment of renal function 
outcomes was 485 and was distributed in the different ARV regimens as shown in 
Table 3.2. Out of the 485 patients, 173 (36%) patients met the selection criteria for 
the control group (Non-TDF group), whilst 312 (64%) met the criteria for the test 
group (TDF group). For the second phase of the study, some patients also had to be 
eliminated from the analysis of immunological outcomes because they did not meet 
the inclusion criteria. A total of 516 patients met the selection criteria for the 
evaluation of immunological outcomes. 
Table 3.2:  ART regimens included in the assessment of  renal function outcomes.  
Group ART Regimen formula Number of 
patients (%) 
Sample size (N, %) 
Non-TDF group D4T+3TC+NVP 1 (0.6%)   
 
 
 
             173 (35.7%) 
 D4T+3TC+EFV 2 (1.2%) 
 AZT+3TC+NVP 58 (33.5%) 
 AZT+3TC+EFV 112 (64.7%) 
TDF group TDF+3TC+NVP 13 (4.2%)   
             312 (64.3%) 
 TDF+3TC+EFV 299 (95.8%) 
Total  485              485 
D4T = Stavudine; 3TC = Lamivudine; NVP = Nevirapine; EFV = Efavirenz; AZT = Zidovudine; and 
TDF = Tenofovir disoproxil fumarate. 
Six ART regimen categories were being taken by the patients included in the study, 
of which two regimens contained TDF. All the patients taking regimens containing 
TDF were put in the TDF group and the patients taking regimens without TDF were 
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put in the non-TDF group. Besides Lamivudine (3TC), which was part of all the 
regimens, Zidovudine (AZT), TDF, Nevirapine (NVP), and Efavirenz (EFV) were the 
main components (97%) of the ART regimens at the two centres included in the 
study. Two-thirds of the patients ( See Table 3.2) were on TDF-containing regimens. 
Only a few patients (3%) were on Stavudine (D4T) because the drug was in the 
process of being phased out countrywide. 
3.3.2 Study population 
As outlined in section 3.3.1, the analysis of renal function outcomes was based on 
485 patients. On the other hand, the analysis of immunological outcomes based on 
516 patients. Figure 3.1 clarifies how the sample sizes were distributed in the two 
study phases and how the study sampling fitted into the research process. 
3.3.3 Inclusion and exclusion criteria 
To address the objectives of the study, the selection criteria for the patients were 
based on two main variables; serum creatinine values and CD4 counts. The specific 
requirements for inclusion and exclusion of patients in the study are outlined in the 
sections on inclusion and exclusion criteria. 
3.3.3.1 Inclusion criteria 
i. Patients treated for HIV with TDF or non-TDF based ART regimen from December 
2006 up to December 2012; 
ii. Patients with at least one baseline creatinine value recorded while still ART-naïve;  
iii. Male or female adult HIV patients aged 18 or older at baseline;  
iv. Patients who had been on TDF or non-TDF based ART for at least six months; 
v. Patients who had the baseline CD4 counts recorded in the medical records and at 
least one other CD4 count result recorded over six months.  
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Figure 3.1: Summary of study population and objectives 
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3.3.3.2 Exclusion criteria 
The following patient categories were excluded from the study: 
i. Patients on TDF or non-TDF based ART regimen who were younger than 18 years 
ii. Pregnant women; 
iii. Patients on TDF or non-TDF based ART regimen who had no recorded values of 
serum creatinine at baseline; 
iv. Patients who had been on ART regimen for less than six months; 
v. Patients who had no baseline CD4 counts recorded or patients who had no other 
CD4 count values recorded after baseline.  
3.4 Data Collection 
3.4.1 Data collection tool 
The data collection tool was designed using Microsoft Access® 2007 (Microsoft 
Corporation, Redmond, USA). After setting up all the variables required for the 
assessment of renal function outcomes and the assessment of immunological 
outcomes based on CD4 counts in database format, the data collection tool was 
compressed into a single data collection form (See Appendix B). The data collection 
tool was pilot-tested for suitability and functionality at St Joseph’s Mission Hospital 
before it was used to collect the final data. 
3.4.2 Data collection procedure 
Demographic data, diagnoses, treatments and laboratory values of HIV-positive 
patients were extracted from patients’ medical records according to the inclusion 
criteria. Baseline data collected included demographic data such as weight, age and 
gender; WHO clinical stage, blood pressure, CD4 count, serum creatinine, blood 
urea nitrogen (BUN), full blood count (FBC), differential count, and liver function test 
(LFT) profile. The collection also included baseline ART regimen, ART drug 
switches, date of ART commencement, and TB treatment dates. The data collection 
procedure was repeated at six month intervals up to seven data sets or up until the 
entire patient’s records were captured, whichever came first. 
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3.5 Statistical Analysis 
3.5.1 Data cleaning 
The data collected in Microsoft Access® 2007 database (Microsoft Corporation, 
Redmond, USA) were then exported to Microsoft Excel® 2007 (Microsoft 
Corporation, Redmond, USA) for data cleaning and conversion of non-binary data 
such as medical conditions to binary data as shown in Appendix C1.  The data were 
then exported to STATA® version 11 (StataCorp, Texas, USA) for analysis.  
3.5.2 Assessment of renal function outcomes 
STATA® version 11 was used to analyse the data. Patients’ clinical profiles were 
categorized using the cross tabulation functions available in STATA® according to 
the criteria shown in Appendix C2. Throughout data analysis, sub-optimal renal 
function outcome was defined as serum creatinine clearance below 50ml/min 
(Young et al., 2007). Creatinine clearance was calculated using the Cockcroft-Gault 
equation as follows:  
Creatinine clearance (ml/min) = [(140-age) x weight (kg)] / [serum creatinine (µmol/l) 
x 1.23 (men) or 1.04 (women)]  
Blood pressure measurements were classified into different stages of hypertension 
as outlined in section 2.5.4 using the algorithm shown in Appendix C1.2. Diabetes 
mellitus, Hepatitis B or C, was defined by physician diagnosis or receipt of drugs 
indicating presence of the conditions.  
Due to the unavailability of height data which are required for calculating body mass 
index (BMI), a cut-off value for defining underweight had to be adopted. Patients 
weighing less than 50 kg were subjectively classified as underweight. 
Summary statistics which included mean, median and inter-quartile ranges for 
patients’ characteristics at baseline and at six-month intervals were tabulated and 
the variables were assessed for normality graphically. Graphical histograms were 
plotted to assess for skew in the data and for visual comparisons of the differences 
in patients’ characteristics between the TDF group and non-TDF group at baseline 
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and during treatment. Differences in patients’ clinical profiles at baseline and at six-
month intervals were analysed for significance using the t-test and Fisher’s exact 
test (See Appendix C2). Patient’s clinical profiles in non-numerical form such as 
patient medical conditions and prescribed drugs were converted to numerical data 
as outlined in Appendix C2.1.3 
Renal function was further categorised into CrCl>50 ml/min and CrCl<50 ml/min 
where CrCl<50 ml/min represented patients with baseline renal function 
contraindicated for TDF (Young et al., 2007). For full analysis of baseline renal 
function and renal function outcomes, CrCl values were categorised as follows: 
normal (90 ml/min), mild (60–89 ml/min), moderate (30–59 ml/min) and severe renal 
impairment (CrCl <30 ml/min) (Young et al., 2007). However, the classification of 
CrCl into two categories of CrCl<50 ml/min and CrCl>50 ml/min was used in the 
determination of the variables associated with sub-optimal renal function outcomes 
(CrCl<50 ml/min). 
Univariate and multivariate logistic regression analyses were done to determine 
significant variables associated with creatinine clearance less than 50 ml/min versus 
creatinine clearance greater than 50 ml/min at baseline. P-value and odds ratio 
outputs of the different variables tested were then compared. The variables tested 
for significance included age, weight, gender, baseline CD4 count, use of 
concomitant drugs, WHO clinical stage, conditions diagnosed, haematological 
factors, baseline serum creatinine clearance, the ART regimen, duration of 
treatment, among other variables. Duration of treatment was calculated as shown in 
Appendix C2.1.3. 
Predictors with p-values less than 0.1 in the univariate analysis were included in 
multivariate logistic regression analysis. Significant variables (p<0.05) were selected 
to remain in the final regression model.  
Due to limitations in the data recorded in the medical records, sub-optimal renal 
function outcomes were defined as follows:  
i. Renal function outcome where the latest value of CrCl was less than 50 ml/min 
ii. Renal function outcome where baseline CrCl was greater than 50 ml/min and the 
latest value of CrCl was less than 50 ml/min 
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iii. Renal function outcome where baseline CrCl was less than 50 ml/min and the 
latest value of CrCl was less than 50 ml/min 
iv. Renal function outcome where baseline CrCl was less than 50 ml/min and the 
latest value of CrCl was greater than 50 ml/min 
v. Renal function outcome where the average of CrCl values after baseline dropped 
by 25% or more from baseline 
vi. Renal function outcome where the latest value of CrCl dropped by 25% or more 
from baseline 
The six definitions above were developed into algorithms for detecting and 
classifying renal function outcomes. Definition (II) defined the primary outcome 
which was renal impairment as an outcome from normal baseline renal function. 
Definition number (I) was used to define the incidence of renal impairment, definition 
number (III) was used to define failure to improve renal function during treatment. 
Definition number (IV) was used to define improved renal function outcomes. 
Definitions (V) and (VI) which were adopted from Nishijima et al. (2011), were used 
to define the overall change in renal function during treatment. The actual algorithms 
generated from the definitions of impaired renal function are shown in Appendix 
C2.1.4.1. 
Univariate and multivariate logistic regression analyses were done for the different 
predictors comparing CrCl<50 ml/min and CrCl>50 ml/min outcomes as defined by 
definition (II) above. Predictors with a p-value less than 0.1 in the univariate analysis 
were included in multivariate logistic regression. Significant variables (p<0.05) were 
selected to remain in the final regression model.  
To put into perspective the effect of the variables that emerged as significantly 
associated with impaired renal function outcomes, case studies of patients with 
severe or end-stage renal impairment were constructed from the clinical profiles of 
the patients in those categories. Clinical profiles of patients with severe or end-stage 
renal impairment outcomes were generated as shown in Appendix C2.1.4.2.3. 
3.5.3 Assessment of immunological outcomes 
Three criteria were used to define immunological failure. Criterion (I) was adopted 
from Kantor et al. (2009). Criterion (II) and (III) were adopted from the WHO, (2010) 
Chapter 3: Methodology 
 
98 
 
criteria for defining immunological failure. Therefore, immunological failure was 
defined according to the following criteria: 
i. The latest CD4 count values which were less than baseline CD4 count by more 
than 25%;  
ii. Patients with the latest CD4 count values which were less than 50% of the peak 
CD4 count result. 
iii. Patients with the latest CD4 count results which were lower than 100 cells/mm3.  
The three definitions above were developed into algorithms for detecting 
immunological failure. The actual algorithms are shown in Appendix C2.2.3. 
Logistic regression analyses were performed to determine the variables associated 
with immunological failure. P-value and odds ratio outputs of the different variables 
tested were then compared. 
Possible variables tested included age, weight, gender, baseline (BL) CD4 count, 
WHO clinical stage, conditions diagnosed, the ART regimen, among other variables. 
Predictors with a p-value less than 0.1 in the univariate analysis were included in the 
multivariate logistic regression. Significant covariates (p<0.05) were selected to 
remain in the final regression model.  
To put into perspective the variables associated with immunological failure, patients 
with latest CD4 count values below 100 cells/mm3 were further categorised as 
having critical immunological failure and case studies were constructed from the 
characteristics of the patients in that category as shown in Appendix C2.2.6. 
3.6 Ethical Clearance 
The research protocol was submitted for ethical approval to the Ministry of Health 
and Social Welfare in Lesotho. The study was approved by the ethics review 
committee of the Ministry of Health and Social Welfare. Letters of approval are 
shown in Appendices D1–D3.  
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CHAPTER 4: RESULTS  
The chapter presents results of the two study phases–namely: renal function 
outcomes based on serum creatinine clearance and immunological outcomes based 
on CD4 counts. Phase 1 begins by comparing the baseline clinical profiles of 
patients in the non-TDF group and the TDF group. Then the following results are 
presented: renal function outcomes and the variables associated with impaired renal 
function outcomes. Phase 2 of the study begins by presenting the clinical profiles of 
the patients followed by variables associated with sub-optimal immunological 
outcomes.  
4.1 Renal Function Outcomes and the Variables Associated with 
Impaired Renal Function Outcomes  
4.1.1 Clinical profile of the study population at baseline 
Phase 1 presents results of the 312 patients who met the inclusion criteria for the 
sample group (TDF group) and 173 patients who met the inclusion criteria for the 
control group (non-TDF group). The presentations of the results begin by analysing 
differences in the clinical profiles of the TDF group compared to the non-TDF group. 
The ages of the study population ranged from 20 to 78 (See Figure 4.1). Age was 
normally distributed both in the TDF and the non-TDF groups. However, the 30-39 
age group was the most prevalent age group included in the study.  
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Figure 4.1: The age profile of patients in the study 
Table 4.1 presents the clinical profile of the patients. With respect to gender, the 
number of females was higher than the number of males in both the TDF group and 
the non-TDF group. The number of females in the non-TDF group was 63.6% 
compared to the number of males which was 36.4%. However, there were no 
significant differences in gender distribution between the TDF and the non-TDF 
group (p=0.258).  
Although the clinical profiles of the patients in the TDF group were generally 
comparable to the non-TDF group, a few variables were significantly different. For 
example, the mean baseline weight in the TDF group was significantly lower than 
the mean baseline weight in the non-TDF group (p<0.001). The TDF group also had 
a higher proportion of patients (29.8%) with baseline weight below 50 kg compared 
to the non-TDF group (18.5%). 
 
Chapter 4: Results 
 
 
102 
 
Table 4.1:  Clinical profile of the study population.  
Baseline (BL) characteristic Non-TDF Group (n=173) TDF Group (n=312) P-value 
Age, median years (Range) 42 (20-69) 38 (20-78) 0.235 
Gender, male  63 (36.4%) 130 (41.7%) 0.258 
Gender, female  110 (63.6%) 182 (58.3%) 0.258 
Weight (kg), mean (IQR) 58.9 (50.1-65.7)  54.9 (48.0-60.0) <0.001  
Weight (>60)  67 (38.7%) 84 (26.9%) 0.005 
Weight  (50-60)  74 (42.8%) 135 (43.3%) - 
Weight (<50)  32 (18.5%) 93 (29.8%) - 
WHO stage  I—III 165 (95.4%) 299 (95.8%) 0.819 
WHO stage IV  8 (4.6%) 13 (4.2%) - 
CD4 count: median(IQR) 142 (76-209) 167 (76.5-257) 0.029 
Low CD4 count (<50 cells/mm3) 23 (13.3%) 41 (13.1%) 1.000 
Hypertension stage I or II  24 (17.5%) 53 (20.4%) 0.593 
Systolic BP mean (IQR)  119.4 (110-130) 116.5 (100-120) 0.120 
Diastolic BP mean (IQR)  75.4 (70-80) 74.6 (70-80) 0.556 
Tuberculosis  12 (6.9%) 49 (15.7%) 0.006 
Hepatitis B or C  0 0 1.000 
Anaemia  94 (54.3%) 162 (52.8%) 0.775 
Haemoglobin less than 10.0 g/dl 13 (7.5%) 51 (16.6%) 0.005 
Raised ALT (ALT > 60)  12 (7.4%) 16 (5.3) 0.415 
Mean CrCl (IQR)  74.6 (55-90%) 72.1 (56-84%) 0.318 
CrCl<50 ml/min  32 (18.5%)  56 (17.95%) 0.902 
Normal CrCl (>90 ml/min)  44 (25.4%) 61 (19.6%) - 
Mild CrCl (60-90) ml/min  73 (42.2%) 153 (49.0%) - 
Moderate CrCl (30-60) ml/min  55 (31.8%) 98 (31.4%) - 
Severe CrCl (15-30) ml/min  1 (0.6%) 0 - 
CrCl = serum creatinine clearance; ALT = alanine amino-transferase; IQR = inter-quartile range; BP 
= blood pressure in mmHg; CD4 count is in cells/mm3; Significant p-values are highlighted in yellow. 
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Another baseline variable that was notably different between the non-TDF and the 
TDF groups was the baseline CD4 count of patients in the TDF group which was 
significantly higher than the baseline CD4 counts in the non-TDF group (p = 0.029).  
Tuberculosis was significantly more common in the TDF group than in the non-TDF 
group (p=0.006). The number of patients with hypertension stage I or II at baseline 
was high (about 20%) although there was no statistically significant difference 
between the TDF and the non TDF group with respect to the number of patients with 
hypertension (p=0.593). No patients were positive for Hepatitis B or C at baseline, 
both in the TDF group and the non-TDF group.  
There were no significant differences between the non-TDF and the TDF group with 
respect to the number of patients who were in WHO clinical stage IV; the number of 
patients with hypertension; Hepatitis B or C; anaemia; baseline laboratory values of 
ALT; and baseline serum creatinine clearance (CrCl). This means the baseline 
clinical features of the patients between the two groups were comparable. 
Concerning blood pressure levels at baseline, the TDF group and the non-TDF 
group did not differ significantly with respect to systolic (p=0.120) and diastolic       
(p=0.556) blood pressure. The numbers of patients with hypertension stage I or II 
also did not differ significantly between the two groups (p=0.593). However, the 
number of patients with hypertension was generally high considering that the 
percentage of patients with hypertension was about 20% across the two groups. 
When the baseline CrCl values were categorised according to Chronic Kidney 
Disease (CKD) stages, there were no significant differences in baseline renal 
function between the TDF and the non-TDF group. Two of the patients with liver 
disease at baseline were in the TDF group and the other two were in the non-TDF 
group.  
When the ranges of haemoglobin values were compared, the TDF group had a 
significantly higher number of patients with haemoglobin values less than 10 g/dl 
(p=0.005), meaning that there were more severe cases of anaemia in the TDF 
group than in the non-TDF group. The distributions of anaemia types in the TDF and 
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the non-TDF group are presented in Figure 4.2. There was a higher proportion of 
normocytic anaemia in both the TDF and the non-TDF groups.  
 
Figure 4.2: Anaemia types at baseline in the non-TDF and TDF groups 
4.1.2 Variables associated with impaired renal function at baseline 
Underweight, hypertension stage I or II, and older age were significant predictors of 
baseline CrCl<50 ml/min in univariate logistic regression analysis (See Table 4.2). 
For instance, considering odds ratios (OR), patients with a baseline body weight 
less than 50 kg were eight times more likely to have CrCl<50 ml/min outcome 
(p=0.001); and patients aged 60 or older were 24 times more likely to have baseline 
CrCl<50 ml/min (p=0.001). Furthermore, patients with hypertension stage I or II 
were more than three times more likely to have renal insufficiency at baseline. 
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Table 4.2:  Variables of the study population associated with impaired baseline renal function (CrCl<50 ml/min).  
 Variable CrCl>50 ml/min  
(n=397) 
CrCl<50 ml/min  
(n=88)  
Unadjusted OR  
(95% CI)  
P- value Adjusted OR  
(95% CI) 
P-value  
Age 20-29  61 (15.4%) 3 (3.4%) 1 - 1 - 
Age 30-39  156 (39.3%) 14 (15.9%) 1.8 (0.5-6.6) 0.358 2.1 (0.4-10.6) 0.351 
Age 40-49  111 (28.0%) 24 (27.3%) 4.4 (1.3-15.2) 0.019 8.6 (1.8-40.9) 0.007 
Age 50-59  53 (13.4%) 28 (31.8%) 10.7(3.1-37.4) <0.001 20.9 (4.3-102) <0.001 
Age 60-78  16 (4.0%) 19 (21.6%) 24.1(6.3-91.9) <0.001 82.2 (13.8-488) <0.001 
Weight>60 kg  141 (35.5%) 10 (11.4%) 1 - 1 - 
Weight 50-60 kg  176 (44.3%) 33 (37.5%) 2.6 (1.3-5.5) 0.010 4.4 (1.8-10.8) 0 .001 
Weight<50 kg  80 (20.2%) 45 (51.1%) 7.9 (3.8-16.6) <0.001 21.0 (8.0-54.9) <0.001 
Male    168 (42.3%) 25 (28.4%) 1 - 1 - 
Female  229 (57.7%) 63 (71.6%) 1.8 (1.1-3.1) 0.017 1.8 (0.9-3.6) 0.078 
No HTN 274 (85.1%) 46 (61.3%) 1  - - 
HTN stage I or II 48 (14.9%) 29 (38.7%) 3.6 (2.1-6.3) <0.001 3.0 (1.5-6.0) 0.002 
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CD4>50 cells/mm3 343 (86.4%) 78 (88.6%) 1  - - 
CD4<50 cells/mm3 54 (13.6%) 10 (11.4%) 0.8 (0.4-1.7) 0.575 - - 
WHO stage I—III 380 (95.7%) 84 (95.5%) 1 - - - 
WHO stage IV 17 (4.3%%) 4 (4.15%) 1.1 (0.3-3.2)  0.913 - - 
Anaemia negative  188 (48.0%) 36 (40.9%) 1 - - - 
Anaemia positive  204 (52.0%) 52 (59.1%) 1.3 (0.8-2.0) 0.241 - - 
OR = Odds Ratio; CI = confidence interval; HTN = hypertension; WHO stage = WHO clinical stage; Significant p-values are highlighted in yellow.  
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Although females had about twice as much chance as males of having baseline 
CrCl<50 ml/min (p=0.01), gender had no significant effect on baseline renal function 
(p=0.078). In addition, baseline CD4 counts below 50 cells/mm3 and WHO clinical 
stage had no significant effect on baseline renal function (p=0.575; and p=0.913 
respectively). Having anaemia at baseline was also not a significant predictor of 
having impaired renal function at baseline (p=0.241). Therefore, baseline CD4 
count, anaemia and WHO clinical stage were excluded in the multiple logistical 
regression steps. 
When the variables that were significant in univariate analysis were tested 
concurrently in multiple logistic regression steps, older age (age of 60 or above) 
emerged as the most decisive predictor of baseline CrCl<50 ml/min (OR = 82.2) 
followed by underweight (weight <50 kg) which had OR of 21.0, and lastly high 
blood pressure (OR=3.0). Female gender became insignificant (p=0.078) in multiple 
regression which means the effect of gender was less decisive compared to age, 
body weight and high blood pressure. 
Figure 4.3 presents the proportions of patients who were taking ARVs containing 
TDF despite having baseline CrCl<50 ml/min. On investigating the possible reasons 
why so many patients were taking ARVs containing TDF contrary to the guidelines, 
it appeared as if the ART centres were only calculating patients’ creatinine 
clearance values if the serum creatinine values were at least double the upper limit 
of the normal range irrespective of the patient’s age, gender or weight.  
Having found that underweight, high blood pressure, and older age were significant 
predictors of baseline CrCl<50 ml/min and that close to a fifth (17.9%) of the 
patients were erroneously treated with TDF, the focus switched to the renal function 
outcomes and the variables that were associated with impaired renal function 
outcome.  
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Figure 4.3: Proportion of the study population with impaired baseline renal 
function 
Cut-off value for impaired baseline renal function = CrCl<50 ml/min; CrCl = serum 
creatinine clearance in ml/min 
4.1.3 Renal function outcomes and the variables associated with impaired 
renal function outcomes 
Although the renal function outcomes improved by a median change of +4 ml/min at 
12 months from a baseline median of 69 ml/min (IQR 55-84) to a median of            
73 ml/min (IQR 57-92) and by another median change of +2 ml/min at 24 months, 
10 patients (2.1%) had severe impairment; and three patients had end-stage renal 
disease. Table 4.3 summarises the renal function categories at baseline and during 
treatment.  
The main outcome of interest between the TDF group and the non-TDF group was 
an impaired renal function outcome (CrCl<50 ml/min) with a normal baseline renal 
function because such a result would indicate that the patient developed renal 
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impairment during treatment. However, there were several possible outcomes 
depending on  whether a patient initiated on ART with either a normal baseline renal 
function or impaired  baseline renal function, had an improvement or deterioration 
with respect to renal function during treatment.  
Table 4.3:  Baseline renal function and renal function outcomes of the study 
population.  
 Baseline renal function  
(CrCl in ml/min) 
Renal function outcome  
(Latest CrCl  in ml/min) 
Renal function category in 
ml/min 
Frequency Percentage 
(%) 
Frequency Percentage 
(%) 
Normal GFR (>90) 105 21.7 120 24.7 
Mild (60-89)  226 46.6 216 44.5 
Moderate (30-59)  153 31.5 136 28.0 
Severe (15-29)  1 0.2 10 2.1 
ESRD (<15) 0 0 3 0.6 
Total 485 100.0 485 100 
BL = baseline; CrCl = serum creatinine clearance; and ESRD = end-stage renal disease. 
Table 4.4 presents the outcome combinations together with the results of the 
comparisons between the TDF and the non-TDF group. Table 4.4 also summarises 
how selected variables differed between the TDF and the non-TDF group. The 
variables include the number of patients whose latest absolute values of CrCl in 
ml/min dropped by 25% or more from baseline and the number of patients whose 
mean values of CrCl in ml/min dropped by 25% or more. Other variables include the 
number of patients who lost more than 5% of body weight during treatment and the 
number of patients who tested positive for various comorbidities that include 
tuberculosis and hypertension. 
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Table 4.4:  Renal function (RF) outcomes and variables of the study population.  
Variables Non-TDF Group 
(n=173) 
TDF Group  
(n=312) 
P-value 
Duration on ART in months, median (Range) 31 (6-48) 18 (6-48) <0.001 
Defaulted for 6 months or more  10 (5.8%) 29 (9.3%)  0.222 
Impaired RF outcome with normal or 
impaired baseline RF   
21 (12.4%) 60 (19.3%) 0.043 
Impaired RF outcome with normal baseline 
RF   
11 (5.8%) 40 (12.5%) 0.030 
Impaired RF outcome with impaired baseline 
RF  
10 (5.8%) 20 (6.4%) 0.846 
Normal RF outcome with impaired baseline 
RF  
21 (12.1%) 34 (10.9%) 0.765 
Latest CrCl dropped by >25% from BL  28 (16.5%) 72 (23.2%) 0.100 
Mean CrCl dropped by >25% from BL  20 (11.8%) 57 (18.3%) 0.069** 
Lost more than 5% body weight  25 (14.5%) 21 (6.7%) 0.009 
History of tuberculosis  58 (33.5%) 111 (35.6%) 0.691 
Hypertension stage I or II  36 (25.9%) 68 (25.1%) 0.905 
History of diabetes  0 2 (0.6%) 0.540 
History of Hepatitis B or C  0 1 (0.3%) 1.000 
History of herpes zoster  10 (5.8%) 11 (3.5%) 0.252 
ALT > 60 IU/l   11 (6.5%) 15 (4.8%) 0.527 
Had 1 or more comorbidity from BL 34 (19.7%) 96 (30.8%) 0.010 
CrCl = serum creatinine clearance in ml/min; RF = renal function; LFT = liver function test; IQR = 
inter-quartile range; **= marginally significant p-value; Significant p-values are highlighted in yellow. 
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Significant differences between the TDF group and the non-TDF group during 
treatment were noticed in three variables–namely: duration of treatment, number of 
patients with impaired renal function outcomes, and the number of comorbidities. 
Patients in the non-TDF group had longer duration of treatment than the TDF group 
(p<0.05). There were higher proportions of patients in the TDF group compared to 
the non-TDF group with respect to the incidence of CrCl<50 ml/min outcomes 
(p=0.043), and incidence of comorbidities (p=0.010). There was a marginally 
significant (p=0.069) difference between the number of patients whose mean CrCl 
dropped by 25% or more from baseline between the TDF and the non-TDF group.  
Duration of treatment differed significantly between the TDF and the non-TDF group 
(p<0.001). For instance, patients in the non-TDF group spent more months on 
treatment on average (median = 31 months; Range 6-48) than patients in the TDF 
group (median = 18 months; Range 6-48).  
The number of patients in the TDF group (See Table 4.4) who had impaired renal 
function outcome (19.3%, n=312) was significantly higher (p=0.043) than the 
number of patients with impaired renal function outcome (12.4%, n=173) in the non-
TDF group. When baseline renal function outcome was controlled by excluding 
patients with impaired baseline renal function (CrCl<50 ml/min), the number of 
patients in the TDF group who had impaired renal function outcome (12.5%, n=312) 
remained significantly higher (p=0.030) than the number of patients with impaired 
renal function outcome (5.8%, n=173) in the non-TDF group. 
When positive renal function outcome was considered, 12.1% of the patients in the 
non-TDF group had a positive renal function outcome compared to 10.9% in the 
TDF group. There were no significant differences in the proportion of patients with 
hypertension stage I or II between the TDF and the non-TDF group (p=0.905). 
However, the proportion of patients with hypertension stage I or II was very high 
(close to 25%) in both TDF and non TDF groups (See Table 4.4). The number of 
patients on treatment for hypertension was lower than the number of patients in 
stage I or II of hypertension in both groups (about 30% in patients with CrCl<50 
ml/min and 16% in patients with CrCl>50 ml/min outcome). This could have been 
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due to the fact that some patients whose data indicated stage I of hypertension were 
not put on treatment. 
When changes in CrCl were compared between the groups, the TDF group had a 
marginally significant proportion of patients whose mean CrCl values dropped by 
25% or more from the baseline (p=0.069). Moreover, when the baseline and the 
latest values of CrCl were considered, the proportions of patients with the latest 
absolute values of CrCl that dropped by 25% or more after baseline in the TDF 
group (23.2%) were not significantly different (p=0.100) from the non-TDF group 
(16.5%). However, the TDF group still had a comparatively higher proportion of 
patients with absolute CrCl values that dropped by 25% or more. Therefore, more 
patients in the TDF group had a negative outcome (40 or 12.5%) compared to the 
positive outcome (34 or 10.9%). In the non-TDF group, more patients had a positive 
outcome (21 or 12.1%) compared to the negative outcome (11 or 5.8%). In 
summary, although positive and negative outcomes occurred in both groups, the 
TDF group had a higher inclination towards the negative outcome.  
Figure 4.4 presents renal function outcomes in another perspective. The figure 
reflects that the TDF group had a larger proportion of patients with impaired renal 
function outcomes even when the renal function outcomes were controlled for 
baseline renal function.  
After considering the distribution of the variables of the study population between 
the TDF and the non-TDF group, the variables were analysed by univariate and 
multivariate logistic regression for association with impaired renal function outcomes 
(CrCl<50 ml/min).  
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Figure 4.4: Proportion of patients with impaired renal function outcomes versus 
baseline conditions.  
CrCl = serum creatinine clearance in ml/min 
Table 4.5 presents results for univariate (Unadjusted Odds Ratio)  and multivariate 
(Adjusted Odds Ratio) logistic regression analysis. In the univariate logistic 
regression analysis, the variables that had higher odds of predicting impaired renal 
function outcomes were: (1) use of TDF (OR=1.7); (2) age of 60 or higher 
(OR=14.2); (3) body weight <50 kg (OR=6.3); (4) female gender (OR=2.1); (5) 
hypertension (OR=2.8); and (6) baseline renal insufficiency (OR=4.2). 
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Table 4.5:  Logistic regression analysis of variables associated with impaired renal function outcomes.  
Variable CrCl>50  
(n=403) 
CrCl<50  
(n=82) 
Unadjusted OR   
(95% CI) 
P-value Adjusted OR  
(95% CI) 
P-value 
Non-TDF  152 (87.6) 21 (12.4) 1 - 1 - 
TDF group  251 (80.7) 61 (19.3) 1.7 (1.0-2.9) 0.054** 1.7 (0.9-3.2) 0.122 
Age 20-29  61 (14.8) 3 (3.2) 1 - 1 - 
Age 30-39  145 (37) 25 (31) 3.5 (1.0-12.0) 0.046 3.2 (0.9-11.6) 0.077 
Age 40-49  176 (43.7) 40 (48.8) 4.0 (1.1-13.9) 0.029 3.5 (1.0-12.9) 0.060* 
Age 50-59  176 (43.7) 40 (48.8) 5.6 (1.6-20.0) 0.008 3.8 (1.0-14.9) 0.053** 
Age 60-78  21 (5.2) 14 (17.1) 14.2 (3.7-54.6) <0.001 9.1 (2.0-41.2) 0.004 
Weight >60 kg  142 (35.2) 9 (11.0) 1 - 1 - 
Weight 50-60 kg  169 (41.9) 40 (48.8) 4.1 (1.9-9.1) <0.001 5.3 (2.1-13.6) < 0.001 
Weight <50 kg  92 (22.8) 33 (40.2) 6.3 (2.8-14.4) <0.001 8.6 (3.3-22.8) < 0.001 
Male    232 (57.8) 60 (73.2) 1 - 1 - 
Female  171 (42.4) 22 (26.8) 2.1 (1.2-3.6) 0.005 2.2 (1.2-4.1) 0.016 
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No HTN  267 (79.0) 39 (57.3) 1 - 1 - 
HTN I or II  71 (21.0) 29 (42.7) 2.8 (1.6-4.8) <0.001 2.2 (1.2-4.0) 0.009 
CrCl >50 ml/min  347 (86.1) 50 (60.9) 1 - 1 - 
CrCl <50 ml/min  56 (13.9) 32 (39.0) 4.2 (2.5-7.1) <0.001 1.6 (0.8-3.2) 0.218 
HTN = Hypertension; CrCl = baseline serum creatinine clearance in ml/min; OR= odds ratio;  ** = marginally significant; Significant p-values are highlighted 
in yellow. 
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When multivariate regression analysis was performed, a number of significant 
variables remained in the final model (see Table 4.5). The significant variables 
included old age especially ages over 60 (p=0.004), body weight less than 50 kg 
(p<0.001), female gender (p=0.016), and high blood pressure (p=0.009). Although 
the use of TDF had higher odds ratio of developing impaired CrCl outcome 
(adjusted OR=1.5) compared to the non-TDF group, the use of TDF became 
insignificant in the final adjusted model (p=0.122). When odds ratios (OR) were 
compared, older ages above 60 had the highest odds ratio (adjusted OR=9.1) of 
having CrCl<50 ml/min followed by having a baseline weight less than 50 kg 
(adjusted OR=8.6).  
Table 4.6 presents the number of patients with different categories of renal function 
outcomes. Sixty patients (19.6%) in the TDF group had impaired renal function 
outcome compared to 21 patients (12.1%) in the non-TDF group. Forty patients 
(12.5%) who had CrCl>50 ml/min at baseline developed impaired renal function 
outcomes in the TDF group compared to 11 patients (5.8%) in the non-TDF group.   
Table 4.6:  Categories of renal function outcomes with different baseline renal 
function conditions.  
Renal 
function 
category 
Number of patients with 
impaired renal function 
outcome for the whole 
study population  
Number of patients with 
impaired renal function 
outcome with impaired 
baseline renal function  
Number of patients with 
impaired renal function 
outcome with normal 
baseline renal function 
 Non-TDF group TDF group Non-TDF 
group 
TDF group Non-TDF 
group 
TDF group 
30-50  19 (90.5%) 49 (81.7%) 10 (100%) 15 (75%) 9 (81.8%) 34 (85.0%) 
15-30  1 (4.8%) 9 (15.0%) - 4 (20%) 1 (9.1%) 5 (12.5%) 
< 15  1 (4.8%) 2 (3.3%) - 1 (5%) 1 (9.1%) 1 (2.5%) 
Totals 21 (100%) 60 (100%) 10 (100%) 20 (100%) 11 (100%) 40 (100%) 
Renal function categories are in ml/min; cut-off value for impaired renal function outcome was 
CrCl<50 ml/min; CrCl = creatinine clearance in ml/min. 
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Results for further analysis of clinical profiles of patients who had severe or end-
stage renal impairment are presented in Table 4.7. A review of the patients’ clinical 
profiles indicated that the TDF group had five patients with severely impaired renal 
function outcome (CrCl values between 15 and 30 ml/min) compared to one patient 
in the non-TDF group; and that the patients in the TDF group either had various 
conditions at baseline associated with impaired renal function outcome or were 
diagnosed of the conditions during treatment. The two patients who had end-stage 
renal disease; one in the TDF group and the other one in the other non-TDF group; 
also had conditions associated with impaired renal function outcome. For example, 
the one patient in the TDF group had hypertension, low baseline weight, and 
tuberculosis whilst the other one patient in the non-TDF group had tuberculosis and 
raised CrCl at baseline.  
The clinical profiles of the patients presented in Table 4.7 further illustrate the 
importance of baseline renal function screening. For instance, most of the patients 
on TDF who had severely impaired renal function outcomes had baseline serum 
creatinine close to the upper limit of the normal range.  
While still on the clinical profiles of the patients with severely impaired renal function 
outcome or worse, the effect of the variables that emerged as significant predictors 
of impaired renal function outcome became apparent. For example, the four patients 
who developed severe renal impairment were taking ARVs and anti-TB drugs such 
as Rifampicin concurrently.  
4.1.4 Renal function outcomes: Summary of the findings 
Overall, the renal function outcomes improved by a median change of +4 ml/min 
from a baseline median of 69 ml/min (IQR 55-84) to a median of 73 ml/min (IQR 57-
92) at 12 months and by a median change of +2 ml/min (IQR 56-92) at 24 months. 
Ten patients (2.1%) developed severe renal impairment outcomes and three 
patients developed end-stage renal disease outcomes.  
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Table 4.7:  Clinical profiles of patients with severely impaired renal function and 
end-stage renal disease outcomes.  
Severely impaired renal function outcome (CrCl: 15-30ml/min) with baseline CrCl>50 ml/min  
Non-TDF Group (n=1) TDF Group (n=5) 
Female aged 38; was 
diagnosed with TB while on 
ART; was taking anti TB 
drugs; BL creatinine (69 
µmol/l); had normocytic 
anaemia at BL with 
neutropaenia; had macrocytic 
anaemia after six months; Had 
raised ALT at BL(160 IU/l) and 
normal ALT& AST at six 
months; was on 
AZT+3TC+EFV; with BL CD4 
count of (62-381 cells/mm3) 
1. Male aged 41 with a low BL weight (49); was in WHO stage III at 
BL; BL creatinine (99 µmol/l); CD4 count (164-399 cells/mm3) 
2. Female aged 52 with BL weight (62.1 kg); BL creatinine (80 
µmol/l); normal BL ALT and AST; CD4 count (254-311 
cells/mm3) 
3. Male aged 48, in stage III at BL who lost weight and had IMF. 
Normal BL liver profile; BL creatinine (98 µmol/l); had 
neutropaenia with macrocytosis at BL; CD4 count (28-27 
cells/mm3) 
4. Female aged 49 diagnosed with TB while on ART; was taking 
anti-TB drugs; was anaemic at BL (Hb less than 10.0); BL 
creatinine (96 µmol/l); CD4 count (63-550 cells/mm3), had 
hypertension 
5. Male aged 70 with a low BL weight (52 kg); Had TB at BL; lost 
weight during ART; normal BL ALT and AST. CD4 count (199-
408 cells/mm3). Patient 1 to 5 were all on TDF+3TC+EFV  
End-stage renal disease (CrCl <15ml/min) with baseline CrCl>50 ml/min 
Non-TDF Group(n=1) TDF Group (n=1) 
Female aged 46 who had TB 
at BL; BL weight (56 kg); 
WHO stage III at BL; was 
taking anti-TB drugs. Had BL 
creatinine (100 µmol/l) and 
urea 3.4 mmol/l; normal BL 
ALT(45 IU/l)  
Female aged 53 diagnosed with TB while on ART; was taking anti-
TB drugs. Baseline creatinine (66 µmol/l); Low baseline weight (42 
kg); BL ALT(57); ALT at six months (88 IU/l); had hypertension; was 
on TDF+3TC+EFV; CD4 (274-400 cells/mm3)  
BL= baseline; Values of considered parameters are given in brackets where available; For CD4 
count results, the BL CD4 count and the latest CD4 counts are given. 
When patients were categorised according to TDF and non-TDF groups, 60 patients 
(19.5%) in the TDF group and 21 patients (12.1%) in the non-TDF group had 
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impaired renal function outcomes. Five patients (1.6%) in the TDF group compared 
to one patient (0.6%) in the non-TDF group (CrCl>50 ml/min) developed severe 
renal impairment and one patient in the TDF group compared to one patient in the 
non-TDF group developed end-stage renal disease despite having baseline 
CrCl>50 ml/min. 
The use of ARVs containing TDF emerged as a marginally significant factor 
associated with impaired renal function outcomes in the univariate logistic 
regression analysis (p=0.054) but emerged as an insignificant factor (p=0.122) in 
the multivariate analysis. CrCl<50 ml/min outcomes were significantly associated 
with underweight (p<0.001), high blood pressure (p=0.009), female gender 
(p=0.016) and older age above 60 (p=0.004). 
4.2 Immunological Outcomes and the Variables Associated with 
Sub-optimal Immunological Outcomes 
4.2.1 Clinical profile of the study population  
Phase 2 of the study presents results of the 516 patients who met the selection 
criteria for the assessment of immunological outcomes based on CD4 counts. The 
presentations of the results begin by analysing differences in the clinical profiles of 
the patients who developed immunological failure (IMF) compared to the patients 
who did not. As a recap, patients were categorised as having IMF if their latest CD4 
count values were less than the baseline CD4 count by more than 25%; had latest 
CD4 counts less than 50% of the peak CD4 count result; or if the latest CD4 counts 
values were below 100 cells/mm3, whichever was the case. 
Table 4.8 presents the clinical profiles of the patients included in the study. More 
males had results indicating IMF than females (p=0.002). Regarding age, there was 
no significant difference in age between the group that developed IMF and the 
group that did not (p=0.238). However, age was not equally represented in the 
study. The most prevalent age group was the 30-39 age group. Almost half (48.6%) 
of the 35 patients with IMF belonged to the 30-39 age group. Only one patient from 
the 60-78 age group had IMF.  
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Table 4.8:  Clinical profiles of the patients analysed for immunological outcomes.  
Variables IMF negative (n=481) IMF positive (n=35) P-value 
Male  183 (38.1%) 23 (65.7%) 0.002 
Female  298 (61.9%) 12 (34.3%) - 
Age, median (Range) 40 (19-71) 36 (21-78) 0.084 
Age 19-29)  59 (12.3%) 6 (17.1%) 0.238 
Age 30-39)  172 (35.8%) 17 (48.6%) - 
Age 40-49)  133 (27.6%) 9 (25.7%) - 
Age 50-59)  80 (16.6%) 2 (5.7%) - 
Age 60-78)  37 (7.7%) 1 (2.9%) - 
Baseline weight , median (IQR)  55 (49-60) 53.7 (50-60) 0.493 
Baseline weight (>60 kg)  141 (29.3%) 9 (25.7%) 0.733 
Baseline weight (50-60 kg)  211 (43.9%) 18 (51.4%) - 
Baseline weight (<50 kg)  129 (26.8%) 8 (22.9%) - 
Baseline CD4, median (IQR) 151 (76-241) 89 (32-262) 0.082 
Baseline CD4 (>200)  165 (34.3%) 10 (28.6%) 0.014 
Baseline CD4 (100-200)  164 (34.1%) 6 (17.1%) - 
Baseline CD4 (50-100)  83 (17.3%) 7 (20.0%) - 
Baseline CD4 (<50)  69 (14.4%) 12 (34.3%) - 
History of TB  171 (35.6%) 13 (37.1%) 0.856 
History of hypertension  78 (18.9%) 5 (23.8%) 0.572 
History of diabetes  1 (0.2%) 0 1.000 
Hepatitis B positive  4 (0.9%) 0 1.000 
History of Herpes zoster  21 (4.5%) 0 1.000 
History of anaemia  298 (61.9%) 22 (61.4%) 1.000 
History of abnormal LFT  8 (17.4%) 0 1.000 
WHO clinical stage I—III  461 (95.8%) 34 (97.1%) 1.000 
WHO clinical stage IV 20 (4.2%) 1 (2.9%) - 
TDF Group  300 (62.4%) 24 (68.6%) 0.587 
Non-TDF Group  181 (37.6%) 11 (31.4%) - 
LFT = liver function test; IQR = Inter-quartile range; Significant p-values are highlighted in yellow. 
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With respect to baseline weight, there was no significant difference in median 
baseline weight between the group that developed IMF and the group that did not 
(p=0.493). However, a number of patients who developed IMF had baseline weight 
below 50 kg. For example, in the group that did not develop IMF, just over one 
quarter (26.8%, n=481) weighed below 50 kg at baseline.  
Baseline CD4 count values for the group that developed IMF were significantly 
lower than the group that did not develop IMF (p=0.014). Although the median value 
for the CD4 counts for the IMF group were not significantly lower than the group that 
did not develop IMF (p=0.082), the IMF group generally, had a lower median 
baseline CD4 count value (89 cells/mm3) compared to the other group (151 
cells/mm3). Moreover, about one-third (34.3%, n=35) of the patients who developed 
IMF outcomes, had baseline CD4 count below 50 cells/mm3.  
The other variables such as the proportion of patients having tuberculosis, hepatitis, 
diabetes and hypertension were not significantly different between the group that 
developed IMF outcomes and the group that did not. In addition, the proportion of 
patients having Herpes zoster, anaemia or liver disease were also not significantly 
different between the group that developed IMF outcomes and the group that did not 
develop IMF outcome. Similarly, the proportions of patients who were categorised 
under WHO clinical stage IV as well as the proportion of patients on TDF-based 
ART were also not significantly different between the group that developed IMF 
outcomes and the group that did not develop IMF outcome. 
4.2.2 Immunological outcomes and the variables associated with 
immunological failure 
Having presented the results on the clinical profiles of the patients, the focus 
switched to presentation of detailed results of the immunological outcomes and the 
variables associated with IMF outcomes obtained after carrying out logistic 
regression analysis. The presentation is carried out in this order: (1) summaries of 
the immunological outcomes of the study population; (2) analysis of immunological 
outcomes relative to ART regimens; (3) analysis of the variables associated with 
IMF. 
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Although on average 6.8% of the patients developed IMF, the benefits of ART were 
still noticeable based on the CD4 counts. Generally, CD4 counts increased 
significantly by more than double (233%) from a baseline average of 163 cells/mm3 
to an average of 380 cells/mm3 after treatment (p<0.001). The histogram of CD4 
counts after treatment was more normally distributed compared to the histogram of 
CD4 counts at baseline (See Figure 4.5).  
 
Figure 4.5: Histogram of baseline CD4 counts and CD4 count outcomes 
The three different criteria used to define IMF yielded different results. Table 4.9 
highlights the distribution of IMF results by criteria used to detect IMF outcomes. Out 
of the 516 patients included in the study, 35 patients (6.8%) had sub-optimal 
treatment outcome based on CD4 counts. Fourteen patients had the latest CD4 
count values below 100 cells/mm3 and 15 patients had the latest CD4 count values 
which were below the baseline CD4 count values by 25% or more. Only six patients 
had CD4 counts that indicated a 50% drop from the peak value. Therefore, the most 
critical indicators of IMF were: (1) having the latest CD4 count below the baseline 
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CD4 count by 25% or more; and (2) having the latest CD4 count value lower than 
100 cells/mm3. 
Table 4.9:  Distribution of immunological failure results by criteria of detecting 
immunological failure 
Criteria for determining IMF IMF (%)  
(n=35) 
% of study population 
(n=516) 
Latest CD4 count < 75% of BL CD4 count  15 (42.9) 2.9 
Latest CD4 count <50% peak CD4 count  6 (17.1) 1.2 
Latest CD4 count lower than 100 cells/mm3  14 (40.0) 2.7 
Total 35 (100) 6.8 
IMF = immunological failure; % = percentage 
When baseline CD4 count cut-off values and ART regimens were tabulated against 
IMF results (See Table 4.10), three important points were noted: (1) D4T-based 
ART regimens had the least number of patients (11 out 516) in the study meaning 
that TDF and AZT-based ART regimens were the two main regimens evaluated in 
the study; (2) highest rates of IMF outcomes for AZT-based and TDF-based 
regimens occurred in the patient category with baseline CD4 counts below 50 
cells/mm3; (3) The proportion with Immunological failure outcome for TDF-based 
regimens (7.4%, n=309) was not significantly different (p=0.458) from that of AZT-
based regimens (5.7%, n=192). This indicates that immunological outcomes of TDF-
based ART regimens were not significantly different from AZT-based regimens.  
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Table 4.10:  Comparison of immunological failure (IMF) outcomes versus ART 
regimens and baseline CD4 cut-off values.  
BL CD4 cut-off values D4T+3TC+ 
EFV/NVP 
AZT+3TC+ 
EFV/NVP 
TDF+3TC+ 
EFV/NVP 
Total  
<50 cells/mm3 [IMF (n)] 
IMF% 
0 (5) 
0 
4 (32) 
12.5 
6 (44)  
13.6 
10 (81) 
12.3  
50-100 cells/mm3 [IMF (n)] 
IMF% 
0 (4) 
0 
3 (35)  
8.6 
3 (51) 
5.9  
6 (90) 
6.7 
100-200 cells/mm3 [IMF (n)] 
IMF% 
0 (5)  
0 
3 (70)  
4.3 
4 (95) 
4.2 
7 (170) 
4.1 
>200 cells/mm3 [IMF (n)] 
IMF% 
1 (1) 
100 
1 (55) 
1.8 
10 (119) 
8.4 
12 (175) 
6.9 
Total [IMF (n)] 
IMF% 
1 (11) 
9.1 
11 (192) 
5.7 
23 (309) 
7.4 
35 (516) 
6.8 
BL = baseline; IMF = immunological failure outcomes; %IMF = Percentage of patients with IMF in 
each category; CD4 counts are in cells/mm3; AZT = Zidovudine; EFV = Efavirenz; D4T = Stavudine; 
and 3TC = Lamivudine; EFV/NVP means regimen contained either EFV or NVP. 
As a recap, the analysis of the variables associated with IMF was based on 
univariate and multivariate logistic regression analysis. Several variables were 
analysed for possibility of association with IMF outcome, including gender, age, 
body weight, baseline CD4 count, use of TDF-based ART regimens, and patients’ 
adherence to treatment. 
Table 4.11 presents variables that were significantly associated with IMF in the 
univariate analysis.  
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Table 4.11:  Variables and baseline CD4 cut-off points associated with immunological failure outcomes.  
Variables IMF Negative  
(n=481) 
IMF Positive  
(n=35) 
Unadjusted OR 
(95% CI) 
P-value Adjusted OR  
(95% CI) 
P-value 
Female  298 (61.0%) 12 (34.3%) 1    
Men  183 (38.0%) 23 (65.7%) 3.1 (1.5-6.4) 0.002 2.8 (1.3-5.8)  0.005 
Age 19-29  59 (12.3%) 6 (17.1%) 1    
Age 30-39  172 (35.8%) 17 (48.6%) 1.0 (0.3-2.6) 0.954 - - 
Age 40-49  133 (27.6%) 9 (25.7%) 0.6 (0.2-2.0) 0.459 - - 
Age 50-59  80 (16.6%) 2 (5.7%) 0.2 (0.04-1.3) 0.093   
Age 60-78  37 (7.7%) 1 (2.9%) 0.3 (0.03-2.3) 0.228 - - 
BL Weight>60  141 (29.3%) 9 (25.7%) 1    
BL Weight 50-60  211 (43.9%) 18 (51.4%) 1.3 (0.6-3.1) 0.492 - - 
BL Weight <50  129 (26.8%) 8 (22.9%) 1.0 (0.4-2.5) 0.954 - - 
Weight loss <5%  440 (91.5%) 29 (82.9%) 1  1  
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Weight loss >5%  41 (8.5%) 6 (17.1%) 2.2 (0.8-5.6) 0.095** 2.3 (0.9-6.0)  0.095 
No treatment default  440 (91.5%) 33 (94.3%) 1  - - 
Defaulted treatment  41 (8.5%) 2 (5.7%) 0.7 (0.2-2.8) 0.564 - - 
Non-TDF Group  181 (37.6%) 11 (31.4%) 1    
TDF Group  300 (62.4%) 24 (68.6%) 1.3 (0.6-2.8) 0.465 - - 
BL CD4>200 cells/mm3  165 (34.3%) 10 (28.6%) 1 - 1  
BL CD4 100-200 cells/mm3  164 (34.1%) 6 (17.1%) 0.6 (0.2-1.7) 0.339 0.6 (0.2-1.7) 0.308 
BL CD4 50-100 cells/mm3  83 (17.3%) 7 (20.0%) 1.4 (0.5-3.8) 0.518 1.3 (0.5-3.7) 0.584 
BL CD4<50 cells/mm3  69 (14.4%) 12 (34.3%) 2.8 (1.2-7.0) 0.020 2.5 (1.0-6.1) 0.049 
BL = baseline; ** Marginally significant; OR = Odds ratio; IMF = immunological failure; Significant p-values are highlighted in yellow. 
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The variables that were significantly associated with IMF in the univariate analysis 
included male gender (p=0.002); baseline CD4 counts below 50 cells/mm3 
(p=0.020); and weight loss of more than 5% from baseline (only significant at 90% 
confidence level).  
In multivariate analysis, male gender (p=0.005) and baseline CD4 count below 50 
cells/mm3 (p=0.049) remained significant predictors of IMF outcome. Although 
weight loss of 5% or more was an important variable determining the development 
of sub-optimal immunological outcomes (p=0.097), the variable was not statistically 
significant at 95% confidence level (p=0.095).  
With respect to the use of TDF-containing ART, there were no significant differences 
in immunological responses between the patients using TDF and the other patients 
using non-TDF based ARVs (p=0.587). Therefore, the use of TDF-based ARVs had 
immunological outcomes that were essentially similar to non-TDF-based ARVs. 
To put into perspective the variables associated with IMF, patients with the latest 
CD4 counts below 100 cells/mm3 were categorised as having critical IMF and their 
clinical profiles were further analysed. This was done to highlight the significance of 
the variables associated with IMF outcomes. 
More than half (57%) of the patients with IMF had critical IMF. Most of the patients 
with critical IMF were males. Only two patients out of the 20 patients with IMF were 
aged 50 or higher which means critical IMF was not associated with old age. One 
fifth of the patients with critical IMF lost at least 5% body weight. Interestingly, all the 
five patients who had weight loss during treatment had baseline CD4 counts below 
100 cells/mm3. Apparently, advanced baseline WHO clinical stages such as stage III 
and IV did not make a decisive trend. Only one patient was in WHO clinical stage IV 
at baseline. Therefore, the clinical stage of the disease was not a critical factor 
determining critical IMF outcome. Although the disease TB was not a significant 
predictor of critical IMF outcome, just above one-third (35%) had TB at baseline or 
had the disease TB diagnosed during treatment. Only two patients had records 
confirming failure to collect ARVs on at least one occasion. Therefore, the 
occurrence of immunological failure could not be explained by treatment defaulting.  
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4.2.3. Immunological outcomes: Summary of the findings 
Generally, CD4 counts increased significantly by more than double (233%) from a 
baseline average of 163 cells/mm3 to an average of 380 cells/mm3 after treatment 
(p<0.001). However, out of the 516 patients included in the study, 35 patients 
(6.8%) had sub-optimal immunological outcomes based on CD4 counts. Twenty of 
the 35 patients with IMF had critical IMF defined in the study as CD4 outcome below 
100 cells/mm3. Further analysis of the 20 patients with critical IMF showed that most 
of the patients with critical IMF had multiple variables associated with IMF.  
With respect to gender, the male gender was a significant predictor of IMF               
(p=0.005). One of the reasons for males having a higher likelihood of developing 
IMF could be poor adherence to ART. Although weight loss of 5% or more was an 
important variable determining the development of sub-optimal immunological 
outcomes, the variable was not statistically significant at 95% confidence level 
(p=0.095).  
The other important variable determining the likelihood of a patient developing IMF 
was baseline CD4 count below 50 cells/mm3 (p=0.049). However, baseline CD4 
count was a confounding variable in the study because baseline CD4 count values 
for the group that developed IMF were significantly lower than that for the group that 
did not develop IMF (p=0.014). 
There were no significant differences in immunological responses between the 
patients using TDF and the other patients using non-TDF based ARVs (p=0.587). 
The two main regimens in use were TDF and AZT-based regimens. When TDF and 
AZT-based regimens were compared, there was no significant difference between 
the two with respect to the proportion with immunological outcomes (p=0.458). 
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CHAPTER 5:   DISCUSSIONS 
The chapter presents discussions of the results presented in chapter 4 in the same 
order in which the results were presented. The chapter begins with discussions on 
renal function outcomes based on serum creatinine clearance and then moves on to 
discussions on immunological outcomes based on CD4 counts.  
5.1 Renal Function Outcomes 
5.1.1 Clinical profile of the study population and renal function at baseline  
5.1.1.1 Clinical profile of the study population at baseline 
Although there was no significant difference between the TDF and the non-TDF 
group with respect to age (p=0.235), the 30-39 age group constituted more than 
one-third of the study population. The high frequency of this age group might mean 
that there is a higher risk of HIV infection in this age group. The results were similar 
to the results of another study conducted in Lesotho by Nagesh (2008), who 
reported that the 30-39 age group constituted up to 43.7% (n=255) of the study 
population. 
The most common infection at baseline was tuberculosis. This was in line with the 
national TB statistics. According to the WHO (2008), there was a phenomenal 
increase in the number of TB cases between 2006 and 2008 in Lesotho possibly 
because of the increase in the number of HIV and AIDS cases. Moreover, according 
to a report by the Government of Lesotho, about three-quarters (76%) of TB patients 
in Lesotho are co-infected with HIV (GoL, 2012). 
Patients in the TDF group had higher baseline CD4 counts than patients in the non-
TDF group. This could be due to the change in the national guideline on CD4 count 
threshold below which patients could begin ART in Lesotho. Beginning in 2007, HIV 
patients were put on ART when the CD4 count fell below 350 CD4 cells/mm3 (GoL, 
2010). Before then, HIV patients were only put on ART if the CD4 count fell below 
200 cells/mm3. Interestingly though, there was no significant difference in the 
proportions of patients with very low CD4 counts (CD4 count <50 cells/mm3) 
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between the TDF and the non-TDF group (p=1.00) as reflected in Table 4.1 on page 
104.  
The distribution of anaemia types in the TDF and the non-TDF group, which had a 
higher proportion of normocytic anaemia in both the TDF and the non-TDF group, 
was consistent with a typical anaemia profile in HIV and AIDS disease. Normocytic 
anaemia is common in HIV and AIDS patients (Wilson et al., 2008). However, 
anaemia was not a significant predictor of having impaired renal function at 
baseline. 
Although the current guidelines do not indicate an upper age limit at which patients 
may not be given TDF, some patients older than 70 were put on TDF-containing 
regimens. Older patients were at a higher risk of having impaired renal function 
outcome than younger patients because according to Thomson (1995) & Naughton 
(2008), GFR decreases with age. 
Although the percentages of patients who had baseline renal impairment in the two 
groups were not significantly different, when the levels of serum creatinine 
clearance values at baseline were looked at closely, two interesting points became 
clear: 56  (17.9%) were put on TDF-based regimens despite having compromised 
baseline renal function; and some patients with creatinine clearance values as low 
as 32 were put on TDF contrary to the guideline which states that patients with 
baseline CrCl below 50 ml/min should not be put on TDF (GoL, 2010). This implies 
that some clinicians might not have been informed enough about the screening 
criteria. 
5.1.1.2 Variables associated with impaired renal function at baseline 
Having TB at baseline and WHO clinical stage IV were not significant predictors of 
having impaired renal function at baseline. The study findings concurred with the 
findings by Bygrave et al. (2011a) who also did not find WHO clinical stage and 
having TB at baseline to be significant predictors of having impaired renal function 
at baseline. 
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Having anaemia at baseline was not a significant predictor of having impaired renal 
function at baseline (p=0.241). The results of the study differed from the findings in 
Zambia by Mulenga, Kruse, Lakhi, Cantrell & Reid (2008), who reported that having 
anaemia was predictive of impaired renal function at baseline. However, the results 
concurred with the findings by Bygrave et al. (2011a) who also did not find anaemia 
to be a significant predictor of having impaired renal function at baseline. 
The results of the study concurred with the findings in the UK by Nelson et al. (2007) 
and in the USA by Crum-Cianflone et al. (2010) with respect to the variables that 
emerged as significant predictors of having impaired renal function at baseline. The 
two studies reported that underweight, female gender and older age were significant 
predictors of impaired renal function at baseline.  
The results of this study were also similar to the findings at another site in Lesotho 
by Bygrave et al. (2011a) with respect to gender and age but differed with respect to 
CD4 counts. Whereas findings by Bygrave et al. (2011a) showed that having 
baseline low CD4 counts was predictive for the development of renal impairment, 
this study did not show that low baseline CD4 was a significant predictor for 
development of renal impairment. The results might have differed from the results 
reported by Bygrave et al. (2011a) due to differences in the study populations. 
5.1.2 Renal function outcomes and variables associated with impaired renal 
function outcomes 
Use of low baseline CD4 as a criterion for determining who should be screened, as 
suggested by Bygrave et al. (2011a), might pose a challenge. The baseline CD4 
counts for the same patients were inconsistent, with some patients having baseline 
CD4 counts equal to or greater than 200 cells/mm3 despite having severe or end-
stage renal impairment. Bygrave et al. (2011a) investigated the feasibility of 
screening for renal function only for the patients of ages above 40 and CD4 count 
less than 200 cells/mm3.  
Five (1.6%) of the nine patients who had baseline CrCl>50 ml/min in the study 
developed severe renal impairment. A study in Spain by Padilla, Gutiérrez, Masiá, 
Cánovas & Orozco (2005), reported that five patients (4%, n=122) in the TDF group 
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versus 1 out of 194 patients in the control group developed moderate renal 
impairment. Another study by Young et al. (2007) in the USA reported that renal 
disease was diagnosed in seven patients (1%, n=593) who were exposed to TDF 
and three patients (0.5%, n=521) who were not exposed to TDF. Nelson et al. 
(2007) in the UK reported that 51 (0.5%, n=10 343) developed severe renal disorder 
whilst 227 patients (2.2%, n=10 343) developed moderate renal impairment. 
Another study by Patel et al. (2010) in India reported that 79 patients (6.2%,        
n=1 271) developed moderate renal impairment and five patients (0.4%, n=1 271) 
developed Fanconi’s syndrome. 
In this study, the four patients who developed severe renal impairment were taking 
ARVs and anti-TB drugs such as Rifampicin concurrently. Rifampicin is associated 
with interstitial nephritis (Schetz et al., 2005; Loh & Cohen, 2009). Attributing 
impaired renal function outcomes to TDF alone, therefore, becomes a challenge. 
However, one reason why the use of nephrotoxic medications was not a significant 
factor in the study could be because one of the drugs defined as nephrotoxic in the 
study, Rifampicin, was used in almost equal proportions between the TDF (35.6%, 
n=312) and non-TDF group (33.5%, n=173).  
In this study, six out of 312 patients in the TDF group had end-stage renal disease 
compared to two out of 172 patients in the non-TDF group. In terms of renal function 
outcomes, these results are more or less comparable to findings by Young et al. 
(2007) who reported that renal disease occurred in seven patients in the TDF group     
(n=593) and three patients in the non-TDF group (n=521).  
The overall prevalence of moderate renal insufficiency (30-60 ml/min) at baseline 
which was 31.5% in this study almost concurred with the findings by Mulenga et al. 
(2008) who reported a prevalence rate of 23.4% for moderate renal insufficiency in 
Zambia. However, the prevalence of mild renal insufficiency at baseline in this study 
was higher than the one reported by Franey, Knott, Barnighausen, Dedicoat & 
Cooke (2009), in South Africa which was 13.1% (n=2 189). There are differences in 
age groups assessed for renal function in the studies. For instance, Franey et al. 
(2009) considered patients whose median age was 36 (IQR 30-43).  The median 
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age in this study was 40 (IQR 32-49). This study therefore considered older 
patients, which may explain the higher prevalence of mild renal insufficiency. 
The results are also similar to findings by Padilla et al. (2005) who reported that five 
patients in the TDF group (n=122) versus one patient in the non-TDF group (n=194) 
developed serum creatinine elevations associated with WHO stage I or higher 
kidney disease. Other studies with findings that concur with the findings of this study 
to some extent, were by: Post, Moyle, Stellbrink, Domingo, Podzamczer, Fisher, 
Norden, Cavassini, Rieger, Khuong-Josses, Branco, Pearce, Givens, Vavro & Lim 
(2010), in the UK; De Beaudrap et al. (2010) in Senegal; Tordato, Cozzi, Lepri, 
Cicconi, De Luca, Antinori, Colangeli, Castagna, Nasta, Ladisa, Giacometti, 
d'Arminio & Gori (2011), and Calza et al. (2011) in Italy, who reported that there 
were increases in markers of tubular dysfunction in the TDF groups but did not 
observe significant differences between the TDF and the non-TDF groups and that 
the observed differences between the TDF and the non-TDF groups were only mild 
changes with little clinical significance.  
The results from the study by Brennan et al. (2011) in South Africa which showed 
that TDF may only worsen a pre-existing renal disorder, also concurred with the 
results of this study. Screening for pre-existing renal disorder therefore may need to 
be emphasised in Lesotho. The results of the study showed that there were many 
leakages (20 patients or 19.5%) in the screening of baseline renal function before 
patients were put on ARVs containing TDF. Therefore, selective screening of 
baseline serum creatinine may be controversial because of the high likelihood of 
missing patients with impaired renal function at baseline. According to the study 
carried out in the area of Morija in Lesotho by Bygrave et al. (2011a), selective 
screening of baseline renal function missed 14 patients (or 8%) with CrCl<50 ml/min 
at baseline, two of whom had CrCl<40 ml/min at baseline. 
The results of this study differed from a number of studies that did not find any 
association between the use of TDF and the development of renal toxicity. Notable 
among the studies that found no evidence linking TDF and renal toxicity was a study 
by Viganò et al. (2011) in Italy. The study however only included patients with age 
groups up to the young adult category. Another study whose results did not agree 
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with the results was by O'Donnell et al. (2011) which did not find any correlation 
between impaired renal function outcomes and exposure to TDF.  
According to Bygrave et al. (2011a) in Lesotho, TDF-associated renal toxicity was 
rare and the authors concluded that there may be no need to switch patients who 
develop renal toxicity while on TDF because the renal toxicity that may occur while 
taking TDF is only transient. Although the number of patients with impaired (CrCl<50 
ml/min) baseline renal function (176 or 18.9%) was similar to the number of patients 
with baseline CrCl<50 ml/min in the study (56 or 18.0%), more patients developed 
impaired renal function outcomes in this study than in the study by Bygrave et al. 
(2011a). While only 31 (5.5%) of the patients with baseline CrCl>50 ml/min 
developed renal toxicity while on TDF during follow up and only 3 developed severe 
impairment, 40 patients (12.8%) with baseline CrCl>50 ml/min in the study 
developed renal toxicity while on TDF.  
Although there were differences in underlying conditions, age, gender and body 
weight between the patients in the study and the study by Bygrave et al. (2011a) 
which may make comparisons less effective, the results of this study still showed 
that use of TDF might be a contributing factor towards impaired renal function 
outcomes. 
Moreover, the debate on what to do with patients who develop renal impairment 
while taking TDF is another issue which may be difficult to resolve given the limited 
number of alternative ART regimens available in Lesotho. The patients who 
developed renal toxicity while taking TDF in the study by Bygrave et al. (2011) were 
not switched and three patients developed severe renal impairment. In this study, 
despite the guidelines recommending an ART switch in patients who develop 
impaired renal function outcomes, only three of the six patients who developed 
severe renal impairment, were switched to Abacavir-based ART regimens.   
The results of this study did not show that having comorbidities such as Hepatitis B 
or C are significant variables that contribute towards the development of impaired 
renal function outcomes as found by Young et al. (2007). Why these results might 
have deviated from findings by Young et al. (2007) and Nelson et al. (2007) may be 
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because of a smaller sample size compared to other studies and probably the 
limited number of patients who were tested for Hepatitis B or C. For instance, in the 
study by Young et al. (2007), 70 patients were positive for Hepatitis C in the non-
TDF group and 70 patients were positive for the same condition in the TDF group 
from a sample size of 521. From a sample size of 485 used in this study, only two 
patients were positive for Hepatitis B. However, according to Ford et al. (2012), 
many cases of Hepatitis B or C are undiagnosed in Lesotho. 
High blood pressure, which was high (about 20%) among the patients included in 
this study, poses a huge challenge as a critical contributing factor to renal 
impairment. Therefore, in addition to the need for screening for hypertension at 
baseline, patients diagnosed with hypertension may need frequent screening for 
renal function while taking ART drugs that may cause or exacerbate renal 
impairment.   
TDF was not a significant predictor for the development of impaired renal function 
outcomes in the multivariate analysis, despite being marginally significant in the 
univariate analysis. The results might indicate that TDF may be a contributing factor 
towards renal impairment but probably with less power of influence when compared 
to other variables such as female gender, high blood pressure, older age, and 
underweight. 
5.1.3 Limitations of the study  
The clinical profiles of the patients in the TDF group and the non-TDF group differed 
in a number of variables. The variables that were were significantly different 
between the two groups were namely: (1) the mean baseline weight (p<0.001); (2) 
baseline CD4 count (p=0.029); (3) number of patients with tuberculosis at baseline 
(p=0.006); (4) the number of patients with anaemia at baseline (p=0.005). The 
disproportionate distribution of these variables between the TDF and the non-TDF 
groups means that these variables were confounders in the study.  
Several other limitations might have had a negative impact on the analysis of the 
effect of TDF on renal function. The sample size of the data collected (539) was 
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66% of the calculated target sample size (816). There was a significant discrepancy 
in number of patients belonging to cases group (312 or 64%) compared to the 
number of patients belonging to the control group (173 or 36%) as intended in the 
study design.  
Data on patients’ height which is required for the calculation of body mass index 
(BMI) was not available. Lesotho does not measure patients’ heights as part of the 
ART program. Therefore, the effect of BMI on kidney function was not assessed in 
the study. 
According to the guidelines for case control studies by Lwanga (1991), the total 
sample size required to address the objectives of the study was 816 assuming an 
estimated odds ratio of 2 at 95% confidence level, and relative precision of 25%. 
However, due to resource limitations, poor accessibility, the selection criteria and 
the data cleaning procedure, only 539 patients who met the set inclusion criteria 
from the two centres were included in the study. 
The disproportionate numbers of patients between the TDF and the non-TDF group 
was a major limitation of the study. Close to two-thirds (64%) of the patients 
included in the study were in the TDF group mainly due to the scarcity of serum 
creatinine data for patients in the non-TDF group. Therefore, further studies are 
necessary in African settings where the number of patients in the non-TDF group is 
more proportional to the number of patients in the TDF group. 
The duration of treatment for the patients varied from 6 to 48 months. Moreover, the 
data on other adverse drug reactions which was important for the evaluation of ART 
outcomes was scarcely indicated in the medical records which again made 
comparisons disproportionate. The data for diagnosis of diabetes which depended 
solely on diagnostic reports of diabetes in the medical records or reported use of 
anti-diabetic drugs had limited reliability. Actual data on blood glucose levels for the 
patients were largely unavailable. 
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5.2 Immunological Outcomes 
5.2.1 Clinical profile of the study population at baseline 
With regard to clinical profiles of the patients at baseline, more males had results 
indicating IMF than females (p=0.002) although there was no indication that males 
defaulted treatment more than females. Defaulting rates between males and 
females did not differ significantly (p=0.564). 
With respect to baseline CD4 count, the baseline CD4 count values for the group 
that developed IMF were significantly lower than the group that did not develop IMF 
(p=0.014). This means that baseline CD4 count was a confounding variable in the 
study. Therefore, the effect of low baseline CD4 count on immunological outcome 
needed to be interpreted in the context of other variables.  
5.2.2 Immunological outcomes and the variables associated with 
immunological failure 
The proportion of patients with IMF (6.8%) was lower than the one found by Eshun-
Wilson, Taljaard & Nachega (2012), who reported a failure rate of 20.4% in a study 
they carried out in South Africa. However, the results of this study were closer to 
findings by Reynolds et al. (2009) in Uganda who reported that 11.0% of the 
patients had IMF. 
The low predictive value of CD4 counts in detecting treatment failure emphasises 
the need for viral load tests. Without viral load tests, some of the patients in this 
study may be switched to second line probably inappropriately. According to Kantor 
et al. (2009), using CD4 count results unconfirmed by viral load tests resulted in 
inappropriate switching of 43% of the patients who had latest CD4 counts which 
were lower than 50% of the baseline CD4 cell count.  
The low predictive value of CD4 counts in detecting virological failure is a major 
challenge in limited settings. For example, the number of patients who had 
virological failure according to Reynolds et al. (2009) in Uganda was 20.8% out of 
125 patients who had immunological failure. In another study by Amenyah et al. 
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(2006) in Ghana, 31 patients (77%) had virological failure out of 40 patients who had 
immuno-virological failure. 
The reasons why the rates of immunological failure differ by wide margins from 
virological failure rates may be because of low specificity of the CD4 count results in 
detecting treatment failure and the differences in the definitions of immunological 
failure. While most settings use the criteria recommended by WHO (2010), some 
settings define immunological failure as a decrease in CD4 counts by more than 
25% from baseline (Kantor et al., 2009).  
Another reason why reports of immunological failure differ widely may be because 
of the different thresholds at which patients start ART. For example, in this study, 
the median baseline CD4 count value was 154 cells/mm3 (IQR 11-641) which 
means that some patients started ART despite having CD4 counts above 500 
cells/mm3 (patients sometimes start ART with higher baseline CD4 counts if they 
happen to have a life-threatening condition such as TB). Unfortunately, using the 
criteria for defining immunological failure without modifications in such patients may 
lead to errors because patients with higher baseline CD4 counts would probably 
need a higher percentage decrease in CD4 counts before the CD4 counts can 
indicate immunological failure. 
A closer look at the clinical profiles of the patients with critical IMF further highlights 
the challenge of measuring poor adherence to treatment in Lesotho. According to 
Tiam (2008), poor adherence to treatment is the most common cause of ART 
treatment failure in Lesotho. Male patients on ART especially migrant workers who 
work in South Africa sometime default treatment due to constant relocations 
(Bygrave, 2010). A study in Central African Republic by Péré, Charpentier, 
Mbelesso, Dandy, Matta, Moussa, De Dieu Longo, Grésenguet, Abraham & Bélec 
(2012), reported that 24% of patients with virological failure showed wild-type 
viruses, which indicated poor adherence. The existence of poor adherence in 
African settings therefore poses a major setback to the success of ART 
programmes.  
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According to Prabhakar et al. (2011), low baseline CD4 count is one of the risk 
variables for immunological failure. Prabhakar et al. (2011) recommended close 
monitoring of patients with baseline CD4 counts below 100 cells/mm3 to ensure 
strict adherence to ART. The results of this study therefore further emphasize the 
need to closely monitor patients with low baseline CD4 counts. 
Adherence to ART drugs could be one possible reason why the male gender was 
more likely to have immunological failure than females. However, there were no 
significant differences in the defaulting records of males and females (p=0.556).  
This study did not find any significant association between the development of IMF 
and poor adherence and co-morbidities such as Hepatitis B or C as reported by 
Prabhakar et al. (2011) possibly because of the small sample size of patients who 
were positive for Hepatitis B or C. 
The results of this study did not confirm that having TB condition was a significant 
predictor of IMF. According to a study in Brazil by Bello, Correia, Marins, Merchan-
Hamann & Kanzaki (2011), TB was a significant predictor of virological failure. In 
this study, the number of patients who had TB and IMF was 13 (37.1%) of the total 
number of patients with IMF and TB was not a significant predictor of IMF. However, 
the proportion of patients in the group with IMF was slightly higher than the 
prevalence rate (35.6% or 184 patients) in the group of patients considered in the 
study.  Moreover, 8 of the 20 patients (40%) who were classified as having critical 
IMF based on CD4 count results, had TB. 
5.2.3 Limitations of the study 
The major limitation of this study was that the number of patients who had 
immunological failure was not compared to the number of patients who had 
virological failure. This was due to the fact that Lesotho does not test for viral load in 
many of the patients whose CD4 count results indicate immunological failure due to 
resource limitations. However, the results may indicate the need for viral load tests 
in Lesotho to reduce the number of patients switched to second line therapy 
inappropriately. 
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Another major limitation of the study was baseline CD4 counts. Baseline CD4 count 
below 50 cells/mm3 was a significant predictor of developing IMF (p=0.049). 
However, baseline CD4 count was a confounding variable because baseline CD4 
count values for the group that developed IMF were significantly lower than those 
for the group that did not develop IMF (p=0.014). Therefore, more studies with 
comparable baseline CD4 counts are warranted in this regard.  
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CHAPTER 6: CONCLUSIONS  
Following the results presented in chapter 4 and discussed in chapter 5, conclusions 
on the following are drawn: renal function outcomes following the use of TDF; the 
variables associated with sub-optimal renal function; the occurrence of sub-optimal 
immunological outcomes based on CD4 counts; and the variables associated with 
sub-optimal immunological outcomes. The chapter ends with recommendations on 
how the occurrence of sub-optimal renal function outcomes and sub-optimal 
immunological outcomes may be minimised in light of the results obtained. 
6.1 Renal function outcomes 
Although the overall renal function outcomes were positive, more patients in the 
TDF group had a negative outcome (40 or 12.5%) compared to the positive 
outcome (34 or 10.9%). In the non-TDF group, more patients had a positive 
outcome (21 or 12.1%) compared to the negative outcome (11 or 5.8%). Although 
positive and negative outcomes occurred in both groups, the TDF group had a 
higher inclination towards negative outcomes.  
The proportion of patients with impaired (CrCl<50 ml/min) baseline renal function 
(176 or 18.9%) in the study was similar to the proportion reported by Bygrave et al. 
(2011a) in Lesotho which was (56 or 18.0%). However, about twice as many 
patients (40 or 12.8%) developed impaired renal function outcomes in this study 
compared to the study by Bygrave et al. (2011a) where 31 or 5.5% developed renal 
function impairment with baseline CrCl>50 ml/min. Furthermore, in the study by 
Bygrave et al. (2011a), only one patient (0.2%) developed severe impairment and 
none developed end-stage renal disease. In this study, five patients (1.6%) in the 
TDF group developed severe renal impairment and one patient in the TDF group 
developed end-stage renal disease.  
The use of ARVs containing TDF emerged as a marginally significant factor 
associated with impaired renal function outcomes in the univariate logistic 
regression analysis (p=0.054) but was an insignificant factor (p=0.122) when 
adjusted for age (p<0.05), gender (p=0.005), high blood pressure (p=0.009), and 
body weight (p<0.05). The results indicated that TDF may be a weak contributing 
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factor towards the development of renal impairment when compared to other 
variables such as female gender, high blood pressure, older age, and underweight 
or TDF may only worsen a pre-existing renal disorder as reported by Brennan et al. 
(2011) in South Africa.  
The reported incidence of severe renal impairment following the use of TDF ranges 
from below 0.5% to just above 2%. The results of this study showed that 1.6% 
(n=312) of the patients developed severe renal impairment. The proportion with 
severe renal impairment was comparable to proportions reported in other studies. 
For example, a proportion of 1% was reported in the USA by Young et al. (2007), 
0.5% in the UK by Nelson et al. (2007); and 0.4% in India by Patel et al. (2010). 
With reference to the effect of baseline variables, the results of the study concurred 
with the findings by Bygrave et al. (2011a) at another site in Lesotho with respect to 
the effect of gender and age but differed with respect to CD4 counts. The results did 
not show that low baseline CD4 count was a significant predictor for development of 
impaired renal function outcome. The reason could be due to the wider range of 
baseline CD4 counts in the study than the patients in the study by Bygrave et al. 
(2011a).  
The results of this study did not show that having comorbidities such as Hepatitis B 
or C is a significant factor that may contribute towards the development of renal 
impairment as found by Young et al. (2007). A number of reasons may explain why 
these results differed from other studies–namely: (1) differences in clinical profiles of 
the study populations; (2) a smaller sample size in this study compared to other 
studies; (3) the limited number of patients who were tested for Hepatitis B or C. As 
reported by Ford et al. (2012), many patients remain untested for Hepatitis B or C in 
Lesotho.  
Differences in methodologies used in the studies may explain why the results in 
some studies were different. For example, the study by Viganò et al. (2011) in Italy 
included patients with age groups up to the young adult category. The impasse over 
TDF nephrotoxicity is likely to continue unless more research studies that include 
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large sample sizes selected from as many patient groups as possible are 
undertaken.     
6.2 Immunological outcomes 
Out of the 516 patients included in the study, 35 patients (6.8%) had sub-optimal 
immunological outcomes based on CD4 counts. The proportion of patients with sub-
optimal immunological outcomes or IMF was therefore low. The benefits of ART 
were noticeable based on the CD4 counts as indicated by the increase in CD4 
counts from a baseline average of 163 to 380 cells/mm3 during treatment. There 
were no significant differences in immunological responses between TDF and non-
TDF based ARVs (p=0.442). This means that TDF-containing regimens were more 
or less equally effective with respect to immunological response. 
In multivariate analysis, male gender (p=0.005) and baseline CD4 count below 50 
cells/mm3 (p=0.049) remained significant predictors of IMF outcome. Although 
weight loss of 5% or more was an important variable determining the development 
of sub-optimal immunological outcomes (p=0.097), the variable was not statistically 
significant at 95% confidence level (p=0.095). 
The proportion of patients with IMF (6.8%, n=516) was lower than the one from a 
study by Eshun-Wilson et al. (2012) who reported an immunological failure rate of 
20.4% in South Africa. However, the results of the study were closer to findings by 
Reynolds et al. (2009) in Uganda who reported that 11.0% of the patients had IMF. 
The differences in the definitions of IMF might contribute to the differences in the 
reported rates of IMF.  
There is also a knowledge gap in Lesotho with respect to the reasons why more 
men have higher rates of immunological failure than women. Interestingly, this study 
did not find any significant association (p=0.556) between the development of IMF 
and poor adherence and co-morbidities such as Hepatitis B or C as reported by 
Prabhakar et al. (2011). However, the small number of patients with documented 
evidence of poor adherence and patients who were positive for Hepatitis B or C in 
this study may explain why the results of this study differed from those of Prabhakar 
et al. (2011). 
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The results of this study did not indicate that having TB was a significant predictor of 
IMF. According to a study by Bello et al. (2011) in Brazil, having TB was a significant 
predictor of virological failure. However, in this study, 8 (40%) of the 20 patients who 
had critical IMF defined as having an endpoint CD4 count below 100 cells/mm3, had 
TB. Therefore, further studies are necessary to establish the interaction between the 
TB and sub-optimal immunological outcomes.  
6.3 Recommendations 
6.3.1 Renal function outcomes 
i. The screening for pre-existing renal disorder therefore may need to be 
emphasised in Lesotho.  
ii. Female gender, high blood pressure, older age and underweight are the variables 
that should be closely monitored for changes in renal function while on ART.     
iii. Patients who develop impaired renal function outcomes while on TDF-based 
regimens need to be switched to other regimens such as Abacavir-based 
regimens. 
iv. Testing of Hepatitis B or C in HIV patients need to be up-scaled to the maximum 
level that the available resources may allow. 
v. The numerous exit points for the patients in the study made the assessment of the 
effect of duration of treatment on renal function outcomes less effective. More 
studies with controlled exit points may be necessary to study the effect of duration 
of treatment on renal function outcomes. 
6.3.2 Immunological outcomes 
i. Male patients, patients with baseline CD4 count less than 100 cells/mm3, and 
patients who fail to gain weight should be monitored more closely especially for 
adherence to drugs.  
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ii. Although the extent to which patients may be monitored for adherence to drugs 
may be limited, giving extra counselling to patients at risk of developing IMF may 
probably reduce the development of IMF.  
iii. The recommendation for close monitoring of males may face some challenges in 
Lesotho due to push factors among males which tend to force males to relocate to 
South Africa in search of employment. The challenge may be addressed by 
moving towards more integrated HIV treatment programmes between South Africa 
and Lesotho. 
iv. There is need to up-scale viral load tests. Although it may not be feasible to test all 
patients on ART, there is need to ensure that the patients whose CD4 counts 
indicate IMF are tested for viral load. 
In conclusion, the results of this study indicated that there is a weak association 
between use of TDF and the development of renal impairment (p=0.054) before 
controlling for other variables and no association when the results were controlled 
for other variables (p=0.122). Therefore, TDF is a weak contributing factor 
associated with renal impairment outcomes compared to other variables such as 
hypertension, older age, underweight and female gender. More research on long 
term effects of TDF is recommended. Baseline renal function screening should be 
improved to minimise leakages of patients contraindicated of TDF.  
The proportion of patients who developed immunological failure in this study was 
low (6.8%, n=516). The mean CD4 counts of the study population increased 
significantly after treatment (p<0.001). Therefore, generally immunological outcomes 
were favourable. There were no significant differences in immunological responses 
between TDF and non-TDF based ART (p=0.465) which means TDF-based ART 
has comparable effect on immunological outcomes. However, males and patients 
with low baseline CD4 counts should be monitored closely while on ART. 
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Appendix B:  Microsoft Access® data collection tool 
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Appendix C: Data Analysis Procedures 
Appendix C1:  Summary of data cleaning, and preparation in Microsoft 
Excel®  
START EXCEL PROGRAM 
C1.1: Data cleaning 
         All numerical data such as age and weight, serum creatinine, CD4 counts, 
LFTs were checked for validity using the following formulae: 
          =IF(data is outside normal range) OR (cell contains string data), check data 
validity 
C1.2: Medical conditions and use of concurrent Non-ART nephrotoxic drugs 
     The presence of a specific medical condition such as Hepatitis C was 
detected by combining IF; OR; and ISNUMBER(SEARCH) formula functions 
available in Microsoft Excel® 2007 using the formula: 
             =IF(OR(ISNUMBER(SEARCH("Condition name", Cell# for conditions))), 
"1","0") where Cell# = Cell address 
 Hypertension was defined and graded into the stages of hypertension by 
assessing the maximum values for the systolic and diastolic blood pressure 
readings for each patient by combining MAX and IF formula functions. The 
syntax for the MAX IF formula is:  
   =MAX( IF ( logical test, value if true, value if false ) ) 
        Maximum BP level for each patient was given by: 
  =MAX(IF(AND(Systolic+Diastolic BP = BLANK),NA(),MAX(Systolic BP + 
Diastolic BP))) where BP = Blood pressure in mmHg, and NA() was used for 
censorship of missing data.  
  Systolic and Diastolic blood pressure was given by: 
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 Systolic BP =IF(ISBLANK(BP),"",IF(AND(120<=BP,BP<140),1, IF(AND 
(140<=BP, BP<160), 2,IF(BP=160,3,0))))  
       Diastolic BP =IF(ISBLANK(BP),"",IF(AND(80<=BP,BP<90),1,IF(AND(90<= 
BP,BP<100),2, IF(BP>=100,3,0)))) 
   Similarly, history of treatment for hypertension (BP) was assessed by: 
   =MAX(IF(AND(BP = BLANK),NA(),MAX(BP))) where again, NA() was 
included to detect missing data. 
    Patients were screened for use of nephrotoxic drugs against a database of 
non-ART nephrotoxic medications using the following formula: 
 =IF(OR(ISNUMBER(SEARCH("Drug name", Cell#)))),"1","0") where Cell# = 
Cell address 
C1.3: Presence of anaemia and classification based on MCV 
    The presence of anaemia was detected based on haematological reference 
ranges of the people of Basotho lineage outlined in Table 2.6 using the 
formula: 
 =IF(AND(Gender="Male",Hb<13.7),1,IF(AND(Gender="Female",Hb<12.7),1,
0) 
   Anaemia was classified as microcytic, normocytic, and macrocytic using the 
results from the formula above as follows: 
 =IF(AND(anaemia=1,MCV < 80),"microcytic anaemia", IF(AND(anaemia 
=1,MCV>80, MCV<100),"normocytic anaemia", IF(AND(anaemia =1,MCV > 
100),"macrocytic anaemia",0))) 
C1.4: Liver condition 
            Liver condition was classified based on ALT, AST and GGT as follows: 
 =IF(OR(ALT>60)+(GGT>50)+(AST>60),1,0) 
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Export data to STATA® Version 11 
END EXCEL PROGRAM 
Appendix C2: Summary of data analysis steps in STATA® Version 11  
START STATA PROGRAM 
C2.1: Stage 1: analysis of renal function outcomes 
C2.1.1: Tests for normality of continuous data  
        Tests for normality of continuous data were performed as: 
  Plot histograms AND RUN Sktest for continuous variables 
C2.1.2: Demographic and baseline data summary 
       Demographic and baseline data were summarised as: 
       Tabulate demographic characteristics versus Non-TDF and TDF 
groups 
       Re-group continuous variables AND generate new group variables 
       Tabulate variables versus baseline CrCl<50 ml/min and baseline CrCl 
>50ml/min: Where CrCl = creatinine clearance in ml/min 
      Re-group baseline CrCl according to CKD classification AND generate 
new group variables  
C2.1.3: Conditions post-baseline: Tabulation summary 
       Re-group continuous variables, Generate new group variables  
      IF variable is non-numeric, convert to binary using regular expressions: 
 gen binary variable = regexm(non-numeric variable 1, "seach term 
1") OR regexm(non-numeric variable 2, "seach term") 
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ELSE  
Tabulate variables versus TDF group and Non-TDF group 
            Duration of treatment was calculated as: 
       Treatment duration in months = (year (latest record date) – year 
(ART start date)) x 12 + month (latest record date) – month (ART start 
date)  
             Siginificance of the differences between the TDF and Non-TDF group was 
calculated as: 
      Tabulate TDF group vs variables, AND do Fishers exact test (if 
variable is categorical) or Ttest (if the variable is continuous) 
 Summary row data for blood pressure measurements (For example, 
Systolic BP) were tabulated as: 
bysort  BP Treatment Status: summ Row Mean of Systolic BP  
where Row Mean of Systolic BP was calculated as: 
 egen Row Mean of Systolic BP = rowmean (baseline Systolic BP– 
latest Systolic BP)  
C2.1.4: Analysis of renal function outcomes 
        Renal function outcomes were analysed as: 
Generate variable latest CrCl value = rowlast (baseline CrCL up to 
latest CrCl value)   
        Re-group variable latest CrCl value according to CKD classification, 
Generate new group variable  
C2.1.4.1: Definitions of sub-optimal renal function outcomes: 
        Sub-optimal renal function outcomes were detected and defined by: 
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Generate outcome variable 1 IF CrCl outcome<50 ml/min AND 
baseline CrCl < 50 ml/min  OR baseline CrCl>50  
        Generate outcome variable 2 IF CrCl outcome<50 ml/min AND 
baseline CrCl>50  
        Generate outcome variable 3 IF CrCl outcome<50 ml/min AND 
baseline CrCl<50 
       Generate outcome variable 4 IF CrCl outcome>50 ml/min AND 
baseline CrCl<50  
C2.1.4.2: Factors associated with renal insufficiency at baseline: 
C2.1.4.2.1: Analysis of variables associated with impaired baseline CrCl 
(baseline CrCl<50) 
         RUN Logistic Regression for baseline CrCl<50 ml/min versus categorical 
variables, Show Odds Ratio results  
        RUN Logistic Regression for baseline CrCl<50 ml/min versus all categorical 
variables significant in univariate analysis, Show Odds Ratio results 
C2.1.4.2.2: Analysis of variables associated with sub-optimal renal function 
outcomes  
        RUN Logistic Regression for CrCl <50 ml/min outcome versus test 
categorical variables, Show Odds Ratio results   
        RUN Logistic Regression for CrCl <50 ml/min outcome versus all test 
categorical variables significant in univariate analysis, Show Odds Ratio 
results 
        Repeat Multivariate analysis step until significant variables remain in the 
multivariate model, Show Odds Ratio results 
C2.1.4.2.3: Clinical profile of patients with sub-optimal renal function 
outcomes 
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         Clinical profiles of patients with sub-optimal renal function outcomes were 
generated as: 
List demographic data, laboratory data, conditions, concomitant 
treatment, baseline CrCl and Latest values of CrCl IF the patient has 
normal baseline renal function AND severe or end-stage renal 
impairment outcome 
C2.2.1: Stage 2: analysis of immunological outcomes based on CD4 counts 
        Test for normality of continuous data were performed as: 
       Plot histograms for CD4 counts and other continuous variables 
        RUN Sktest for continuous variables  
C2.2.2: Definitions of CD4 count variables 
        Summary statistics for CD4 count values were generated as:  
Re-group baseline CD4 count AND Generate group variable 
        Generate (latest CD4 value) = rowlast (baseline CD4 count up to latest 
CD4 value)  
         Generate (CD4 row mean) = rowmean (baseline CD4 count up to 
latest CD4 value)  
        Generate (CD4 row max) = rowmax (baseline CD4 count up to latest 
CD4 value)  
C2.2.3: Definitions of immunological failure (IMF) 
       Sub-optimal immunological response was defined as: 
Generate outcome variable 1 if  latest CD4 value <(baseline 
CD4×0.75)  
        Generate outcome variable 2 if latest CD4 value <(CD4 row max×0.5) 
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       Generate outcome variable 3 if latest CD4 value <100  
        Generate IMF result if variable 1 OR variable 2 OR variable 3 = 1 
C2.2.4: Testing significance of the differences in characteristics between 
patients with and without immunological failure outcomes  
        Testing significance of the differences in characteristics between patients 
with and without immunological failure (IMF) outcomes was performed as: 
Tabulate IMF versus test variables, AND do Fishers exact test (if 
variable is categorical) or Ttest (if variable is continuous) 
C2.2.5: Univariate and multivariate analysis of the factors associated with 
immunological failure outcome 
        Univariate and multivariate analysis of the factors associated with 
immunological failure (IMF) outcome was performed as: 
RUN logistic regression for IMF result versus categorical variables, 
Show Odds Ratio results 
      RUN logistic regression for IMF result versus all categorical variables 
significant in univariate analysis, Show Odds Ratio results 
C2.2.6: Clinical profiles of patients with critical sub-optimal immunological 
outcomes 
         Clinical profiles of patients with critical sub-optimal immunological outcomes 
were defined and listed as: 
Define critical IMF outcome as latest value of value of CD4 count is 
<100 cells/mm3 
         List patient’s demographic data, BL CD4 counts and Cd4 count 
outcomes if the patient has a critical IMF outcome  
END STATA PROGRAM 
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Appendix D:  Study Ethical Approval Letters 
Appendix D1: Study ethical approval letter from the Ministry of Health 
and Social Welfare Research and Ethics Committee  
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Appendix D2: Study approval letter from St Joseph’s Hospital 
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Appendix D3: Study approval letter authorizing data collection from 
Nazareth Health Centre 
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Addendum: Map of Lesotho showing Health Centres in Roma 
 
Map of Lesotho showing Roma Health Service Area (RHSA). RHSA (highlighted in red colour) is 
comprised of St Joseph’s Hospital (A) and 5 Health Centres (B—F): B = Nazareth; C = Fatima;                   
D = St. Benedict; E = St. Bernard and F = Tlali. Adapted from Geoatlas (2010). 
 
Reference: 
Geoatlas. 2010. [Online] Available at www.geoatlas.com/africa. Accessed: 04/08/2013  
